Oxazolidinone liposomal compositions

By using phosphatidylcholine, cholesterol and PEG polymers in liposomes to conjugate lipids, combined with chelating agents, encapsulating zolidinone compounds, the problem of degradation of liposome compositions during storage is solved, and stability is achieved drug delivery and antibacterial effects.

CN118900689APending Publication Date: 2024-11-05AKAGERA MEDICINES INC
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
CN202280089711.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-22
Filing Date
2022-12-22
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing liposome compositions are prone to degradation during storage, resulting in insufficient stability of therapeutic compounds and difficulty in efficient delivery of antibiotics such as zolidinone compounds.

Method used

Using liposomes containing phosphatidylcholine, cholesterol and PEG polymer conjugated to lipids, stable liposome vesicles are formed to encapsulate zolidinone compounds by adjusting the molar ratio and adding chelating agents such as deferroamine. Improve storage stability.

Benefits of technology

It significantly improves the storage stability of zolidinone compounds, reduces the degradation of cholesterol and phospholipids, prolongs the presence of drugs in liposomes, and enhances the antibacterial effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900689A_ABST
    Figure CN118900689A_ABST
Patent Text Reader

Abstract

Some aspects of the present disclosure relate to various liposome compositions of # imgabs 0 # oxazolidinone compounds, and related methods of making and using # imgabs 1 # oxazolidinone liposome compositions. In some embodiments, the liposome compositions have improved storage stability in terms of component degradation.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This patent application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 292,899, filed on December 22, 2021, which is incorporated herein by reference in its entirety. Technical Field

[0003] This disclosure relates to Liposome composition of oxazolidinone compound, preparation method thereof and aminoalkyl Use of oxazolidinone compounds in treating Mycobacterium tuberculosis and other Gram-positive bacterial infections. Background Art

[0004] Liposomal compositions can be used to deliver therapeutic compounds. Liposomal compositions can comprise liposomes that encapsulate a therapeutic compound within a vesicle formed by a membrane formed from lipids. Liposomes are generally characterized by having an interior space that is isolated from the external medium by one or more bilayer membranes that form a microscopic pouch or vesicle.

[0005] However, liposomes encapsulating therapeutic compounds can degrade during storage and prior to therapeutic administration. For example, oxidative degradation of liposome components and changes in liposome particle size or polydispersity index (PDI) can occur during storage of liposome compositions containing therapeutic compounds. There remains a need for liposome compositions containing therapeutic agents that have improved storage stability, exhibiting reduced liposome degradation during storage. Summary of the Invention

[0006] Provided herein are liposomal compositions and methods for treating methicillin resistant Staphylococcus aureus (MRSA) bacterial infections.

[0007] Some aspects of the present disclosure relate to liposomal compositions of a compound of formula (I), or a pharmaceutically acceptable salt thereof,

[0008]

[0009] wherein R1 is a tetrazole ring substituted with an aminoalkyl group at the 2' position; and R2 is an amine or an acetamide; wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is encapsulated in liposomes in an aqueous medium at a pH greater than 6.7; and wherein the liposomes comprise phosphatidylcholine, cholesterol, and a PEG polymer-conjugated lipid, wherein there is 50 to 65 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomes.

[0010] In some embodiments, R2 is acetamide (NHCOCH3). In some embodiments, R1 is selected from:

[0011]

[0012] In some embodiments, the amount of PEG polymer conjugated lipid is 5mol% relative to phosphatidylcholine. In some embodiments, the sulfate of formula (I) compound is encapsulated in liposomes comprising phosphatidylcholine, cholesterol and PEG polymer conjugated lipid in a molar ratio of 45:55:2.25. In some embodiments, phosphatidylcholine is distearoylphosphatidylcholine (DSPC) or hydrogenated soyphosphatidylcholine (HSPC). In some embodiments, PEG polymer conjugated lipid is PEG (molecular weight 2,000)-distearoylglycerol (PEG-distearoylglycerol, PEG-DSG) or PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine (PEG-distearoylphosphatidylethanolamine, PEG-DSPE). In some embodiments, the liposome composition further comprises a chelating agent selected from deferoxamine (DFO) and EDTA, wherein the concentration of the chelating agent is 0.1 to 1 mM.

[0013] In some embodiments, the compound of formula (I) is a compound selected from the group consisting of AKG-38, AKG-39, and AKG-40, or a pharmaceutically acceptable salt thereof:

[0014]

[0015] In some embodiments, the compound of Formula (I) is the sulfate salt of AKG-38.

[0016] In some embodiments, the pH of the liposome composition exceeds 7 and does not exceed 8. In some embodiments, the pH of the liposome composition is 7.3 to 7.7. In some embodiments, the pH of the liposome composition is 7.5.

[0017] In some embodiments, the compound of formula (I) is the sulfate salt of AKG-38,

[0018]

[0019] wherein the compound is encapsulated in liposomes formed from hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and PEG (2000) -DSPE in a molar ratio of 45:55:2.25 in an aqueous medium at a pH of 7.3 to 7.7. In some embodiments, the liposome composition further comprises a chelating agent, wherein the chelating agent is deferoxamine (DFO), and wherein the concentration of the chelating agent is 0.1 to 1 mM. In some embodiments, the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the composition is 430 to 680 g / mol. In some embodiments, the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the composition is 600 g / mol. In some embodiments, the liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm; and the polydispersity index of the liposome composition is less than 0.15. In some embodiments, the ratio of encapsulated AKG-38 to total AKG-38 of the liposome composition is at least 90%. In some embodiments, the aqueous medium further comprises sodium chloride. In some embodiments, the osmolality of the aqueous medium is 270 to 330 mOsmol / kg; the concentration of sodium chloride is 130 to 150 mM; and the concentration of the chelating agent is 0.5 mM. In some embodiments, the aqueous medium comprises ammonium ions at a concentration of 20 to 60 mM, and the concentration of sodium chloride is 50 to 80 mM. In some embodiments, the liposome composition further comprises HEPES or a phosphate buffer.

[0020] Some aspects of the present disclosure relate to AKG-38 liposome compositions having a pH of at least 7.0 and not more than 8.0, comprising lipids HSPC, cholesterol, and PEG(2000)-DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1, and a pharmaceutically acceptable salt of AKG-38,

[0021]

[0022] wherein the liposome composition is further characterized by any one or more of the following features: (a) the liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm, or the liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 100 to 130 nm; (b) the polydispersity index of the liposome composition is less than 0.15 or the polydispersity index of the liposome composition is less than 0.10; (c) the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 430 to 480 g / mol, or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 500 to 650 g / mol; or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is The drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 430 to 650 g / mol; or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 450 g / mol; or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 450 g / mol; or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 600 g / mol; or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 600 g / mol; (d) the total concentration of AKG-38 in the liposome composition is 12 to 25 mg / mL, or the total concentration of AKG-38 in the liposome composition is 13.5 to (e) the ratio of encapsulated AKG-38 to total AKG-38 in the liposomal composition is at least 90%, or the ratio of encapsulated AKG-38 to total AKG-38 in the liposomal composition is at least 95%, or the ratio of encapsulated AKG-38 to total AKG-38 in the liposomal composition is at least 97%, or the ratio of encapsulated AKG-38 to total AKG-38 in the liposomal composition is at least 98%; (f) the liposomal composition comprises sodium chloride and optionally ammonium ions. (g) the aqueous medium has an osmolarity of 270 to 330 mOsmol / kg, or the aqueous medium has an osmolarity of 270 to 310 mOsmol / kg; (h) the aqueous medium comprises ammonium ions at a concentration of 20 to 60 mM, or the aqueous medium comprises ammonium ions at a concentration of 50 to 80 mM, or the aqueous medium comprises ammonium ions at a concentration of less than 0.5 mM, or the aqueous medium comprises ammonium ions at a concentration of less than 1 mM, or the aqueous medium comprises ammonium ions at a concentration of 1 to 10 mM; (i) the aqueous medium comprises sodium chloride at a concentration of 130 to 150 mM; (j) the aqueous medium further comprises a buffer, wherein the buffer buffers the liposome composition at a pH of 7.3 to 7.7 or a pH of 7.5; (k) the aqueous medium further comprises HEPES or a phosphate buffer, or the aqueous medium further comprises HEPES or a phosphate buffer at a concentration of 5 to 50 mM, or the aqueous medium further comprises HEPES or a phosphate buffer at a concentration of 20 mM; (l) the aqueous medium further comprises a chelating agent, or the aqueous medium further comprises a chelating agent at a concentration of 0.1 to 1 mM, or the aqueous medium further comprises a chelating agent at a concentration of 0.5 mM, or the aqueous medium further comprises deferoxamine (DFO) or EDTA, or the aqueous medium further comprises deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM, or the aqueous medium further comprises deferoxamine (DFO) or EDTA at a concentration of 0.5 mM; (m) the liposome composition is storage stable; or (n) AKG-38 is encapsulated in the liposomes as the sulfate salt of AKG-38.

[0023] Some aspects of the present disclosure relate to the use of (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Isotonic AKG-38 liposome dispersion prepared with oxazolidin-2-one or a pharmaceutically acceptable salt thereof, wherein the liposome comprises hydrogenated soybean phosphatidylcholine (HSPC), cholesterol and (PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine, PEG-DSPE) (PEG (2000)-DSPE), and the aqueous medium comprises a chelating agent selected from the group consisting of deferoxamine (desferrioxamine, Desferal), ethylenediamine tetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA), nitrilotriacetic acid (nitrilotriacetic acid) and dapoxetine. acid, NTA), ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), N-(2-hydroxyethyl)ethylenediamine-N,N',N'-triacetic acid (HEDTA), and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).

[0024] In some embodiments, the pH of the isotonic AKG-38 liposomal dispersion is greater than 6.7 and does not exceed 8.0. In some embodiments, the pH of the isotonic AKG-38 liposomal dispersion is 7.5. In some embodiments, the liposomes are formed from hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and PEG (2000) -DSPE in a molar ratio of 45:55:2.2. In some embodiments, the chelating agent is deferoxamine. In some embodiments, the liposomal dispersion comprises lipid vesicles formed from a composition comprising phosphatidylcholine, 55 mol% cholesterol, and 5 mol% PEG-DSG or 5 mol% PEG-DSPE.

[0025] Some aspects of the present disclosure relate to methods of treating methicillin-resistant Staphylococcus aureus (MRSA) bacterial infections comprising administering to a subject in need thereof a therapeutically effective amount of a liposome composition.

[0026] Some aspects of the present disclosure relate to methods for preparing liposome compositions comprising the steps of: (a) dissolving one or more phospholipids, cholesterol, and a PEG-lipid derivative in ethanol to obtain a lipid solution; (b) combining the lipid solution from step (a) with a capture agent solution to obtain a uniform lipid suspension having a desired phospholipid concentration; and (c) extruding the lipid suspension from step (b) through a membrane having a defined pore size, e.g., a nominal pore size. (d) purifying the liposomes from an extraliposomal capture agent in the extruded lipid suspension to obtain a purified extruded liposome preparation; (e) contacting the liposomes with a compound of formula (I) in an aqueous medium to achieve encapsulation of the compound in the liposomes; (f) optionally removing unencapsulated compound; and (g) providing the liposomes in a physiologically acceptable medium suitable for parenteral use; wherein the capture agent solution in step (b) comprises an aqueous ammonium sulfate solution at a concentration greater than 0.25 M, and wherein the physiologically acceptable medium in step (g) comprises a chelating agent.

[0027] In some embodiments, the capture agent solution in step (b) comprises ammonium sulfate at a concentration of 0.5 M. In some embodiments, the chelating agent is deferoxamine. In some embodiments, the liposomes extruded in step (c) are unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm.

[0028] Provided herein are liposomal compositions and methods for treating mycobacterial infections.

[0029] In some embodiments, the liposome composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 is an amine (NH2). In some embodiments, R1 is selected from:

[0030]

[0031] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is encapsulated in liposomes in an aqueous medium with a pH greater than 6.7; and the liposomes comprise phosphatidylcholine, cholesterol, and PEG polymer conjugated lipids, wherein 50 to 65 mol% cholesterol is present relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomes. In some embodiments, the amount of PEG polymer conjugated lipids is 5 mol% relative to phosphatidylcholine. In some embodiments, the sulfate of the compound of formula (I) is encapsulated in liposomes comprising phosphatidylcholine, cholesterol, and PEG polymer conjugated lipids in a molar ratio of 45:55:2.25. In some embodiments, phosphatidylcholine is distearoylphosphatidylcholine (DSPC) or hydrogenated soybean phosphatidylcholine (HSPC). In some embodiments, the PEG polymer conjugated lipid is PEG (molecular weight 2,000)-distearoylglycerol (PEG-DSG) or PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine (PEG-DSPE). In some embodiments, the liposome composition further comprises a chelating agent selected from deferoxamine (DFO) and EDTA, wherein the concentration of the chelating agent is 0.1 to 1 mM.

[0032] The compound of formula (I) is a compound selected from the group consisting of AKG-28, AKG-29, AKG-30, AKG-31, AKG-38 and AKG-39 or a pharmaceutically acceptable salt thereof:

[0033]

[0034] In some embodiments, the compound of formula (I) is the sulfate salt of AKG-28,

[0035]

[0036] The compounds were encapsulated in liposomes formed by hydrogenated soybean phosphatidylcholine (HSPC), cholesterol, and PEG (2000)-DSPE at a molar ratio of 45:55:2.25 in an aqueous medium at pH 7.3 to 7.7.

[0037] Some aspects of the present disclosure relate to AKG-28 liposome compositions comprising liposomes and a pharmaceutically acceptable salt of AKG-28 encapsulated in the liposomes, wherein the liposomes comprise lipids HSPC, cholesterol, and PEG(2000)-DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1.

[0038]

[0039] wherein the liposome composition is further characterized by any one or more of the following features: (a) the liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm, or the liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 100 to 130 nm; (b) the polydispersity index of the liposome composition is less than 0.15, or the polydispersity index of the liposome composition is less than 0.10; (c) the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 99 to 530 g / mol PhL, or 85 to 456 g / mol PhL as AKG-28 free base (FB); 99 to 470 g / mol PhL; PhL, or 85 to 400 g / mol as AKG-28 free base (FB); 230 to 280 g / mol, or 190 to 240 g / mol as AKG-28 free base (FB); or a drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition of 290 to 360 g / mol, or 245 to 305 g / mol as FB; or a drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition of 300 to 340 g / mol, or 256 to 290 g / mol as FB; or a drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition of 250 g / mol, or 215 g / mol as FB; or a drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition of ) has a drug / lipid ratio of 330 g / mol or 280 g / mol as FB; or the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 330 g / mol or 280 g / mol as FB; (d) the total concentration of AKG-28 in the composition is 8 to 15 mg / mL or 6.8 to 12.8 mg / mL as FB; or the total concentration of AKG-28 in the composition is 9 to 11 mg / mL or 7.6 to 9.4 mg / mL as FB; or the total concentration of AKG-28 in the composition is 10 mg / mL or 8.5 mg / mL as FB; or the total concentration of AKG-28 in the composition is 10 mg / mL (100 mg in a 10 mL vial) or 8.5 mg / mL (85 mg in a 10 mL vial); (e) the ratio of encapsulated AKG-28 to total AKG-28 in the liposomal composition is at least 90%; or the ratio of encapsulated AKG-28 to total AKG-28 in the liposomal composition is at least 95%; or the ratio of encapsulated AKG-28 to total AKG-28 in the liposomal composition is at least 97%; or the ratio of encapsulated AKG-28 to total AKG-28 in the liposomal composition is at least 98%; (f) the liposomal composition comprises an aqueous medium containing sodium chloride and optionally ammonium ions; (g) the osmolarity of the aqueous medium is 270 to 330 mOsmol / kg; or the osmolarity of the aqueous medium is 270 to 310 mOsmol / kg; or the aqueous medium is isotonic; (h) the aqueous medium contains ammonium ions at a concentration of 20 to 60 mM; or the aqueous medium contains ammonium ions at a concentration of 50 to 80 mM; or the aqueous medium contains ammonium ions at a concentration of less than 0.5 mM; or the aqueous medium contains ammonium ions at a concentration of less than 1 mM. ions; or the aqueous medium contains ammonium ions at a concentration of 1 to 10 mM; or the aqueous medium contains ammonium ions at a concentration of less than 130 mM; (i) the aqueous medium further contains a buffer, wherein the buffer buffers the liposome composition at a pH of 7.3 to 7.7 or pH 7.5; (j) the aqueous medium further contains HEPES or phosphate buffer; or the aqueous medium further contains HEPES or phosphate buffer at a concentration of 5 to 50 mM; or the aqueous medium further contains HEPES or phosphate buffer at a concentration of 20 mM. buffer; (k) the composition further comprises a chelating agent; or the composition further comprises a chelating agent at a concentration of 0.1 to 1 mM; or the composition further comprises a chelating agent at a concentration of 0.5 mM; or the composition further comprises deferoxamine (DFO) or EDTA; or the composition further comprises deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM; or the composition further comprises deferoxamine (DFO) or EDTA at a concentration of 0.5 mM; or (l) AKG-28 is encapsulated in the liposomes as the sulfate salt of AKG-28.

[0040] Some aspects of the present disclosure relate to methods for preparing liposome compositions, the methods comprising the steps of: (a) dissolving one or more phospholipids, cholesterol, and a PEG-lipid derivative in ethanol to obtain a lipid solution; (b) combining the lipid solution of step (a) with a capture agent solution to obtain a uniform lipid suspension having a desired phospholipid concentration; (c) extruding the lipid suspension of step (b) through a membrane having a defined pore size, such as a polycarbonate track-etched (PCTE) membrane having a nominal pore size of 50 to 200 nm; and (d) performing a filtration step during extrusion. (e) contacting the liposomes with a compound of formula (I) in an aqueous medium to achieve encapsulation of the compound in the liposomes; (f) optionally removing unencapsulated compound; and (g) providing the liposomes in a physiologically acceptable medium suitable for parenteral use; wherein the capture agent solution in step (b) comprises an aqueous ammonium sulfate solution having a concentration greater than 0.25 M, and wherein the physiologically acceptable medium in step (g) comprises a chelating agent.

[0041] In some embodiments, the capture agent solution in step (b) comprises ammonium sulfate at a concentration of 0.5 M. In some embodiments, the chelating agent is deferoxamine. In some embodiments, the liposomes extruded in step (c) are unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm. In some embodiments, the chelating agent is deferoxamine, and the liposomes extruded in step (c) are unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm.

[0042] Some aspects of the present disclosure relate to methods for treating mycobacterial infection, comprising administering to a subject in need thereof a therapeutically effective amount of a liposome composition. In some embodiments, the mycobacterial infection is an infection with Mycobacterium tuberculosis, or an infection with a multidrug resistant (MDR) strain of Mycobacterium tuberculosis, or an infection with an extremely drug resistant (XDR) strain of Mycobacterium tuberculosis.

[0043] Provided herein are uses of liposome compositions for treating mycobacterial infections.

[0044] Provided herein are uses of liposome compositions for treating methicillin-resistant Staphylococcus aureus (MRSA) bacterial infections.

[0045] In some embodiments, there is provided a In some embodiments, the liposomal formulation comprises greater than 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal composition and has a pH of 7 or greater. The oxazolidinone liposome compositions have unexpectedly improved storage stability properties. In some embodiments, the addition of a chelating agent (e.g., deferoxamine or EDTA) reduces the storage stability of the liposomes. In some embodiments, the oxazolidinone liposome composition contains ammonium Oxazolidinone liposome compositions exhibit improved storage stability of phosphatidylcholine: the ammonium The oxazolidinone drug is displaced from the liposomes containing the ammonium sulfate capture agent during loading (eg, by omitting post-loading buffer exchange).

[0046] In some embodiments, provided herein The oxazolidinone liposome composition is composed of lipids, wherein the lipids are composed of HSPC, cholesterol and PEG-DSPE in a mass ratio of about 5:3:1. In some embodiments, provided herein The oxazolidinone liposome composition is composed of lipids, wherein the lipids are composed of HSPC, cholesterol and PEG-DSPE in a molar ratio of 45:55:2.25. In some embodiments, The oxazolidinone liposome composition comprises AKG-28 or a pharmaceutically acceptable salt thereof. In some embodiments, The oxazolidinone liposome composition comprises AKG-38 or a pharmaceutically acceptable salt thereof. Oxazolidinone.

[0047] In some embodiments, there is provided a method comprising a liposome vesicle and In some embodiments, there is provided a liposome composition comprising encapsulated sulfuric acid Liposomal vesicles of oxazolidinone Oxazolidinone Liposome Compositions. In some embodiments, the liposomal vesicles are in an aqueous medium.

[0048] In some embodiments, Oxazolidinone compounds and their salts can be used to prepare liposome compositions. In some embodiments, The oxazolidinone liposome composition can be obtained by a method comprising the steps of: The oxazolidinone compound is combined with the purified extruded lipid suspension to effectively form The purified extruded lipid suspension may comprise a lipid component consisting of phospholipids, cholesterol, and an optional PEG-lipid derivative combined at desired concentrations in an aqueous medium, and a capture agent (e.g., ammonium sulfate (AS). In some embodiments, the lipid component of the extruded lipid suspension consists of HSPC, cholesterol, and PEG (2000) -DSPE. In some embodiments, the lipid component of the extruded lipid suspension comprises HSPC and cholesterol in a molar ratio of 45:55. In some embodiments, the lipid component of the extruded lipid suspension comprises HSPC and cholesterol in a weight ratio of 5:3. In some embodiments, the lipid component of the extruded lipid suspension consists of HSPC, cholesterol, and PEG (2000) -DSPE in a molar ratio of 45:55:2.25. In some embodiments, the lipid component of the extruded lipid suspension consists of HSPC, cholesterol, and PEG (2000) -DSPE in a weight ratio of 5:3:1.

[0049] In some embodiments, the purified extruded lipid suspension is obtained by a method comprising the following steps: (a) dissolving one or more phospholipids, cholesterol, and PEG-lipid derivatives in ethanol; (b) combining the lipid solution in step (a) with a capture agent solution (e.g., 0.5 M ammonium sulfate) to obtain a uniform lipid suspension having a desired phospholipid concentration (e.g., 60 mM phospholipid); (c) extruding the lipid suspension in step (b) through a membrane having a defined pore size, such as a polycarbonate track-etched (PCTE) membrane having a nominal pore size of 50 to 200 nm; and (d) purifying the liposomes from the extraliposomal capture agent in the extruded lipid suspension (e.g., by tangential flow filtration on a hollow fiber cartridge) to obtain a purified extruded liposome preparation. In some embodiments, the liposomes are unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm or 100 to 130 nm. In some embodiments, the liposomes are unilamellar or oligolamellar vesicles having a polydispersity index of less than 0.15 or less than 0.10.

[0050] The purified extruded liposomes can be loaded in a subsequent drug loading step Oxazolidinone drugs. The drug stock solution of the oxazolidinone drug compound or its salt is combined with the extruded lipid suspension purified in step (d) at the desired drug and phospholipid concentrations under conditions effective to load the drug into the liposomes within the purified extruded liposome preparation to form a drug-liposome mixture. In some embodiments, the drug loading step comprises combining the capture agent ammonium cation with Exchange of the oxazolidinone compound across the liposome bilayer membrane results in the generation of extraliposomal ammonium in the drug-liposome mixture, which is displaced from the liposome during the drug loading process.

[0051] Following the drug loading process, the unencapsulated drug compound can be purified from the drug-liposome mixture (e.g., by size exclusion chromatography, SEC, dialysis, or diafiltration, such as tangential flow filtration), and the liposomes containing the drug compound can be isolated and stored. Composition of oxazolidinone drug liposomes.

[0052] In some embodiments, the compound is entrapped in the liposome vesicle with the aid of a capture agent, wherein the capture agent comprises a polyanion. In some embodiments, the capture agent is sucrose octasulfate triethylammonium or ammonium sulfate. In some embodiments, the capture agent is sucrose octasulfate triethylammonium. In some embodiments, the capture agent is ammonium sulfate.

[0053] In some embodiments, the liposome composition comprises a salt of the compound, wherein the salt is a sulfate salt, a citrate salt, a thiosaccharide salt, a salt with a phosphorylated or sulfated polyol, or a salt with a phosphorylated or sulfated polyanionic polymer. In some embodiments, the liposome composition comprises a sulfate salt of the compound. For example, in some embodiments, the liposome composition comprises Formula (I) Sulfate or bisulfate salts of oxazolidinone compounds. In some embodiments, the liposome composition comprises a sulfate or bisulfate salt of (AKG-28). In some embodiments, the liposome composition comprises a sulfate or bisulfate salt of (AKG-38).

[0054] In some embodiments, the water solubility of the compound in the liposomal vesicles is less than 1 mg / mL. In some embodiments, the water solubility of the compound in the liposomal vesicles is less than 0.1 mg / mL.

[0055] In some embodiments, the liposome vesicle comprises a film containing phosphatidylcholine and cholesterol. In some embodiments, the liposome vesicle comprises a film containing phosphatidylcholine and cholesterol, wherein the film separates the inside of the liposome vesicle from an aqueous medium. In some embodiments, phosphatidylcholine is distearoylphosphatidylcholine (DSPC) or hydrogenated soybean phosphatidylcholine (HSPC). In some embodiments, the mol ratio of phosphatidylcholine to cholesterol is about 60:40 to 35:65. In some embodiments, the mol ratio of phosphatidylcholine to cholesterol is about 55:45 to about 35:65. In some embodiments, the mol ratio of phosphatidylcholine to cholesterol is about 50:50 to about 40:60. In some embodiments, the mol ratio of the phosphatidylcholine to cholesterol is about 50:50 to about 45:55. In some embodiments, the film also comprises a polymer-conjugated lipid. In some embodiments, the liposome vesicles comprise HSPC, cholesterol, and polymer-conjugated lipids in a molar ratio of about 45:55:2.75. In some embodiments, the liposome vesicles comprise HSPC, cholesterol, and polymer-conjugated lipids in a molar ratio of 45:55:2.25. In some embodiments, the polymer-conjugated lipid is PEG (molecular weight 2,000)-distearoylglycerol (PEG-DSG) or PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine (PEG-DSPE). In some embodiments, the Z-average particle size of the liposomes in the liposome composition is about 80 to about 130 nm.

[0056] In some embodiments, the drug liposomes are provided in an aqueous medium comprising sodium chloride and, optionally, ammonium displaced from the liposomes during the drug loading process. In some embodiments, the concentration of sodium chloride in the liposome composition is 50 to 80 mM. In some embodiments, the concentration of sodium chloride in the liposome aqueous composition is 130 to 150 mM. In some embodiments, the drug liposomes are provided in an aqueous medium comprising 20 to 60 mM ammonium, which is displaced from the liposomes during the drug loading process. In some embodiments, the concentration of ammonium in the liposome aqueous medium is less than 0.5 mM. In some embodiments, the osmolarity of the aqueous medium of the liposome composition is 270 to 330 mOsmol / kg. In some embodiments, the osmolarity of the aqueous medium of the liposome composition is 270 to 310 mOsmol / kg.

[0057] In some embodiments, The pH of the oxazolidinone liposome composition is greater than about 6.7. In some embodiments, The pH of the oxazolidinone liposome composition is 7 to 8. In some embodiments, The oxazolidinone liposome composition further comprises a buffer to bring the pH of the liposome aqueous medium to about 7.3 to 7.7. In some embodiments, The oxazolidinone liposome composition further comprises a buffer to bring the pH of the liposome aqueous medium to about 7.5. In some embodiments, The oxazolidinone liposome composition comprises a buffering substance selected from HEPES and phosphate. In some embodiments, The oxazolidinone liposome composition comprises a HEPES buffer. In some embodiments, The oxazolidinone liposome composition comprises a phosphate buffer. In some embodiments, The oxazolidinone liposome composition comprises a buffer substance selected from HEPES and phosphate at a concentration of 5 to 50 mM. The oxazolidinone liposome composition comprises a buffer substance selected from HEPES and phosphate at a concentration of 20 mM.

[0058] In some embodiments, The oxazolidinone liposome composition further comprises a chelating agent. In some embodiments, The oxazolidinone liposome composition further comprises a chelating agent selected from the group consisting of: deferoxamine (DFO) and EDTA. The oxazolidinone liposome composition further comprises a chelating agent selected from the group consisting of deferoxamine (DFO) and EDTA at a concentration of 0.1 to 1 mM. The oxazolidinone liposome composition further comprises a chelating agent selected from the group consisting of deferoxamine (DFO) and EDTA at a concentration of 0.5 mM.

[0059] In some embodiments, The oxazolidinone drug compound was efficiently (>95%) loaded into the extruded liposomes at an increased drug to lipid ratio (Example 51), with blood PK profiles approaching those of liposomes with a lower drug to lipid ratio (Example 53).

[0060] In some embodiments, Oxazolidinone liposome formulations can be stabilized by retaining ammonium that is displaced from the intraliposomal entrapment agent during the drug loading process (eg, by omitting a buffer exchange step).

[0061] In some embodiments, The oxazolidinone drug compound is AKG-28, and the liposome composition comprises a sulfate salt of AKG-28 formed within the liposome during the drug loading process. In some embodiments, the liposome composition is prepared by adding (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- AKG-28 liposomes are prepared by dissolving a salt form of oxazolidin-2-one (AKG-28) in a drug stock solution. In some embodiments, salts of AKG-28 are provided, including the hydrochloride salt of AKG-28. The salts of AKG-28 can be used to prepare a drug stock solution for loading AKG-28 liposomes. In some embodiments, AKG-28 ions are exchanged with ammonium displaced from an ammonium sulfate trap within the liposomes, thereby forming an AKG-28 salt within the AKG-28 liposomes.

[0062]

[0063] In some embodiments, the AKG-28 liposome composition has an AKG-28 drug / lipid ratio of 230 to 380 g / mol total phospholipids (PhL). In some embodiments, the AKG-28 liposome composition has an AKG-28 drug / lipid ratio of 230 to 290 g / mol total phospholipids (PhL). In some embodiments, the AKG-28 liposome composition has an AKG-28 drug / lipid ratio of 290 to 360 g / mol total phospholipids (PhL). In some embodiments, the AKG-28 liposome composition has an AKG-28 drug / lipid ratio of 300 to 340 g / mol total phospholipids (PhL). In some embodiments, the AKG-28 liposome composition has an AKG-28 drug / lipid ratio of about 250 g / mol total phospholipids (PhL). In some embodiments, the AKG-28 liposome composition has a drug / lipid ratio of about 330 g / mol of AKG-28 per total phospholipid (PhL). In some embodiments, the total (or combined) concentration of AKG-28 in the liposome composition is between 8 and 15 mg / ml. In some embodiments, the total concentration of AKG-28 in the liposome composition is between 9 and 11 mg / ml. In some embodiments, the ratio of encapsulated AKG-28 to total AKG-28 in the AKG-28 liposome composition is at least 90%, at least 95%, at least 97%, or at least 98%.

[0064] In some embodiments, The oxazolidinone drug compound is AKG-38, and the liposome composition comprises a sulfate salt of AKG-38 formed within the liposome during the drug loading process. In some embodiments, the liposome composition is prepared by adding (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetamido)-1,3- AKG-38 liposomes are prepared by dissolving a salt form of oxazolidin-2-one (AKG-38) in a drug stock solution. In some embodiments, salts of AKG-38 are provided, including the hydrochloride salt of AKG-38. Salts of AKG-38 can be used to prepare a drug stock solution for loading AKG-38 liposomes. In some embodiments, AKG-38 ions are exchanged with ammonium displaced from an ammonium sulfate trap within the liposomes, thereby forming an AKG-38 salt within the AKG-38 liposomes.

[0065]

[0066] In some embodiments, the AKG-38 liposome composition has a drug / lipid ratio of AKG-38 of 430 to 680 g / mol total phospholipids (PhL). In some embodiments, the AKG-38 liposome composition has a drug / lipid ratio of AKG-38 of 500 to 650 g / mol total phospholipids (PhL). In some embodiments, the AKG-28 liposome composition has a drug / lipid ratio of AKG-38 of 550 to 650 g / mol total phospholipids (PhL). In some embodiments, the AKG-38 liposome composition has a drug / lipid ratio of AKG-38 of about 450 g / mol total phospholipids (PhL). In some embodiments, the AKG-38 liposome composition has a drug / lipid ratio of AKG-38 of about 600 g / mol total phospholipids (PhL). In some embodiments, the total concentration of AKG-38 in the liposome composition is 12 to 25 mg / ml. In some embodiments, the total concentration of AKG-38 in the liposome composition is between 13.5 and 16.5 mg / ml. In some embodiments, the total concentration of AKG-38 in the liposome composition is about 15 mg / ml. In some embodiments, the total concentration of AKG-38 in the liposome composition is about 20 mg / ml. In some embodiments, the ratio of encapsulated AKG-38 to total AKG-38 in the AKG-38 liposome composition is at least 90%, at least 95%, at least 97%, or at least 98%.

[0067] exist During accelerated stability testing of oxazolidinone liposome formulations, cholesterol and HSPC degradation was observed in certain AKG-28 and AKG-38 liposome compositions (Examples 54, 65).Figure 17 is a scheme showing the two major cholesterol oxidative degradation products, 7-hydroxycholesterol (α- and β-isomers) and 7-ketocholesterol. Figure 18 This is a scheme showing the breakdown of distearoylphosphatidylcholine (DSPC) into lysophosphatidylcholine (lyso-PC) and stearic acid. Hydrogenated soy phosphatidylcholine (HSPC) is a 1,2-diacyl-sn-glycero-phosphocholine in which the 1st and 2nd acyl chain positions are saturated fatty acids C16 to C22, primarily stearic acid (C18) and palmitic acid (C16). Distearoylphosphatidylcholine is the largest component of HSPC.

[0068] However, in accelerated stability studies, in certain unpurified buffered liposome formulations of AKG-28 prepared without a buffer exchange step, the formation of HSPC degradation products lyso-PC, stearic acid, and palmitic acid was not detected at the point when the formulation had already shown HSPC degradation after buffer exchange (Example 54). Prior to the drug loading step, the liposome extracellular medium in these formulations had increased levels of ammonium displaced from the ammonium sulfate trap contained within the liposomes (displaced ammonium). In some embodiments, the AKG-28 liposomes may contain displaced ammonium in an amount equal to or greater than the molar equivalent of the AKG-28 drug loaded into the liposomes. Similarly, in the absence of post-drug loading buffer exchange, HSPC degradation was minimized during accelerated stability testing in AKG-38 liposomes (Example 55).

[0069] The addition of a deferoxamine chelator to the liposome excipient buffer of AKG-28 and AKG-38 liposome compositions unexpectedly prevented the degradation of cholesterol for at least 3 months under accelerated stability testing at 37°C, wherein the liposome compositions contained more than 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids (Example 56). However, the addition of DFO, EDTA, and DTPA chelators to the drug stock prior to drug loading did not prevent lipid degradation in AKG-28 and AKG-38 liposomes containing HSPC and more than 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids (Example 57). In the absence of chelators (DFO or EDTA), oxidative degradation of cholesterol was observed in AKG-28 and AKG-38 liposome formulations (Examples 58, 67).

[0070] In some embodiments, the liposome composition is stable to the degradation of liposome lipid components, and pH>7.0. It was found that the rate of lipid degradation, particularly the degradation of cholesterol, depends on the liposome formulation pH, and is lower when the pH is higher than 7.0 (Example 65). In some embodiments, the pH of the liposome composition is at least 7.1, at least 7.2, or at least 7.3, and is no more than pH 8.0, no more than pH 7.7, or no more than pH 7.6. In some embodiments, the cholesterol degradation degree after 3 months at 37°C is less than 10%, less than 5%, or less than 1% of the total cholesterol. In some embodiments, the phospholipid degradation degree after 6 weeks at 37°C is less than 10%, less than 5%, or less than 1% of the total phospholipids. In some embodiments, the phospholipid is phosphatidylcholine. In some embodiments, the phospholipid is HSPC, and the pH is pH 7.3 to 7.6.

[0071] In some embodiments, the liposome composition comprises cholesterol and is stable to cholesterol degradation, with the degree of cholesterol degradation after 3 months at 37° C. being less than 10%, less than 5%, or less than 1% of the total cholesterol. It is important to avoid cholesterol degradation because the products of cholesterol degradation are toxic and may cause vascular endothelial damage (Rong et al., Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, Vol. 18, p. 1885-1894; Sevanian et al., J Lipid Res, 1995, Vol. 36, p. 1971-1986). In some embodiments, the liposome composition comprises a chelating agent. In some embodiments, the chelating agent is a chelating agent known to be tolerated in humans. In some embodiments, the chelating agent is deferoxamine (Desferrioxamine, DFO), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), nitrilotriacetic acid (NTA), ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), N-(2-hydroxyethyl)ethylenediamine-N,N',N'-triacetic acid (HEDTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), including pharmaceutically acceptable salts thereof. In some embodiments, the chelating agent is present in the composition at a concentration of at least 0.01 mM, at least 0.05 mM, at least 0.1 mM, at least 0.2 mM, or at least 0.5 mM, and no more than 1 mM, no more than 2 mM, no more than 5 mM, or no more than 10 mM. In some embodiments, the chelator is deferoxamine or deferoxamine mesylate, and the chelator concentration is about 0.5 mM.

[0072] In some embodiments, the external medium of the liposome composition has less than 0.5 mEq / L (milligram-equivalents / liter) of ammonium or substituted ammonium. In some embodiments, the liposome composition contains ammonium or substituted ammonium in the liposome external medium at a concentration of at least 10 mEq / L, at least 15 mEq / L, or at least 20 mEq / L, and no more than 200 mEq / L, no more than 150 mEq / L, no more than 100 mEq / L, no more than 80 mEq / L, or no more than 60 mEq / L. In some embodiments, the liposome composition contains ammonium or substituted ammonium at a concentration of at least 10 mEq / L, at least 15 mEq / L, or at least 20 mEq / L, and no more than 200 mEq / L, no more than 150 mEq / L, no more than 100 mEq / L, no more than 80 mEq / L, or no more than 60 mEq / L in the extraliposome medium, and is stable to phospholipid degradation, with phospholipid degradation of less than 10%, less than 5%, or less than 1% of total phospholipids after 6 weeks at 37°C. In some embodiments, the phospholipid is phosphatidylcholine. In some embodiments, the phospholipid is HSPC, and the ammonium salt is ammonium chloride, ammonium sulfate, or a combination thereof at an ammonium concentration of 10 to 80 mM or 15 to 60 mM. In some embodiments, the normality of ammonium in the external medium of the liposome composition is within 90% to 110% of the normality of the encapsulated drug in the drug loading step, the normality being the concentration expressed in gram-equivalents / L (eq / L).

[0073] In some embodiments, the liposome composition comprises an encapsulated compound of Formula 1b at a drug / lipid (DL) ratio of 300 to 350 g / mol PhL. In some embodiments, the liposome composition comprises an encapsulated compound of Formula 1b at a DL ratio of 300 to 350 g / mol PhL and is characterized by an in vivo drug release half-life in the blood of CD-1 mice of greater than 80 hours, greater than 200 hours, or greater than 300 hours.

[0074] In some embodiments, the liposome composition comprises encapsulated compound of Formula 1c at a DL ratio of 500 to 650 g / mol PhL.

[0075] In some embodiments, the liposome composition comprises liposomes in an aqueous medium, the liposomes being composed of HSPC, cholesterol, and PEG (2000) -DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1, the liposomes being unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm or 100 to 130 nm and a polydispersity index of less than 0.15 or less than 0.10, the liposomes comprising a drug / lipid (DL) ratio of 230 to 280 g / mol phospholipid (PhL), 290 to 360 g / mol PhL, 300 to 340 g / mol PhL, about 250 g / mol PhL, or about 330 g / mol In some embodiments, the composition comprises an encapsulated compound AKG-28 of 8 to 15 mg / ml or 9 to 11 mg / ml, and the total concentration of AKG-28 in the composition is 8 to 15 mg / ml or 9 to 11 mg / ml, and the ratio of encapsulated AKG-28 to total AKG-28 in the composition is at least 90%, at least 95%, at least 97%, or at least 98%. In some embodiments, the aqueous medium comprises sodium chloride and, optionally, ammonium ions. In some embodiments, the osmolarity of the aqueous medium is 270 to 330 mOsmol / kg or 270 to 310 mOsmol / kg. In some embodiments, the ammonium concentration in the aqueous medium is 20 to 60 mM, and the sodium chloride concentration is 50 to 80 mM. In some embodiments, the ammonia concentration in the aqueous medium is less than 0.5 mM, and the sodium chloride concentration is 130 to 150 mM. In some embodiments, the composition further comprises a buffering substance to bring the pH of the aqueous medium to about 7.3 to 7.7, or about pH 7.5. In some embodiments, the buffer substance is HEPES or phosphate at a concentration of 5 to 50 mM, or about 20 mM. The composition may also contain a chelating agent, which is deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM, or about 0.5 mM. In some embodiments, the liposome composition is storage stable.

[0076] In some embodiments, the liposome composition comprises liposomes in an aqueous medium, the liposomes being composed of HSPC, cholesterol, and PEG(2000)-DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1, the liposomes being unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm or 100 to 130 nm and a polydispersity index of less than 0.15 or less than 0.10, the liposomes comprising a drug / lipid ratio of 430 to 480 g / mol phospholipid (PhL), 500 to 650 g / mol PhL, 550 to 650 g / mol PhL, about 450 g / mol PhL, or about 600 g / mol In some embodiments, the encapsulated compound AKG-38 is present in an amount of 12 to 25 mg / ml, 13.5 to 16.5 mg / ml, about 15 mg / ml, or about 20 mg / ml, and the ratio of encapsulated AKG-38 to total AKG-38 in the composition is at least 90%, at least 95%, at least 97%, or at least 98%. In some embodiments, the aqueous medium comprises sodium chloride and, optionally, ammonium ions. In some embodiments, the osmolarity of the aqueous medium is 270 to 330 mOsmol / kg or 270 to 310 mOsmol / kg. In some embodiments, the ammonium concentration in the aqueous medium is 20 to 60 mM, and the sodium chloride concentration is 50 to 80 mM. In some embodiments, the ammonia concentration in the aqueous medium is less than 0.5 mM, and the sodium chloride concentration is 130 to 150 mM. In some embodiments, the composition further comprises a buffering substance to bring the pH of the medium to about 7.3 to 7.7, or about pH 7.5. In some embodiments, the buffering substance is HEPES or phosphate at a concentration of 5 to 50 mM, or about 20 mM. The composition may further comprise a chelating agent, which is deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM, or about 0.5 mM. In some embodiments, the liposome composition is storage stable.

[0077] In some embodiments, the liposome composition is stable against degradation of the encapsulated compound when stored. In some embodiments, the degradation of the encapsulated compound (as measured by a decrease in compound purity expressed in percentage points) is less than 5%, less than 4%, less than 3%, less than 2%, or about 1% or less when stored under accelerated degradation conditions (37°C) after three months of storage. In some embodiments, the degradation of the encapsulated compound (as measured by a decrease in the total concentration of the intact compound in the liposome composition) is less than 20%, less than 10%, or less than 5% when stored under accelerated degradation conditions (37°C) after three months of storage. In some embodiments, the encapsulated compound is AKG-28 or AKG-38. Thus, a liposomal composition of AKG-38 stored at 37°C for three months showed a significantly low decrease in AKG-38 purity from 98.99% to 98.07% (0.92 percentage points), and a low overall decrease in overall AKG-38 concentration from 19.9 mg / ml to 19.06 mg / ml (4.2% decrease) (Example 68). BRIEF DESCRIPTION OF THE DRAWINGS

[0078] Figure 1 is a graph showing the effect of pH on liposome loading of compounds AKG-3, AKG-5, and AKG-16.

[0079] Figure 2A and Figure 2B is a graph showing the encapsulation of compounds AKG-3, AKG-5, and AKG-16 into liposomes with the aid of TEA-SOS capture agent at different drug to lipid (DL) ratios. Figure 2A Shown is the effect of added drug / lipid (DL0) ratio (in grams of drug per moles of liposomal phospholipid (PhL)) on liposome payload, expressed as the post-loading drug / lipid ratio (DL). Figure 2B Shown is the effect of the DL0 ratio (drug / lipid input ratio) on the liposome loading efficiency, calculated as the percentage of DL0 after loading relative to DL0.

[0080] Figure 3A 、 Figure 3B 、 Figure 3C ,and Figure 3D is a graph showing the encapsulation of compounds AKG-3, AKG-5, and AKG-16 into liposomes using 0.5 M ammonium sulfate as a capture agent at different DL ratios. Figure 3A Shown is the effect of the DL0 ratio on the liposomal payload of AKG-5 and AKG-16. Figure 3B Shown is the effect of the DL0 ratio on the liposome loading efficiency of AKG-5 and AKG-16. Figure 3CShown is the effect of the DL0 ratio on the liposomal payload of AKG-3. Figure 3D Shown is the effect of the DL0 ratio on the liposome loading efficiency of AKG-3.

[0081] Figure 4A and Figure 4B is a graph showing the encapsulation of AKG-28 and AKG-38 with TEA-SOS and ammonium sulfate as capture agents at different DL0 ratios. Figure 4A The effect of the DL0 ratio on liposome payload is shown. Figure 4B The effect of the DL0 ratio on the loading efficiency is shown.

[0082] Figure 5A 、 Figure 5B 、 Figure 5C ,and Figure 5D is shown from the encapsulated compound AKG-28 ( Figure 5A 、 Figure 5C ) and AKG-38( Figure 5B 、 Figure 5D ) liposomes after exposure to mouse (denoted as "mouse") or human (denoted as "human") plasma in vitro, as described in Example 19 below. The liposomes contained 5 mol% PEG (2000) -DSPE (denoted as "DSPE") or PEG-DSG (denoted as "DSG"). Capture agent: 0.5 M ammonium sulfate (AS) ( Figure 5A 、 Figure 5B ), 1N triethylammonium sucrose octasulfate (TEA-SOS) ( Figure 5C 、 Figure 5D ).

[0083] Figure 6 The numbered ring structures of compounds of formula (I) are shown.

[0084] Figure 7 Figure 2 is a graph showing the plasma concentration versus time profile of total drug in Sprague-Dawley rats following administration of a single intravenous dose (IV x 1) of Ls-AKG28 at 10 mg / kg (diamonds), 20 mg / kg (squares), and 40 mg / kg (circles). For comparison, the plasma concentration versus time profile of 50 mg / kg linezolid (single oral dose, PO x 1) in 5% methylcellulose (pH 3 to 4) is also included. The mean and SD concentrations for each time point are shown.

[0085] Figure 8Figure 2 is a graph showing the plasma concentration versus time profile of total drug in Sprague-Dawley rats following administration of a single intravenous dose (IV x 1) of Ls-AKG38 at 20 mg / kg (diamonds), 40 mg / kg (squares), and 80 mg / kg (diamonds). For comparison, the plasma concentration versus time profile of 50 mg / kg linezolid (single oral dose, PO x 1) in 5% methylcellulose (pH 3 to 4) is also included. The mean and SD concentrations for each time point are shown.

[0086] Figure 9A 、 Figure 9B ,and Figure 9C Figures show the results of IV x 1 administration of 10 mg / kg ( Figure 9A )、20mg / kg( Figure 9B ) and 40mg / kg( Figure 9C ) after Ls-AKG28 in Sprague-Dawley rats. The mean and SD concentrations for each time point are shown.

[0087] Figure 10A 、 Figure 10B and Figure 10C Figure 2 shows the effect of IV x 1 administration of 20 mg / kg ( Figure 10A )、40mg / kg( Figure 10B ) and 80mg / kg( Figure 10C ) in Sprague-Dawley rats after administration of Ls-AKG38. The mean and SD concentrations for each time point are shown.

[0088] Figure 11A 、 Figure 11B ,and Figure 11C is a graph showing the effect of liposomal AKG-28 ( Figure 11A ) and liposomal AKG-38( Figure 11B ) lipids (labeled with irreplaceable DiIC18(3)-DS), the plasma concentration profiles of both drugs versus time, and the changes in the plasma drug / lipid ratio (a measure of the rate of drug release from liposomes) for both Ls-AKG28 and Ls-AKG38 in CD-1 mice ( Figure 11C ). The mean and SD for each time point are shown.

[0089] Figure 12Figure 2 is a graph comparing plasma drug concentrations expressed as % injected dose for Ls-AKG28 and Ls-AKG38 for various formulations of liposomal AKG-28 and liposomal AKG-38 after dosing at week 1 and week 4. Mice were injected once / week for a total of 4 injections with the indicated doses and formulations.

[0090] Figure 13A is a graph showing the effect of increasing doses of Ls-AKG28 on body weight in female CD-1 mice over time.

[0091] Figure 13B is a graph showing the effect of increasing doses of Ls-AKG38 on body weight in female CD-1 mice over time.

[0092] Figure 13C are graphs showing the effects of Ls-AKG28 and Ls-AKG38 in combination with BP or BPM on hematological (RBC, HTC, PLT, WBC) and blood biochemistry (ALT, AST) parameters in female CD-1 mice.

[0093] Figure 13D is a heat map showing the effect of monotherapy with Ls-AKG28 or Ls-AKG38 on histopathological findings in female CD-1 mice.

[0094] Figure 14A is a graph showing the effect of Ls-AKG28 in combination with bedaquiline and pretomanid (BP) or bedaquiline, pretomanid, and moxifloxacin (BPM) on body weight in female CD-1 mice over time.

[0095] Figure 14B is a graph showing the effect of Ls-AKG38 combined with BP or BPM on body weight in female CD-1 mice over time.

[0096] Figure 14C are graphs showing the effects of Ls-AKG28 and Ls-AKG38 in combination with BP or BPM on hematological (RBC, HTC, PLT, WBC) and blood biochemistry (ALT, AST) parameters in female CD-1 mice.

[0097] Figure 14D is a heat map showing the effects of Ls-AKG28 and Ls-AKG38 combined with BP or BPM on histopathological findings in female CD-1 mice.

[0098] Figure 15Ais a graph showing the changes in body weight over time in female CD-1 mice treated with Ls-AKG28 injected at 50 mg / kg twice a week (2 qw) or 100 mg / kg once a week (1 qw), alone or in combination with BP.

[0099] Figure 15B is a graph showing changes in body weight of female CD-1 mice treated with Ls-AKG38 injected at 100 mg / kg 2 qw or 200 mg / kg 1 qw, alone or in combination with BP.

[0100] Figure 15C are graphs showing hematological and blood biochemical parameters in female CD-1 mice treated with Ls-AKG28 (at 50 mg / kg for 2 qw or at 100 mg / kg for 1 qw) or Ls-AKG28 (at 100 mg / kg for 2 qw or at 200 mg / kg for 1 qw) alone or in combination with BP.

[0101] Figure 15D is a heat map showing histopathological results in female CD-1 mice treated with Ls-AKG28 (at 50 mg / kg for 2 qw or at 100 mg / kg for 1 qw) or Ls-AKG28 (at 100 mg / kg for 2 qw or at 200 mg / kg for 1 qw) alone or in combination with BP.

[0102] Figure 16A is a graph showing the effect of Ls-AKG28 on body weight over time in male Sprague-Dawley rats treated chronically for a total of eight weeks.

[0103] Figure 16B is a graph showing the effect of Ls-AKG38 on body weight over time in male Sprague-Dawley rats treated chronically for a total of eight weeks.

[0104] Figure 17 is a scheme showing the two major cholesterol oxidative degradation products, 7-hydroxycholesterol (α- and β-isomers) and 7-ketocholesterol.

[0105] Figure 18 This is a scheme showing the breakdown of distearoylphosphatidylcholine (DSPC) into lysophosphatidylcholine and stearic acid. Hydrogenated soy phosphatidylcholine (HSPC) is a 1,2-diacyl-sn-glycero-phosphocholine in which the 1st and 2nd acyl chain positions are saturated fatty acids C16 to C22, primarily stearic acid (C18) and palmitic acid (C16). Distearoylphosphatidylcholine is the largest component of HSPC.

[0106] Figure 19Ais a graph showing cholesterol degradation data of AKG-38 liposome compositions at room temperature for 12 weeks.

[0107] Figure 19B is a graph showing cholesterol degradation data of AKG-28 liposome compositions at room temperature for 12 weeks.

[0108] Figure 20A 、 Figure 20B and Figure 20C Figure 5 is a graph showing the plasma concentration versus time profiles of AKG-28 drug, liposomal lipids (labeled with non-exchangeable DiIC18(3)-DS), and plasma drug to lipid ratio for liposomal AKG-28 batches Ls-338 (sample 71), Ls-339 (sample 74), and Ls-340S (sample 76) following a single intravenous injection in CD-1 mice. Liposome characteristics are given in Example 59. Data points are the average of three animals.

[0109] Figure 21 is a graph showing cholesterol degradation data for AKG-38 liposome composition batch Ls-371 (Example 67) upon storage at 37°C in the presence of varying concentrations of deferoxamine.

[0110] Figure 22 is a graph showing HSPC degradation data for AKG-38 liposome composition lot Ls-371 (Example 67) when stored at 37°C in the presence of different concentrations of deferoxamine.

[0111] Figure 23 is a graph showing the pH change of AKG-38 liposome composition batch Ls-371 (Example 67) upon storage at 37°C in the presence of different concentrations of deferoxamine.

[0112] Figure 24 Synthesis Scheme-1 according to some embodiments of the present disclosure is shown.

[0113] Figure 25 Shown is Synthesis Scheme-2 according to some embodiments of the present disclosure.

[0114] Figure 26 Shown is Synthesis Scheme-3 according to some embodiments of the present disclosure.

[0115] Figure 27 Shown is Synthetic Scheme-4 according to some embodiments of the present disclosure.

[0116] Figure 28 Shown is a synthetic scheme-5 according to some embodiments of the present disclosure. DETAILED DESCRIPTION

[0117] This disclosure describes In some embodiments, the liposome composition comprises a compound of formula (I) encapsulated in lipid vesicles. In some embodiments, the liposome composition comprises a pharmaceutically acceptable salt thereof. Oxazolidinone compounds and lipid vesicles containing phospholipids and cholesterol. In some embodiments, the liposome composition comprises as a pharmaceutically acceptable salt thereof Oxazolidinone compounds and lipid vesicles comprising phospholipids and greater than 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition. In some embodiments, the liposome composition comprises a pharmaceutically acceptable salt thereof. Oxazolidinone compounds and lipid vesicles comprising phospholipids and greater than about 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition. In some embodiments, the liposome composition comprises a pharmaceutically acceptable salt thereof. Oxazolidinone compounds and lipid vesicles comprising phospholipids and 50 to 65 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition. In some embodiments, the liposome composition comprises a pharmaceutically acceptable salt thereof. Oxazolidinone compounds and lipid vesicles comprising phospholipids and 50 to 60 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition. In some embodiments, the liposome composition comprises a pharmaceutically acceptable salt thereof. Oxazolidinone compounds and lipid vesicles comprising phospholipids and 50 to 55 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition. In some embodiments, the liposome composition comprises a pharmaceutically acceptable salt thereof. Oxazolidinone compounds and lipid vesicles comprising phospholipids and 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition. In some embodiments, the liposome composition comprises a pharmaceutically acceptable salt thereof. An oxazolidinone compound and a lipid vesicle comprising a phospholipid and 55 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition.

[0118] In some embodiments, there is provided Oxazolidinone liposome compositions characterized by reduced degradation of phospholipids or cholesterol during storage. In some embodiments, The pH of the oxazolidinone liposome composition is about 7 or greater (e.g., 7 to 8) and comprises phospholipids and greater than 50 mol% cholesterol (e.g., 50 to 65 mol%, 50 to 60 mol%, 50 to 55 mol%, about 50 mol%, or about 55 mol%) relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition. In some embodiments, The oxazolidinone liposome composition further comprises a chelating agent (e.g., DFO or EDTA) in combination with the phospholipids and greater than 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition. In some embodiments, the pH is 7 to 8 (including 7 to 7.7, 7.1 to 7.7, 7.3 to 7.7, and about 7.5). The oxazolidinone liposome composition further comprises a chelating agent, such as DFO or EDTA, in combination with the phospholipids and greater than 50 mol % cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition. The oxazolidinone liposome composition further comprises extraliposomes combined with vesicles comprising phospholipids and greater than 50 mol % cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition. In some embodiments, The oxazolidinone liposome composition further comprises Extraliposomal ammonium generated during loading of the oxazolidinone drug into liposomal vesicles comprising phospholipids and greater than 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposome composition.

[0119] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the compositions and methods of the disclosure.

[0120] definition

[0121] For convenience, certain terms employed in the specification, examples, and appended claims are collected here. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0122] As used herein, the following terms and phrases are intended to have the following meanings:

[0123] As used herein, a noun not qualified by a quantifier refers to one or more than one (ie, at least one) grammatical object. For example, "element" means one element or more than one element.

[0124] As used herein, the terms "comprising" or "including" are used to indicate that compositions, methods, and their corresponding components are present in a given embodiment, but are also open ended and include unspecified elements.

[0125] As used herein, the term "consisting essentially of refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristics of the embodiment of the disclosure.

[0126] The term "consisting of refers to the compositions, methods, and corresponding components thereof as described herein, excluding any elements not recited in this description of the embodiment.

[0127] The term "comprising" as used in this specification includes "consisting of" and "consisting essentially of.

[0128] If "as mentioned above" or "mentioned above" or "above" is mentioned in this specification, it refers to any present disclosure in this specification on any of the preceding pages.

[0129] If reference is made in this specification to "as described herein", "described herein", "provided herein" or "mentioned in this text" or "shown herein", this refers to any of the present disclosure within this specification on any of the preceding or following pages.

[0130] As used herein, the term "about" means acceptable variations within 20%, within 10%, and within 5% of the stated value. In certain embodiments, "about" can mean variations of + / - 1%, 2%, 3%, 4%, 5%, 10%, or 20%.

[0131] The term "effective amount" as used herein with respect to a compound or composition means an amount of the active compound (also referred to herein as an active agent or drug) sufficient to produce a bactericidal or bacteriostatic effect. In one embodiment, the effective amount is a "therapeutically effective amount," meaning an amount of the active compound sufficient to alleviate the symptoms of the bacterial infection being treated.

[0132] As used herein, the term "subject" (or, alternatively, "patient") refers to an animal, preferably a mammal, most preferably a human, receiving prophylactic or therapeutic treatment.

[0133] The term "administer" as used herein includes all modes of introducing a compound or pharmaceutical composition into an object in need thereof, including but not limited to oral, intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, inhalation, buccal, intraocular, sublingual, vaginal, rectal, etc. The administration of a compound or composition is suitably parenteral. For example, a compound or composition can be preferably administered intravenously, but can also be administered intraperitoneally or by inhalation, similar to the liposomal amikacin (amikacin) currently used clinically for the treatment of Mycobacterium avium. (See Shirley et al., Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease. Drugs. 2019 Apr; 79 (5): 555-562).

[0134]

[00146] The terms "treat" and "treatment" are used herein to refer to therapeutic or preventative measures, such as those described herein.

[0135] The term "synergistic effect" as used herein means that the effect achieved by the combined use of compounds is greater than the sum of the effects produced by the individual compounds, ie, greater than the effect predicted based on separate administration of the two active ingredients.

[0136] The term "pharmaceutically acceptable salt" refers to the relatively non-toxic, inorganic or organic acid addition salts of compounds of the present disclosure that possess the desired pharmacological activity.

[0137] The term "alkyl" means a saturated carbon chain, which may be straight or branched, or a combination thereof, unless otherwise defined. Some examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, pentyl, hexyl, heptyl, octyl, and the like.

[0138] The term "aminoalkyl" means an alkyl group in which at least one carbon of the alkyl carbon chain forms a bond to an amino group, wherein the amino group is a primary amino group, a monoalkyl-substituted (secondary) amino group, a dialkyl-substituted (tertiary) amino group, or an alkyl-substituted amino group in which the amine nitrogen atom forms a heterocyclic ring with the alkyl chain substituted with hydrogen.

[0139] The term "liposome" means a vesicle composed of a bilayer (monolayer) and / or a concentric series of multiple bilayers (multilayers) separated by aqueous compartments formed by amphiphilic molecules (e.g., phospholipids) surrounding a central aqueous compartment. In liposomal drug products, the drug substance is typically contained in the liposome. Typically, water-soluble drugs are contained in the aqueous compartment, while hydrophobic drugs are contained in the lipid bilayer of the liposome. The release of the drug from the liposomal formulation and other characteristics (e.g., liposome clearance and circulation half-life) can be improved by the presence of polyethylene glycol and / or cholesterol or other potential additives in the liposome.

[0140] "Unilamellar liposomes," also known as "unilamellar vesicles," are liposomes that contain a lipid bilayer membrane that defines a single, closed aqueous compartment. The bilayer membrane comprises two layers of lipids; an inner layer and an outer layer (the leaflet). The lipid molecules in the outer layer are oriented with their hydrophilic ("heads") portions facing the external aqueous environment and their hydrophobic ("tails") portions pointing downwardly toward the interior of the liposome. The inner layer of lipids is directly beneath the outer layer, with the lipids oriented with their heads facing the aqueous interior of the liposome and their tails toward the tails of the outer layer of lipids.

[0141] "Multilamellar liposomes," also known as "multilamellar vesicles," contain more than one lipid bilayer membrane defining more than one enclosed aqueous compartment. The membranes are arranged concentrically so that different membranes are separated by aqueous compartments.

[0142] The terms "encapsulate" and "encapsulate" as used herein refer to The oxazolidinone agent is incorporated into or associated with the liposomes.

[0143] The terms "DL," "DL ratio," "D / L," or "D / L ratio" are used interchangeably and refer to the ratio of drug to liposomal lipid. Unless otherwise indicated, it is expressed as grams of drug per mole of liposomal phospholipid (PhL).

[0144] The term "mol%" with respect to cholesterol refers to the molar amount of cholesterol expressed as a percentage relative to the sum of the molar amounts of cholesterol and non-PEGylated phospholipids. For example, "55 mol% cholesterol" in a liposome comprising cholesterol and HSPC refers to a composition of 55 mol parts cholesterol / 45 mol parts HSPC.

[0145] The term "mol%" with respect to PEG-lipid refers to the ratio of the molar amounts of PEG-lipid to non-PEGylated phospholipid expressed as a percentage. For example, "5 mol.% PEG-DSPE" in a liposome comprising HSPC and PEG-DSPE means a composition having 5 mol. parts PEG-DSPE per 100 mol. parts HSPC.

[0146] The terms "sucrose octasulfate," "thiosugar ester," and "sucrose sulfate" refer to the same compound, sucrose octasulfate or its anion, and are used interchangeably herein.

[0147] The symbols "Ac," "Me," and "Et," as seen in chemical formulae, refer to an acetyl group (CH3CO), a methyl group (CH3), and an ethyl group (C2H5), respectively.

[0148] The term "free base concentration" or "FB concentration" is used to represent the mass concentration of a salified compound in its free base form. By default, for a compound synthesized and isolated in salt form (e.g., the hydrochloride of a dihydrochloride), the concentration or ratio based on mass (e.g., mg / ml or g / mol phospholipids) is expressed as the concentration or ratio of the salt form. However, when stated, the concentration of a compound isolated in salt form (e.g., AKG-28 dihydrochloride) is also expressed as the equivalent concentration (FB concentration) of the compound as an anhydrous free base. In order to obtain the FB concentration, the calculated molecular weight of the compound in free base form is divided by the calculated molecular weight of the salt form, and the concentration is multiplied by the factor. For example, the molecular weight of AKG-28 as a free base is 426.46, and the molecular weight of the dihydrochloride form (wherein the compound is isolated) is 499.37. Therefore, the factor used to calculate the AKG-28 concentration based on the FB is 426.46 / 499.37 = 0.854, so that, for example, the FB concentration of 10 mg / ml of AKG-28 dihydrochloride is 8.54 mg / ml. When the compound also contains a known amount of water (e.g., AKG-28 dihydrochloride monohydrate), correction is also made for the known water content. The mass concentration of a compound isolated as the free base (e.g., AKG-38) is always expressed as the FB concentration.

[0149] Although the mass concentrations and ratios disclosed herein depend on the salt form of the compound, the concentrations and ratios of the compound can be expressed in molar units independent of its salt form. To convert the mass concentration or amount of, for example, AKG-28 cited herein (based on its isolated dihydrochloride salt synthetic product form) into a molar concentration, the mass concentration or amount is divided by the molecular weight of AKG-28 dihydrochloride salt of 499.4 g / mol. Thus, the DL ratio of AKG-28 in a liposome composition cited herein as 330 g / mol PhL is expressed as 330 / 499.4 = 0.661 mol / mol PhL; the concentration of AKG-28 cited as 10 mg / mL is expressed as 10 / 499.4 = 20.0 mM. When the concentration is quoted based on the free base of the compound, the mass amount and concentration are divided by the molecular weight of the free base of the compound. Thus, the DL ratio of AKG-38 in a liposome composition cited herein as 600 g / mol PhL is expressed as 600 / 468.5 = 1.281 mol / mol PhL, with AKG-38 isolated from synthesis as a free base with a molecular weight of 468.5. Thus, a concentration of AKG-38 cited as 20 mg / mL is expressed in molar terms as 20 / 468.5 = 42.7 mM.

[0150] Various aspects and embodiments are described in further detail in the following subsections.

[0151] Compound

[0152] In some embodiments, there is provided a Liposomal compositions of oxazolidinone compounds.

[0153] Oxazolidinone is a synthetic antibiotic that exerts its function by inhibiting protein synthesis. Linezolid (LZD) is a drug that exhibits antibacterial activity against Mycobacterium tuberculosis (M. tuberculosis). However, LZD administration can lead to serious side effects such as anemia, thrombocytopenia, and peripheral neuropathy. Tedizolid is a dapoxetine that has been shown to inhibit Gram-positive bacteria. Oxazolidinone compounds. Although experience with long-term administration of tedizolid phosphate (such as required for the treatment of tuberculosis) is limited compared with the extensive experience with linezolid, the side effects of tedizolid phosphate are similar but generally less severe than those observed with linezolid.

[0154] Some aspects of this disclosure relate to Compounds of aminoalkyl derivatives of oxazolidinone (see Figure 6 In some embodiments, the compound has the following chemical formula (I) and its pharmaceutically acceptable salts:

[0155]

[0156] Wherein R2 is an amine (NH2) or an acetamide (NHCOCH3),

[0157] wherein R1 is a tetrazole ring substituted with an aminoalkyl group at the 2' position.

[0158] In some embodiments, aminoalkyl is dimethylaminoalkyl. In some embodiments, Aminoalkyl derivatives of oxazolidinone compounds are included in An amine or acetamide group at the R2 position of the oxazolidinone ring and a dimethylaminoethyl group on the tetrazole ring.

[0159] In other embodiments, the compound has the following chemical formula (I) and pharmaceutically acceptable salts thereof:

[0160]

[0161] wherein R2 is an amine (NH2) or an acetamide (NHCOCH3), and

[0162] wherein R1 is a tetrazole ring substituted with an aminoalkyl group.

[0163] As described in Example 1, the chemical structure of Table 1 below was synthesized. Aminoalkyl derivatives of oxazolidinone compounds.

[0164] The compounds of the present disclosure may exist in free form (e.g., as a free base, or as a free acid, or as a zwitterion), or may exist in salt form. The salt may be any salt, which is an organic or inorganic addition salt or co-crystal, in particular any pharmaceutically acceptable organic or inorganic addition salt or co-crystal commonly used in pharmacy. It should be understood that a chemical formula showing a compound in a particular salt form or ionic form also discloses the compound in its undissociated free base (or free acid) form.

[0165] The present disclosure encompasses all stereoisomeric forms of the compounds. In some embodiments, the compounds of Table 1 below are substantially pure (i.e., at least 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, for example 100%).

[0166] Table 1

[0167]

[0168]

[0169]

[0170]

[0171] In some embodiments, the compound has the following formula:

[0172]

[0173] In some embodiments, the compound has the following formula:

[0174]

[0175] In some embodiments, the compound of Formula 1b is crystallized from aqueous ethanol.In some embodiments, the compound of Formula 1b is in the form of the dihydrochloride salt or the dihydrochloride monohydrate.

[0176] In some embodiments, the compound has the following formula:

[0177]

[0178] In some embodiments, the compound has the following formula:

[0179]

[0180] In some embodiments, the compound has the following formula:

[0181]

[0182] Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts thereof useful for treating mycobacterial infections. In some embodiments, the compound has formula 1a, 1b, 1c, 1d, or 1e. In some embodiments, the compound has formula 1b. In some embodiments, the minimum inhibitory concentration (MIC) of the compound of formula (I) (e.g., against Mycobacterium tuberculosis) is 0.1 μg / ml to 1 μg / ml, 0.25 μg / ml to 1 μg / ml, 0.5 μg / ml to 1 μg / ml, 0.1 μg / ml to 0.25 μg / ml, 0.1 μg / ml to 0.5 μg / ml, 0.25 μg / ml to 0.5 μg / ml, 0.01 μg / ml to 1 μg / ml, 0.01 μg / ml to 0.25 μg / ml, 0.01 μg / ml to 0.5 μg / ml, 0.01 μg / ml to 0.1 μg / ml. In some embodiments, the minimum inhibitory concentration (MIC) of the compound of formula (I) (e.g., against Mycobacterium tuberculosis) is less than 1 μg / ml, less than 0.25 μg / ml, or less than 0.1 μg / ml. In some embodiments, the MIC of the compound of formula (I) is 0.01 μg / ml to 0.25 μg / ml. In some embodiments, the MIC of the compound of formula (I) is 0.01 μg / ml to 0.1 μg / ml. It should be understood that the MIC value can be lower or lower than the range provided herein, depending on the bacteria.

[0183] In some embodiments for treating mycobacteria (e.g., Mycobacterium tuberculosis), the MIC of the compound (AKG-28 or AKG-38) is less than 0.1 μg / mL. In some embodiments for treating mycobacteria (e.g., Mycobacterium tuberculosis), the compound has a selectivity index (selectivity index, SI) for killing Mycobacterium tuberculosis relative to human kidney cells (VERO) of at least 1,000. In some embodiments for treating mycobacteria (e.g., Mycobacterium tuberculosis), the MIC of the compound is less than 0.1 μg / mL and has a selectivity index (SI) for killing Mycobacterium tuberculosis relative to human kidney cells (VERO) of at least 1,000. In some embodiments, the compound has the structure of AKG-28 (Formula 1b) or AKG-38 (Formula 1c). In some embodiments, the MIC is less than 0.05 μg / mL, and the selectivity index (SI-MPS) of MIC relative to mitochondrial protein synthesis inhibition in Mycobacterium tuberculosis is greater than 20, for example, for AKG-28.

[0184] In some embodiments, the compounds described herein have a 2- to 20-fold (about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20) increase in potency compared to linezolid against Mycobacterium tuberculosis.

[0185] In some embodiments for treating methicillin-resistant Staphylococcus aureus (MRSA), the MIC of the compound for MRSA strains is less than 2 μg / mL. In some embodiments for treating methicillin-resistant Staphylococcus aureus (MRSA), the IC50 of the compound for human VERO kidney cells is greater than 100 μg / mL. In some embodiments for treating methicillin-resistant Staphylococcus aureus (MRSA), the MIC of the compound for MRSA strains is less than 2 μg / mL, while the IC50 for human VERO kidney cells is greater than 100 μg / mL. In some embodiments, the compound has the structure of AKG-38 (Formula 1c), AKG-39 (Formula 1e) and AKG-40 (Formula 1d).

[0186] water solubility

[0187] In some embodiments, the compound is in salt form (e.g., hydrochloride or mesylate) and is dissolved in water with greater than 1 mg / ml and preferably greater than 10 mg / ml (and up to 1 g / ml) before being encapsulated in liposomes. Other salts before encapsulation can include but are not limited to benzenesulfonate, bitartrate, carbonate, citrate, ethanesulfonate, gluconate, glutamate, glycolate, lactate, malate, maleate, mandelate, methylsulfate, naphthylsulfonate, phosphate, propionate, salicylate, succinate, tartrate, and toluenesulfonate. In some embodiments, the compound is in hydrate or solvate or cocrystal form before being encapsulated in liposomes.

[0188] In some embodiments, the drug is entrapped inside the liposomes in the form of different salts with reduced water solubility (e.g., less than 1 mg / mL, and preferably less than 0.1 mg / mL (0.1 to 0.001 mg / mL)). Once entrapped in the liposomes, the salts of the compound include, but are not limited to, sulfates, citrates, phosphates, sulfosaccharides, or a variety of phosphorylated or sulfated polyols or polyanionic polymers. Some exemplary polyols include, but are not limited to, sucrose, erythritol, mannitol, xylitol, sorbitol, inositol, and combinations thereof. Some exemplary polyanionic polymers include, but are not limited to, copolymers of polyvinyl sulfonates, polyvinyl sulfates, polyphosphates, acrylic acid, and vinyl sulfate, and combinations thereof.

[0189] The working material of compound is prepared as follows: 1 to 1.5 equivalents of HCl in the form of 1N aqueous solution are added to an aliquot of the compound (free base) in powder form, and the mixture is vortexed until uniform. To the resulting cake or syrup, water is usually added to a final 10 mg / ml and complete dissolution is observed. In some cases, 0.95 equivalents of HCl are added to the drug in free base form, and a 20 mg / ml stock solution is prepared.

[0190] The aqueous solubility of the Compounds of the Disclosure was demonstrated by the following observations that visually clear solutions were obtained:

[0191]

[0192] These results demonstrate that the compounds provided herein have higher water solubility than the known water solubilities of:

[0193] -Linezolid (3mg / ml) (www.drugbank.ca / drugs / DB00601)

[0194]

[0195] -Sutezolid (0.237 mg / ml) (www.drugbank.ca / drugs / DB11905)

[0196]

[0197] - Tedizolid (0.382 mg / ml) (www.drugbank.ca / drugs / DB14569)

[0198]

[0199] In some embodiments, the aqueous solubility of the compounds described herein prior to encapsulation into liposomes is The amount of the oxazolidinone may be at least 5 times, at least 10 times, at least 20 times, at least 30 times, or at least 40 times that of the oxazolidinone.

[0200] The excellent aqueous solubility of the compounds described herein and their amphipathic weak base properties allow for the effective use of methods based on transmembrane gradients and intraliposome complexation (active loading) to produce liposome-encapsulated forms of these compounds with high drug / carrier (drug / lipid) ratios and pharmacokinetic properties, which are beneficial for delivering the drug to infected tissues after systemic administration of the encapsulated drug. As used herein, the pKa of amphipathic weak bases is 7 to 12, and the logP is 1 to 6. Liposomal loading properties and antimycobacterial activity.

[0201] One of the important characteristics of compounds described herein is its amphipathic weak base property, which is conducive to driving the transmembrane gradient to load these compounds into liposomes. In some embodiments, the weak base property of compounds of the present disclosure is characterized by an electrolytic dissociation constant with a pKa range of 7.0 to 12.0, 7.5 to 11.0, 7.8 to 10.5, or 8.0 to 10.0. In some embodiments, the amphipathic property of compounds described herein is characterized by a logP parameter of 0.5 to 5.0, 1.0 to 4.0, 1.0 to 3.5, or 1.0 to 3.0. Surprisingly, it has been found that certain embodiments with these favorable properties for liposome loading also have excellent antimycobacterial activity, which rivals or exceeds the activity of similar compounds in drugs of the same class, and the characteristic of the drug is less conducive to effective and stable liposome encapsulation.

[0202] Liposome composition

[0203] Disclosed are compositions and uses of the compositions for treating tuberculosis and other mycobacterial and gram-positive bacterial infections. These compositions provided herein contain highly effective and selective agents that are encapsulated with high efficiency to maximize the potential for administration of low-toxicity drugs. The invention relates to a composition comprising a oxazolidinone and a oxazolidinone, and is stable in the presence of plasma. In some embodiments, the composition is long-circulating and maintains its encapsulated drug while in circulation after intravenous administration to allow effective accumulation at the site of bacterial or mycobacterial infection. In some embodiments, when combined with the long-circulating properties and highly stable retention of the drug, high doses can be achieved, thereby allowing for reduced frequency of administration, when compared to once-daily or twice-daily administration of other drugs commonly used to treat these infections.

[0204] Disclosed herein are pharmaceutical compositions for treating bacterial infections, particularly Mycobacterium tuberculosis infections. In some embodiments, the pharmaceutical compositions comprise polyanions or sulfates containing polyanions and aminoalkyl Liposomal compositions of oxazolidinone compounds.

[0205]

[0014] Other aspects of the present disclosure relate to methods of treating bacterial infections comprising administering to a subject in need thereof a therapeutically effective amount of a liposome composition provided herein.

[0206] In some embodiments, the bacterial infection is a Mycobacterium tuberculosis infection. In some embodiments, the minimum inhibitory concentration (MIC) of the compound in the liposomal vesicle is about 0.01 μg / ml to about 0.25 μg / ml. In some embodiments, the minimum inhibitory concentration (MIC) of the compound in the liposomal vesicle is about 0.01 μg / ml to about 0.1 μg / ml.

[0207] In some embodiments, the composition comprises liposomes in a medium, wherein the intraliposomal space comprises an aqueous phase having a polyanion and a compound of formula (I). In some embodiments, the composition comprises liposomes in a medium, wherein the intraliposomal space comprises a polyanion or a sulfate containing a polyanion and compound AKG-16, AKG-28, or AKG-38. In some embodiments, the medium is an aqueous medium, wherein the major component of the medium is a compound of formula (I) and a corresponding capture agent.

[0208] The compounds of formula (I) can be entrapped within liposomes using suitable polyanions, such as sucrose octasulfate (e.g., derived from a triethylammonium sucrose octasulfate (TEA-SOS) gradient) or sulfate (e.g., derived from an ammonium sulfate gradient). Additional polyanion trapping agents include, but are not limited to, phytates, inositol hexaphosphate, polyvinylsulfonate, dextran sulfate, citrate, polyphosphate, and suramin.

[0209] The external aqueous medium is generally composed of a suitable buffer and an isotonic agent. Suitable buffers may include histidine, citrate, HEPES, MOPS, MES, TRIS, phosphate, glycine, and imidazole, borate, carbonate, and succinate. Isotonic agents may include salts (e.g., sodium chloride, potassium chloride), sucrose, glycerol, dextrose, or mannitol.

[0210] In some embodiments, the composition comprises a compound of formula (I) or formula 1a, 1b, 1c or 1d or a pharmaceutically acceptable salt thereof encapsulated with a polyanion in a predominantly unilamellar vesicle, the vesicle being formed by one or more phospholipids, sterols and optionally conjugated lipids with a hydrophilic polymer (polymer-conjugated lipid). In some embodiments, the composition may comprise a compound of formula (I) or formula 1a, 1b, 1c or 1d, or a pharmaceutically acceptable salt thereof, encapsulated with a polyanion in a unilamellar and multilamellar vesicle (e.g., having two or three layers). It should be understood that multilamellar vesicles can be cleared from the circulation faster than unilamellar vesicles. In some embodiments, the phospholipid is hydrogenated soy phosphatidyl choline (HSPC), distearoylphosphatidyl choline (DSPC), or egg sphingomyelin (ESM). As used herein, the term "phospholipid" refers to any phospholipid or combination of phospholipids capable of forming liposomes. Neutral phospholipids can include diacylphosphatidylcholine, dialkylphosphatidylcholine, sphingomyelin and diacylphosphatidylethanolamine.Phosphatidylcholine (phosphatidylcholine, PC), including those obtained from egg, soybean or other plant sources or those partially or completely synthesized or with variable lipid chain length and degree of unsaturation, is suitable for the composition of the present invention.Synthesis, semi-synthesis and natural product phosphatidylcholine, including but not limited to distearoylphosphatidylcholine (DSPC), hydrogenated soybean phosphatidylcholine (HSPC), soybean phosphatidylcholine (soy PC), egg phosphatidylcholine (egg PC), hydrogenated egg phosphatidylcholine (hydrogenated egg phosphatidylcholine, HEPC), dipalmitoylphosphatidylcholine (DPPC) and dimyristoylphosphatidylcholine (DMPC) are suitable phosphatidylcholines for the present disclosure. Charged phospholipids can include phosphatidylserine, phosphatidic acid, phosphatidylinositol, phosphatidylglycerol, cardiolipin, or head group modified lipids such as N-succinyl-phosphatidylethanolamine, N-glutaryl-phosphatidylethanolamine, and PEG-derivatized phosphatidylethanolamine.

[0211] Polymer-conjugated lipids can include poly(ethylene glycol)-conjugated (PEGylated) phospholipids (PEG-lipids), such as PEG (molecular weight 2,000) methoxy-poly(ethylene glycol)-1,2-distearoyl-sn-glycerol (PEG(2000)-distearoylglycerol, PEG-DSG), PEG (molecular weight 2,000) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine, PEG-DSPE), or PEG (molecular weight 2,000) N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)-2000]} (PEG-ceramide). The molecular weight of the PEG portion of the PEG-lipid component may also be 500 to 10,000 g / mol, 1,500 to 6000 g / mol, but is preferably about 2,000 MW. Other polymers for conjugation to lipid anchors may include poly (2-methyl-2- Oxazoline) (PMOZ), poly (2-ethyl-2- Examples of the compounds include poly(hydroxyethyl L-asparagine) (PEOZ), poly-N-vinylpyrrolidone (PVP), polyglycerol, poly(hydroxyethyl L-asparagine) (PHEA), and poly(hydroxyethyl L-glutamine) (PHEG).

[0212] In some embodiments, sterol is cholesterol. Other exemplary sterols include but are not limited to ergosterol, phytosterol (such as β-sitosterol) and hopanes. In some embodiments, the ratio of phospholipids to cholesterol is selected to provide the desired amount of liposome membrane rigidity while maintaining the leakage of fully reduced formula (I) compound from liposomes. In some embodiments, optional polymer-conjugated lipids can be added to reduce the trend of liposome aggregation. The type and amount of polymer-conjugated lipids can be selected to provide the desired level of protein binding, liposome stability and circulation time in the bloodstream. For example, liposome vesicles include phosphatidylcholine (such as DSPC or HSPC) and cholesterol in a molar ratio of about 45:55. The molar ratio of phosphatidylcholine to cholesterol can be about 60:40 to 35:65, about 50:50 to 35:65, about 50:50 to about 45:55. In particular, the liposomes may comprise vesicles composed of HSPC, cholesterol and polymer-conjugated lipids (PEG-DSG or PEG-DSPE) in a molar ratio of about 45:55:2.75, corresponding to a PEG-lipid concentration of 5 mol% relative to the phospholipid concentration. The concentration of PEG-lipid relative to (non-PEGylated) phospholipids may be 0.5 to 10 mol%, preferably a ratio of 3 to 10 mol%, and even more preferably a ratio of 4 to 8 mol%.

[0213] In some embodiments, the liposome composition provides the following: desirable pharmacokinetic properties (e.g., extended plasma half-life), measured as the percentage of the injected dose (ID) (or injected amount) remaining in the blood 6 or 24 hours after intravenous injection in immunocompetent mice; and stable encapsulation of the drug in the plasma over a 24-hour period following iv administration in mice, as determined by changes in the drug-to-lipid ratio (DL ratio). In some embodiments, at 6 hours, the percentage of drug remaining in the blood is greater than 20%, preferably greater than 30%, and most preferably greater than 40% of the injected dose. The percentage remaining in the blood after 24 hours is preferably greater than 10%, more preferably greater than 20%, of the injected dose. At 24 hours, the DL ratio is greater than 20%, preferably greater than 50%, and most preferably greater than 80% of the initially injected liposome drug. The desired liposome compositions also exhibit stable entrapment in vitro using a burst release assay in the presence of human plasma, wherein the liposomes retain greater than 50% of the drug within 20 minutes, greater than 60% of the encapsulated drug within 20 minutes, greater than 70%, preferably greater than 80%, and most preferably greater than 90%.

[0214] The liposomes of the present disclosure can be prepared by any method known in the art. See, for example, G. Gregoriadis (ed.), Liposome Technology, Vol. 1-3, 1st edition, 1983; 2nd edition, 1993; 3rd edition, 2006; CRC Press, Boca Raton, Fla. Some examples of methods suitable for preparing the liposome compositions of the present disclosure include membrane extrusion, reverse phase evaporation, sonication, solvent (e.g., ethanol) injection (including microfluidics, Y-connection and T-connection mixing), microfluidization, detergent dialysis, ether injection, and dehydration / rehydration. The size of the liposomes can be controlled by controlling the pore size of the membrane used for extrusion or the pressure used in microfluidization and by quantity or any other suitable method. In some embodiments, the desired lipid is first hydrated by thin film hydration or by ethanol injection, and then sized by extrusion through a membrane with a limited pore size (e.g., 50 nm, 80 nm, 100 nm, or 200 nm, or a combination thereof), producing liposomes with an average size of 70 to 150 nm, or 80 to 130 nm and a polydispersity index of 0.1 or less. The drug compound to be encapsulated can be added to the liposomal lipids before liposome formation, dissolved in an aqueous medium (wherein the liposome is formed by the above method), whereby the drug is isolated in the liposome. In some embodiments, the drug compound is encapsulated in the liposome using a capture agent incorporated into the internal space of the liposome (see Drummond, DC, et al. (2006) in: Liposome Technology, 3rd edition (Ed. Gregoriadis, G.) Vol. 2, p. 149-168).

[0215] In some embodiments, the method for preparing the liposome composition of the present disclosure comprises the following steps: (i) preparing liposomes comprising phospholipids, cholesterol and PEG-lipid in a medium substantially free of the capture agent and having an internal space comprising the capture agent; (ii) contacting the liposomes with the compound of the present disclosure in an aqueous medium to achieve encapsulation of the compound in the liposomes; (iii) removing unencapsulated compounds; and (iv) providing the liposomes in a physiologically acceptable medium suitable for parenteral use. In some embodiments, when the encapsulation efficiency of step (ii) is sufficiently high, typically >95%, >97% or >99%, step (iii), i.e., removing unencapsulated compounds, is omitted.

[0216] In some embodiments, a method of producing liposomes having a compound therein comprises the steps of: (a) preparing liposomes comprising a capture agent comprised of an ammonium or substituted ammonium salt of a polyanion, (b) subsequently removing the capture agent from outside the liposomes to form an electrochemical gradient across the membrane, and (c) contacting the liposomes with the compound under conditions effective for the compound to enter the liposomes and allow a corresponding amount of ammonia or substituted ammonia to exit the liposomes (thereby depleting or lowering the pH gradient of the resulting liposomes). Liposomal compositions comprising a capture agent within the liposomes can be prepared by forming liposomes in a capture agent solution. A transmembrane concentration gradient of the capture agent can be formed on the liposomes by removing the capture agent from the outside of the liposomes or diluting the liposomes after liposome formation or before loading (encapsulating) the drug.

[0217] In some embodiments, the contacting step comprises incubating the liposomes with the drug in an aqueous medium at a temperature above ambient temperature and below the boiling point of water, preferably 30°C to 90°C, 40°C to 80°C, 50°C to 80°C, or 60°C to 75°C. In some embodiments, the incubation is carried out at an ionic strength of 50 mM NaCl or less, or more preferably 30 mM NaCl or less. After incubation, a concentrated salt solution (e.g., NaCl) can be added to increase the ionic strength to above 50 mM NaCl or about 100 mM NaCl. The increase in ionic strength after the drug loading incubation step helps to reduce aggregation after liposome loading. The incubation time can vary in the range of several minutes to several hours. In some embodiments, the incubation time is 5 to 40 minutes, 10 to 30 minutes, or 15 to 25 minutes. After incubation, the liposomes are cooled and then allowed to reach ambient temperature. In some embodiments, the liposomes are cooled to 2 to 15°C. In some embodiments, the liposomes are cooled to 4 to 10° C. After the cooling step, a concentrated salt (e.g., NaCl) solution can be added to increase the ionic strength to above 50 mM NaCl or about 100 mM NaCl. The increase in ionic strength after the drug loading incubation step helps reduce aggregation of the liposomes after loading.

[0218] In other embodiments, loading is performed in the presence of an ionic agent, such as NaCl, KCl, NHCl, NaSO, KSO, or (NH)SO at 20 to 350 mEq / L, 20 to 100 mEq / L, or 50 to 80 mEq / L. Contrary to conventional practice in the field of low ionic strength (low salt concentrations), it has been found that loading the compounds of the present disclosure, particularly AKG-28, into liposomes is more efficient in the presence of relatively high ionic strength agents (e.g., NaCl), particularly when loading is performed at higher drug concentrations. Thus, in a liposome loading mixture with AKG-28 at 10 to 12 mg / ml, loading at 0 to 20 mM NaCl resulted in an encapsulation efficiency of approximately 90% to 94%, whereas loading efficiencies of >97% were achieved at approximately 80 to 360 mM NaCl (Example 62). Thus, in some embodiments of the present disclosure, the loading of the compounds described herein is carried out at an ionic strength agent of 20 to 350 mEq / L, 20 to 100 mEq / L, or 50 to 80 mEq / L. In some embodiments, the ionic agent is NaCl. In some embodiments, the concentration of the added ionic strength agent is selected so that the liposomes are isotonic (with an osmotic concentration of 280 to 310 mOsmol / L, or an osmotic concentration of 270 to 310 mOsmol / kg) after loading. In some embodiments, the drug is AKG-28, the ionic strength agent is NaCl, and the loading is carried out at a drug of about 12 to 13 mg / ml and a NaCl concentration of 50 to 80 mM. An encapsulation efficiency of 95% or higher, 97% or higher, or 98% or higher can be achieved.

[0219] In some embodiments, the contacting step also includes the incubation of liposomes and drugs in an aqueous medium in the presence of an osmotic (tension) balancing agent. In some embodiments, an osmotic balancing agent (also referred to as an osmotic agent herein) is a nonionic agent. Some exemplary nonionic osmotic agents include but are not limited to dextrose (glucose), sucrose, trehalose, lactose, mannitol, sorbitol, and polyvinylpyrrolidone. In some embodiments, the concentration of the osmotic agent has an osmotic concentration (expressed as osmotic or osmotic concentration) equal to the osmotic concentration of the capture agent solution in the liposome internal space before drug loading. Before solution and lipid are combined to form liposomes, the osmotic concentration of the capture agent solution can be measured by methods known in the art. In another embodiment, the osmotic concentration provided by the concentration of the osmotic agent is lower than the osmotic concentration of the capture agent solution, and is less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, or less than about 10% of the osmotic concentration of the capture agent solution. In another embodiment, the concentration of the osmotic agent is 200 to 400mmol / kg, preferably 250 to 350mmol / kg during the drug loading process. In another embodiment, the osmotic agent is dextrose, and the concentration is 45g / L. In another embodiment, the osmotic agent is not used during the incubation of liposomes and the drug. In another embodiment, the incubation is carried out in the presence of an ionic strength regulator. A non-limiting example of an ionic strength regulator is sodium chloride, for example, is added to the liposome-drug solution with a concentration of 5 to 50mM, 10 to 20mM or about 10mM. Contrary to the routine in the liposome field, the compound of the present disclosure (for example AKG-28 and AKG-38) is loaded into the liposome of the present disclosure in a stable and efficient manner, even during the drug-liposome contact step, the osmotic concentration provided by the amount of the osmotic agent is lower than the osmotic concentration of the trapping agent solution (osmotic imbalance liposomes), until there is no osmotic agent added.

[0220] Unexpectedly, for compounds AKG-28 and AKG-38, loading was found to be very efficient (>95% loading, >97% loading, and >98% loading) even at the higher end of the achievable DL ratios (AKG-28, 300 to 350 g / mol PhL; AKG-38, 500 to 600 g / mol PhL) and at high concentrations of drug in the liposome-drug loading mixture (over 16 mg / ml for AKG-38 and over 12 mg / ml for AKG-28). Generally speaking, in some embodiments, liposome loading of AKG-28 is performed at 300 to 350 g / mol PhL and a drug concentration exceeding 6 mg / ml, at least 10 mg / ml or at least 12 mg / ml; and liposome loading of AKG-38 is performed at 500 to 650 mg / ml or 500 to 600 mg / ml of drug and a drug concentration exceeding 8 mg / ml, at least 12 mg / ml or at least 16 mg / ml, and an efficiency of at least 95% loading, at least 97% loading or at least 98% loading is achieved.

[0221] In some embodiments, the compounds of the present disclosure are loaded into liposomes over a wide range of pH values ​​(e.g., pH 4.5 to 7). For AKG-28, optimal loading efficiencies of 95% or greater, or 97% or greater, were achieved within the pH range of 5.5 to 7.0 (Example 62). The loading pH was determined by the pH of the aqueous drug stock solution (40 mg / ml) selected within the pH range of 5.3 to 7.0. In some embodiments, the pH of the 40 mg / ml AKG-28 stock solution was within the pH range of 5.7 to 6.9 adjusted with NaOH.

[0222] Liposomes and other lipid nanoparticle compositions are susceptible to degradation of the lipid components during storage, which adversely affects their pharmaceutical quality. Lipid degradation can be studied in the form of accelerated stability studies, in which liposome samples are stored at temperatures above the recommended storage temperature, so that degradation occurs more rapidly; it is generally assumed to follow the Arrhenius law. Liposomes of the present disclosure, such as those containing compounds AKG-28 and AKG-38 in a lipid composition of PC and cholesterol, have been found to accumulate cholesterol oxidative degradation products ( Figure 17 ) and the products of phosphatidylcholine hydrolysis and degradation ( Figure 18) both. Although it is generally observed that the oxidative degradation of lipids with unsaturated hydrocarbon chains, the oxidative degradation of cholesterol is an unusual phenomenon. The stability of the liposomes containing the encapsulated compounds described herein can be achieved by incorporating chelating agents. Chelating agents are molecules that bind metal ions by forming one or more stable heterocyclic groups including metal bonds and coordination bonds. Exemplary chelating agents are deferoxamine (deferoxamine, Desferrioxamine) (abbreviated as DFO herein), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), nitrilotriacetic acid (NTA), ethylene glycol-O, O'-bis(2-aminoethyl)-N, N, N', N'-tetraacetic acid (EGTA), N-(2-hydroxyethyl)ethylenediamine-N, N', N'-triacetic acid (HEDTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). In some embodiments, the liposome composition comprises cholesterol and is stable to cholesterol degradation, with the extent of cholesterol degradation after 3 months at 37° C. being less than 10%, less than 5%, or less than 1% of the total cholesterol. In some embodiments, the liposome composition comprises a chelating agent. In some embodiments, the chelating agent is deferoxamine (Desferal, DFO), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), nitrilotriacetic acid (NTA), ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), N-(2-hydroxyethyl)ethylenediamine-N,N',N'-triacetic acid (HEDTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), including pharmaceutically acceptable salts thereof. The chelating agent may be present in the composition at a concentration of at least 0.01 mM, at least 0.05 mM, at least 0.1 mM, at least 0.2 mM, or at least 0.5 mM, and no more than 1 mM, no more than 2 mM, no more than 5 mM, or no more than 10 mM. In some embodiments, the chelating agent is deferoxamine or deferoxamine mesylate, and the chelating agent concentration is about 0.5 mM. Deferoxamine has been found to be particularly effective in preventing cholesterol degradation in the liposomes of the present disclosure. The stability of lipids with encapsulated compounds of the present disclosure, particularly AKG-28 and AKG-38, is affected by the pH of the medium outside the liposomes. Although it is generally taught in the art that optimal stability of lipids in liposomes is achieved at a pH of about 6.5, it has been found that for the liposomes of the present disclosure, optimal lipid stability for both the cholesterol and PC components is achieved at a pH above 7.0. In some embodiments, the pH of the liposome composition is at least 7.1, at least 7.2, or at least 7.3, and does not exceed pH 8.0, does not exceed pH 7.7, or does not exceed pH 7.6. In some embodiments, the extent of cholesterol degradation after 3 months at 37° C. is less than 10%, less than 5%, or less than 1% of the total cholesterol.In some embodiments, the extent of phospholipid degradation after 6 weeks at 37° C. is less than 10%, less than 5%, or less than 1% of the total phospholipid content. In some embodiments, the phospholipid is phosphatidylcholine. In some embodiments, the phospholipid is HSPC and the pH is between pH 7.3 and 7.6.

[0223] Another factor that has an unexpected effect on the lipid stability in the liposomes of the present disclosure is the presence of ammonium or substituted ammonium in the external medium. In some embodiments, ammonium salts are used as capture agents to achieve loading of compounds described herein (e.g., AKG-28 or AKG-38) into liposomes. Therefore, for each drug molecule that enters the interior of the liposome, one or two ammonia molecules leave the interior of the liposome and accumulate in the liposome external medium, which is then removed from the accumulated ammonium in the buffer exchange / unencapsulated drug removal step after loading, such as by tangential flow filtration, dialysis, or size exclusion chromatography. Unexpectedly, in an accelerated storage stability study of liposome formulations after loading without buffer exchange, phospholipids were more stable against degradation in buffer exchange formulations. Analysis of ammonium in liposomes after loading with and without buffer exchange showed that buffer exchange liposomes did have significantly lower levels of ammonium in the liposome external medium. Therefore, the presence of ammonium in the liposome external medium, in the amount generated by ammonium-drug transmembrane exchange during the drug loading step ("exchanged ammonium"), is beneficial for reducing storage-related degradation of lipids. It was unexpectedly found that even relatively small amounts of external (extralipid) ammonium, such as 1.7 mEq / L, had a significant stabilizing effect on liposome lipids (Example 71). (For convenience, the term "mM" is used to refer to NH4 +In some embodiments, the external medium of the liposome composition has less than 0.5 mEq / L of ammonium or substituted ammonium. In some embodiments, the liposome composition contains ammonium or substituted ammonium in the external medium of the liposomes at a concentration of at least 1 mEq / L, at least 2 mEq / L, at least 5 mEq / L, at least 10 mEq / L, at least 15 mEq / L, or at least 20 mEq / L, and no more than 200 mEq / L, no more than 150 mEq / L, no more than 100 mEq / L, no more than 80 mEq / L, or no more than 60 mEq / L. In some embodiments, the liposome composition contains ammonium or substituted ammonium at a concentration of at least 1 mEq / L, at least 2 mEq / L, at least 5 mEq / L, at least 10 mEq / L, at least 15 mEq / L, or at least 20 mEq / L, and no more than 200 mEq / L, no more than 150 mEq / L, no more than 100 mEq / L, no more than 80 mEq / L, or no more than 60 mEq / L in the extraliposome medium, and is stable to phospholipid degradation, with phospholipid degradation of less than 10%, less than 5%, or less than 1% of total phospholipids after 6 weeks at 37°C. In some embodiments, the liposome composition contains ammonium or substituted ammonium in the extraliposome medium at a concentration of at least 1 mEq / L, at least 2 mEq / L, at least 5 mEq / L, at least 10 mEq / L, at least 15 mEq / L, or at least 20 mEq / L, and no more than 200 mEq / L, no more than 150 mEq / L, no more than 100 mEq / L, no more than 80 mEq / L, or no more than 60 mEq / L, and is stable to phospholipid degradation, with phospholipid degradation of less than 10%, less than 7%, less than 5%, or less than 4% of total phospholipids after 3 months at 37°C. In some embodiments, the phospholipid is phosphatidylcholine. In some embodiments, the phospholipid is HSPC, and the ammonium salt is ammonium chloride, ammonium sulfate, or a combination thereof at an ammonium concentration of 10 to 80 mM or 15 to 60 mM. In some embodiments, the phospholipid is HSPC and the ammonium salt is ammonium chloride, ammonium sulfate, or a combination thereof at an ammonium concentration of 1 to 10 mM or 2 to 5 mM. In some embodiments, the equivalent concentration of ammonium in the external medium of the liposome composition is within 90% to 110% of the equivalent concentration of the encapsulated drug during the drug loading step, the equivalent concentration being the concentration expressed in gram-equivalents / L (eq / L).

[0224] The desired concentration of ammonium in the extraliposomal medium can be achieved by accumulating extraliposomal ammonium during the drug loading step at the expense of ammonium (used as part of the capture agent) escaping from the liposome interior, as described above. Alternatively, the desired level of extraliposomal ammonium can be contributed by the extraliposomal ammonium remaining in the liposomes after removal of the extraliposomal ammonium prior to drug loading, or by adding an ammonium salt (e.g., ammonium chloride or ammonium sulfate) to the external medium of the liposome preparation. In the latter case, if post-loading purification of the liposomes from unencapsulated material is desired, the ammonium salt can be added to the liposome preparation after the post-loading buffer exchange / unencapsulated drug removal step, or to the exchange buffer.

[0225] In some embodiments, the liposome compositions provided herein may further include a lipophilic free radical scavenger, such as α-tocopherol, in the liposome formulation.

[0226] In some embodiments, provided herein The oxazolidinone liposome composition comprises HSPC, cholesterol and PEG-DSPE in a mass ratio of about 5:3:1. The oxazolidinone liposome composition comprises HSPC, cholesterol, and PEG-DSPE in a molar ratio of about 45:55:2.25. In some embodiments, The oxazolidinone liposome composition comprises AKG-28 or a pharmaceutically acceptable salt thereof. In some embodiments, The oxazolidinone liposome composition comprises AKG-38 or a pharmaceutically acceptable salt thereof. Oxazolidinone.

[0227] How to use

[0228] Disclosed herein are methods for inhibiting the growth of mycobacteria, such as Mycobacterium tuberculosis, or Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA). Other mycobacteria and gram-positive bacteria include, but are not limited to, Mycobacterium avium complex, Mycobacterium leprae, Mycobacterium gordonae, Mycobacterium abscessus, Mycobacterium abscessus, Mycobacterium mucogenicum, Streptococci, vancomycin-resistant enterococci (VRE), Staphylococcus pneumoniae, Enterococcus faecium, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, viridans group streptococci), Listeria monocytogenes, Nocardia, and Corynebacterium. In some embodiments, the compounds and compositions provided herein inhibit the growth of drug-resistant strains of Mycobacterium tuberculosis. In some embodiments, methods of treating mycobacterial infections are provided. In some embodiments, the compounds and compositions provided herein can be used to treat nontuberculous mycobacterial infections. In some embodiments, the method comprises administering to a subject in need thereof a therapeutically effective amount of an aminoalkyl ... In some embodiments, the method comprises administering to a subject in need thereof a therapeutically effective amount of a liposome composition comprising an aminoalkyl ... Oxazolidinone compounds and / or pharmaceutically acceptable salts thereof.

[0229] Mycobacterium is a genus of bacteria that causes tuberculosis (TB). According to the World Health Organization, TB is one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent. Rifampicin is the most effective first-line drug for treating TB. However, an increasing number of cases of infection with Mycobacterium tuberculosis are resistant to rifampicin. Multidrug-resistant tuberculosis (MDR-TB) is a form of TB caused by bacteria that do not respond to isoniazid and rifampicin.

[0230] In some embodiments, the composition is a liquid pharmaceutical preparation for parenteral administration. In some embodiments, the liquid pharmaceutical preparation is a composition comprising an appropriate amount of Liposomal formulation of an oxazolidinone compound, wherein The oxazolidinone compound is encapsulated within the interior of the liposome. In another embodiment, the compound is encapsulated in salt form within the interior of the liposome with a polyanion (e.g., sulfate, citrate, sucrose octasulfate, phytate). In some embodiments, the compound is a precipitated or gelled salt having sulfate within the interior of the liposome composed of a variety of lipid excipients, including but not limited to phosphatidylcholine, cholesterol, and PEGylated phosphatidylethanolamine. The liposomes of the present disclosure exhibit encapsulation efficiencies exceeding 85%, exceeding 90%, and exceeding 95%. In some embodiments, the retained amount of unencapsulated drug is removed from the liposome composition. This can be achieved by various methods (e.g., size exclusion chromatography, ion exchange, dialysis, ultrafiltration, tangential flow filtration, adsorption, or precipitation). During or after the unencapsulated drug removal step, the liposomes can be placed in a desired pharmaceutically acceptable carrier (e.g., normal saline, isotonic dextrose, isotonic sucrose, Ringer's solution, or Hanks solution). Buffer substances can be added to provide the desired physiologically acceptable pH. The liposome composition can be adjusted for the desired drug concentration and sterilized, for example, by sterile filtration through a 0.2 to 0.22 μm filter. In some embodiments, the compound concentration in the liposome composition is 1 to 50 mg / ml, 3 to 30 mg / ml, or 5 to 25 mg / ml.

[0231] In some embodiments, the pharmaceutical preparation comprising the liposome composition provided herein can be sterilized by conventional, well-known sterilization techniques. The aqueous solution can then be packaged for use or filtered and lyophilized under aseptic conditions, and the lyophilized preparation can be combined with a sterile aqueous solution before administration. The composition can include pharmaceutically acceptable auxiliary substances required for close physiological conditions, such as pH adjusting agents and buffers, tension regulators, etc., such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc. In addition, the lipid suspension can include a lipid protective agent that protects lipids from free radicals and lipid peroxidation damage during storage. Lipophilic free radical quenchers, such as α-tocopherol, are suitable.

[0232] In some embodiments, the liposomes are mixed with one or more additional excipients for isotonicity or pH control. In some embodiments, excipients include but are not limited to sodium chloride, Hepes buffer, phosphate buffer, and histidine buffer.

[0233] The liposome composition may also contain other pharmaceutically acceptable substances required to approximate physiological conditions, such as pH regulators and buffers, tonicity regulators, and the like, such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, and the like. In addition, the liposome suspension may contain a lipid protective agent that protects the lipids from free radical and lipid peroxidation damage during storage. Lipophilic free radical quenchers, such as α-tocopherol, are suitable.

[0234] In other embodiments, the composition is an oral formulation. In some embodiments, the composition is a liquid formulation. In some embodiments, the composition is a solid formulation (e.g., tablets, capsules, pills, dragees, caplets, etc.). When intended for oral use, for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared (Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.). Compositions intended for oral use may be prepared according to any method known in the art for preparing pharmaceutical compositions. The composition may contain one or more agents, including antioxidants, sweeteners, flavorings, colorings and preservatives, to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients or adjuvants (which are suitable for tablet manufacture) are acceptable. Suitable excipients or adjuvants include, but are not limited to, for example, inert diluents, solubilizers, suspending agents, excipients, wetting agents, sweeteners, aromatic or flavoring substances, isotonic substances, colloidal dispersants and surfactants.

[0235] Tablets, dragees, capsules, pills, granules, suppositories, solutions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and sprays may be suitable pharmaceutical compositions.

[0236] The compound or composition can be administered topically, orally, parenterally, intraperitoneally, and / or rectally.

[0237] Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response).For example, one or more doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.

[0238] The dosage of the compound and / or its pharmaceutically acceptable salt or liposomes comprising the compound and / or its pharmaceutically acceptable salt can vary within wide limits and should naturally be adjusted in each particular case to the individual condition and the pathogen to be controlled.

[0239] In some embodiments, for use in treating bacterial infections, a compound or pharmaceutical liposomal composition is administered to a subject in need thereof once every 7 days (i.e., once a week), once every 14 days (i.e., once every two weeks), once every 21 days (i.e., once every three weeks), once every 28 days (i.e., once every four weeks), and once every 42 days (i.e., once every six weeks). In some embodiments, the average weekly dose is about 1 mg to about 1500 mg, about 10 to about 700 mg, about 25 to about 500 mg, or about 70 to about 250 mg. In some embodiments, the average weekly dose is from about 1 mg to about 10 mg, from about 10 mg to about 25 mg, from about 25 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 200 mg, from about 200 mg to about 300 mg, from about 300 mg to about 400 mg, from about 400 mg to about 500 mg, from about 500 mg to about 600 mg, from about 600 mg to about 700 mg, from about 700 mg to about 800 mg, from about 800 mg to about 900 mg, from about 900 mg to about 1000 mg, from about 1000 mg to about 1100 mg, from about 1100 mg to about 1200 mg, from about 1200 mg to about 1300 mg, from about 1300 mg to about 1400 mg, from about 1400 mg to about 1500 mg. In some embodiments, the compound or composition is administered for up to one month, up to two months, up to three months, up to four months, or longer. The specific therapeutically effective amount will depend on a variety of factors, including the bacterial infection being treated, the activity of the specific compound being administered, the pharmaceutical composition used, the age, weight, sex, etc. of the subject, the route of administration, the severity of the bacterial infection, the optional drugs / active agents used in combination (sequentially or simultaneously) with the specific compound, and similar factors known to physicians of ordinary skill. In some embodiments, the compound or composition can be used to treat tuberculosis or other mycobacterial infections. In some embodiments, the compound can be used as a single treatment. In some embodiments, treatment may include the simultaneous and / or sequential administration of an effective amount of a compound as described herein and an effective amount of one or more additional active agents to treat Mycobacterium tuberculosis and other Gram-positive bacterial infections. In some embodiments, treatment may include the simultaneous and / or sequential administration of an effective amount of a compound as described herein and an effective amount of two or more (two, three, four, etc.) additional active agents to treat Mycobacterium tuberculosis and other Gram-positive bacterial infections. A synergistic antibacterial effect means that the antibacterial effect is greater than the expected fully additive effect of the individual compounds of the combination. When administered simultaneously, the compound and active agent may be contained in the same composition or in different compositions. When sequentially administered, the composition comprising the compound and the composition comprising the additional active agent can be administered at intervals of, for example, 20 minutes, 40 minutes, 60 minutes or longer. In some embodiments, the additional active agent can be administered using different routes of administration or by different injections.For example, a compound of the disclosure may be administered intravenously, and one or more additional agents may be administered orally.

[0240] In some embodiments, administration of a compound with one or more (e.g., one, two, three, or four) additional active agents can result in a reduced duration of treatment. For example, administration of a compound with one or more (e.g., one, two, three, or four) additional active agents can result in a treatment duration that is at least three times, at least two times, at least 1.5 times shorter than treatment with only one active agent. In some embodiments, the additional agent is an antibacterial agent. In some embodiments, the additional active agent may include, but is not limited to, a fluoroquinoline (e.g., moxifloxacin, gatifloxacin, or levofloxacin), bedaquiline and other diarylquinoline analogs (e.g., TBAJ-587 and TBAJ-876), delamanid, pretomanid, isoniazid, rifampicin, rifapentine, pyrazinamide, clofazimine, spectinamide, ethambutol, streptomycin, kanamycin, capreomycin, amikacin, leucyl-tRNA synthetase (LeuRS) inhibitor GSK 3036656, tryptophan synthase inhibitor GSK839, DprE1 inhibitor OPC-167832 and Macozinone (PBTZ-169), Telecebec, GSK-656, TBA-7371, and amoxicillin plus clavulanate, their respective pharmaceutically acceptable salts, and any combination thereof. For the treatment of Gram-positive infections, additional active agents may include, but are not limited to, vancomycin, gentamycin, daptomycin, teicoplanin, ceftaroline, ceftrobiprole, telavancin, dalbavancin, oritavancin, fluoroquinolines (e.g., delafloxacin), tetracyclines (e.g., eravacycline and omadacycline), sulfonamides (e.g., sulfamethoxazole), and sulfamethoxazole. In some embodiments, the treatment may include the simultaneous and / or sequential administration of an effective amount of a compound described herein and an effective amount of bedaquiline, premanid, pyrazinamide, moxifloxacin, or a pharmaceutically acceptable salt thereof or a combination thereof.

[0241] Actual dosage levels of the active ingredients in the pharmaceutical compositions disclosed herein may be varied without being toxic to the patient in order to obtain an amount, composition, and mode of administration that is effective to achieve the desired therapeutic response for a particular patient.

[0242] As used herein, "parenteral" in the context of administration means modes of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0243] As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral (i.e., through the digestive tract) and topical administration, typically by injection or infusion, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, inhalation, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion. Intravenous injection and infusion are often (but not exclusively) used for liposomal drug administration.

[0244] In some embodiments, the liquid composition is injected intravenously. In some embodiments, the compound or pharmaceutical composition is administered to a subject in need thereof once every 7 days (i.e., once a week), once every 14 days (i.e., once every two weeks), once every 21 days (i.e., once every three weeks), once every 28 days (i.e., once every four weeks), and once every 42 days (i.e., once every six weeks). In some embodiments, the average weekly dose is about 1 mg to about 1500 mg, about 10 to about 700 mg, about 25 to about 500 mg, or about 70 to about 250 mg. In some embodiments, the average weekly dose is from about 1 mg to about 10 mg, from about 10 mg to about 25 mg, from about 25 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 200 mg, from about 200 mg to about 300 mg, from about 300 mg to about 400 mg, from about 400 mg to about 500 mg, from about 500 mg to about 600 mg, from about 600 mg to about 700 mg, from about 700 mg to about 800 mg, from about 800 mg to about 900 mg, from about 900 mg to about 1000 mg, from about 1000 mg to about 1100 mg, from about 1100 mg to about 1200 mg, from about 1200 mg to about 1300 mg, from about 1300 mg to about 1400 mg, from about 1400 mg to about 1500 mg. The specific therapeutically effective amount will depend on a variety of factors, including the bacterial infection being treated, the activity of the specific compound being administered, the pharmaceutical composition used, the age, weight, sex, etc. of the subject, the route of administration, the severity of the bacterial infection, optional drugs / active agents used in combination (sequentially or simultaneously) with the specific compound, and like factors known to physicians of ordinary skill in the art.

[0245] In some embodiments, the liposomal composition is administered parenterally.

[0246] In some embodiments, the method comprises administering one or more additional active agents simultaneously or sequentially. In some embodiments, the one or more active agents comprise bedaquiline, premanil, pyrazinamide, moxifloxacin, a pharmaceutically acceptable salt thereof, or a combination thereof.

[0247] In some embodiments, the liposomal composition is administered from once per week to once every six weeks.

[0248] In some embodiments, 6 hours after administration to a subject in need thereof, the percentage of compound remaining in the blood is greater than 20% of the administered amount. In some embodiments, the percentage of compound remaining in the blood is greater than 10% of the administered amount.

[0249] Some aspects of the present disclosure relate to methods for preparing liposome compositions comprising the steps of: (i) preparing liposomes comprising phospholipids, cholesterol, and PEG-lipids in a medium substantially free of a capture agent and having an interior space comprising the capture agent; (ii) contacting the liposomes with a compound disclosed herein in an aqueous medium to achieve encapsulation of the compound in the liposomes; (iii) removing unencapsulated compound; and (iv) providing the liposomes in a physiologically acceptable medium suitable for parenteral use.

[0250] In some embodiments, for use in treating bacterial infections, the compound or pharmaceutical oral composition is administered once or twice daily. The specific therapeutically effective amount will depend on a variety of factors, including the bacterial infection being treated, the activity of the specific compound being administered, the pharmaceutical composition used, the age, weight, sex, etc. of the subject, the route of administration, the severity of the bacterial infection, the optional drugs / active agents used in combination (sequentially or simultaneously) with the specific compound, and similar factors known to physicians of ordinary skill.

[0251] Other implementation plans

[0252] The following additional embodiments are provided for illustrative purposes.

[0253] 1. AKG-28 liposome composition comprising lipid HSPC, cholesterol and PEG (2000) -DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1 and a pharmaceutically acceptable salt of AKG-28

[0254]

[0255] 2. The composition of embodiment 1, wherein the liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm.

[0256] 3. The composition of embodiment 2, wherein the unilamellar or oligolamellar vesicles have a z-average diameter of 100 to 130 nm.

[0257] 4. The composition of embodiment 1, wherein the polydispersity index of the liposome composition is less than 0.15.

[0258] 5. The composition of embodiment 4, wherein the polydispersity index of the liposome composition is less than 0.10.

[0259] 6. The composition of embodiment 1, wherein the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 230 to 290 g / mol

[0260] 7. The composition of embodiment 1, wherein the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 290 to 360 g / mol

[0261] 8. The composition of embodiment 1, wherein the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 300 to 340 g / mol

[0262] 9. The composition of embodiment 1, wherein the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is about 250 g / mol.

[0263] 10. The composition of embodiment 1, wherein the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is about 330 g / mol.

[0264] 11. The composition of embodiment 1, wherein the total concentration of AKG-28 in the composition is 8 to 15 mg / mL

[0265] 12. The composition of embodiment 1, wherein the total concentration of AKG-28 in the composition is 9 to 11 mg / mL.

[0266] 13. The composition of embodiment 1, wherein the ratio of encapsulated AKG-28 to total AKG-28 in the composition is at least 90%.

[0267] 14. The composition of embodiment 1, wherein the ratio of encapsulated AKG-28 to total AKG-28 in the composition is at least 95%.

[0268] 15. The composition of embodiment 1, wherein the ratio of encapsulated AKG-28 to total AKG-28 in the composition is at least 97%.

[0269] 16. The composition of embodiment 1, wherein the ratio of encapsulated AKG-28 to total AKG-28 in the composition is at least 98%.

[0270] 17. The composition of embodiment 1, wherein the composition comprises liposome vesicles in an aqueous medium comprising sodium chloride and optionally ammonium ions.

[0271] 18. The composition of embodiment 17, wherein the osmolarity of the aqueous medium is 270 to 330 mOsmol / kg

[0272] 19. The composition of embodiment 17, wherein the osmolarity of the aqueous medium is 270 to 310 mOsmol / kg.

[0273] 20. The composition of embodiment 17, wherein the ammonium concentration in the aqueous medium is 20 to 60 mM.

[0274] 21. The composition of embodiment 17, wherein the ammonium concentration in the aqueous medium is 50 to 80 mM.

[0275] 22. The composition of embodiment 17, wherein the concentration of ammonium in the aqueous medium is less than 0.5 mM.

[0276] 23. The composition of embodiment 17, wherein the concentration of ammonium in the aqueous medium is less than 130 to 150 mM.

[0277] 24. The composition of embodiment 1, further comprising a buffer, wherein the buffer buffers the composition at a pH of 7.3 to 7.7.

[0278] 25. The composition of embodiment 1, further comprising a buffer, wherein the buffer buffers the composition at a pH of about 7.5.

[0279] 26. The composition of embodiment 1, further comprising a buffer, wherein the buffer buffers the composition at a pH of 7.5.

[0280] 27. The composition of embodiment 1, further comprising HEPES or phosphate buffer.

[0281] 28. The composition of embodiment 27, wherein the composition comprises HEPES or phosphate buffer at a concentration of 5 to 50 mM.

[0282] 29. The composition of embodiment 27, wherein the composition comprises HEPES or phosphate buffer at a concentration of about 20 mM.

[0283] 30. The composition of embodiment 27, wherein the composition comprises HEPES or phosphate buffer at a concentration of 20 mM.

[0284] 31. The composition of embodiment 1, further comprising a chelating agent.

[0285] 32. The composition of embodiment 1, further comprising a chelating agent at a concentration of 0.1 to 1 mM.

[0286] 33. The composition of embodiment 1, further comprising a chelating agent at a concentration of about 0.5 mM.

[0287] 34. The composition of embodiment 1, further comprising a chelating agent at a concentration of 0.5 mM.

[0288] 35. The composition of embodiment 1, further comprising deferoxamine (DFO) or EDTA.

[0289] 36. The composition of embodiment 1, further comprising deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM.

[0290] 37. The composition of embodiment 1, further comprising deferoxamine (DFO) or EDTA at a concentration of about 0.5 mM.

[0291] 38. The composition of embodiment 1, further comprising deferoxamine (DFO) or EDTA at a concentration of 0.5 mM.

[0292] 39. The composition of embodiment 1, wherein the composition is storage stable.

[0293] 40. The composition of any one of embodiments 1 to 39, wherein the composition comprises AKG-28 as the sulfate salt of AKG-28.

[0294] 41. AKG-38 liposome composition comprising lipids HSPC, cholesterol and PEG (2000) -DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1 and a pharmaceutically acceptable salt of AKG-38

[0295]

[0296] (AKG-38).

[0297] 42. The composition of embodiment 41, wherein the liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm.

[0298] 43. The composition of embodiment 42, wherein the unilamellar or oligolamellar vesicles have a z-average diameter of 100 to 130 nm.

[0299] 44. The composition of embodiment 41, wherein the polydispersity index of the liposome composition is less than 0.15.

[0300] 45. The composition of embodiment 44, wherein the polydispersity index of the liposome composition is less than 0.10.

[0301] 46. ​​The composition of embodiment 41, wherein the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the composition is 430 to 480 g / mol

[0302] 47. The composition of embodiment 41, wherein the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the composition is 500 to 650 g / mol

[0303] 48. The composition of embodiment 41, wherein the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the composition is 430 to 650 g / mol

[0304] 49. The composition of embodiment 41, wherein the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the composition is about 450 g / mol

[0305] 50. The composition of embodiment 41, wherein the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the composition is about 600 g / mol.

[0306] 51. The composition of embodiment 41, wherein the total concentration of AKG-38 in the composition is 12 to 25 mg / mL.

[0307] 52. The composition of embodiment 41, wherein the total concentration of AKG-38 in the composition is 13.5 to 16.5 mg / mL.

[0308] 53. The composition of embodiment 41, wherein the total concentration of AKG-38 in the composition is about 15 mg / mL.

[0309] 54. The composition of embodiment 41, wherein the total concentration of AKG-38 in the composition is about 20 mg / mL.

[0310] 55. The composition of embodiment 41, wherein the ratio of encapsulated AKG-38 to total AKG-38 in the composition is at least 90%.

[0311] 56. The composition of embodiment 41, wherein the ratio of encapsulated AKG-38 to total AKG-38 in the composition is at least 95%.

[0312] 57. The composition of embodiment 41, wherein the ratio of encapsulated AKG-38 to total AKG-38 in the composition is at least 97%.

[0313] 58. The composition of embodiment 41, wherein the ratio of encapsulated AKG-38 to total AKG-38 in the composition is at least 98%.

[0314] 59. The composition of embodiment 41, wherein the composition comprises liposome vesicles in an aqueous medium comprising sodium chloride and optionally ammonium ions.

[0315] 60. The composition of embodiment 59, wherein the osmolarity of the aqueous medium is 270 to 330 mOsmol / kg.

[0316] 61. The composition of embodiment 59, wherein the osmolarity of the aqueous medium is 270 to 310 mOsmol / kg.

[0317] 62. The composition of embodiment 59, wherein the ammonium concentration in the aqueous medium is 20 to 60 mM.

[0318] 63. The composition of embodiment 59, wherein the ammonium concentration in the aqueous medium is 50 to 80 mM.

[0319] 64. The composition of embodiment 59, wherein the concentration of ammonium in the aqueous medium is less than 0.5 mM.

[0320] 65. The composition of embodiment 59, wherein the concentration of ammonium in the aqueous medium is less than about 0.5 mM

[0321] 66. The composition of embodiment 59, wherein the concentration of sodium chloride is 130 to 150 mM.

[0322] 67. The composition of embodiment 41, further comprising a buffer, wherein the buffer buffers the composition at a pH of 7.3 to 7.7.

[0323] 68. The composition of embodiment 41, further comprising a buffer, wherein the buffer buffers the composition at a pH of about 7.5.

[0324] 69. The composition of embodiment 41, further comprising a buffer, wherein the buffer buffers the composition at a pH of 7.5.

[0325] 70. The composition of embodiment 41, further comprising HEPES or phosphate buffer.

[0326] 71. The composition of embodiment 70, wherein the composition comprises HEPES or phosphate buffer at a concentration of 5 to 50 mM.

[0327] 72. The composition of embodiment 70, wherein the composition comprises HEPES or phosphate buffer at a concentration of about 20 mM.

[0328] 73. The composition of embodiment 70, wherein the composition comprises HEPES or phosphate buffer at a concentration of 20 mM.

[0329] 74. The composition of embodiment 41, further comprising a chelating agent.

[0330] 75. The composition of embodiment 41, further comprising a chelating agent at a concentration of 0.1 to 1 mM.

[0331] 76. The composition of embodiment 41, further comprising a chelating agent at a concentration of about 0.5 mM.

[0332] 77. The composition of embodiment 41, further comprising a chelating agent at a concentration of 0.5 mM.

[0333] 78. The composition of embodiment 41, further comprising deferoxamine (DFO) or EDTA.

[0334] 79. The composition of embodiment 41, further comprising deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM.

[0335] 80. The composition of embodiment 41, further comprising deferoxamine (DFO) or EDTA at a concentration of about 0.5 mM.

[0336] 81. The composition of embodiment 41, further comprising deferoxamine (DFO) or EDTA at a concentration of 0.5 mM.

[0337] 82. The composition of embodiment 41, wherein the composition is storage stable.

[0338] 83. The composition of any one of embodiments 1 to 82, wherein it comprises AKG-28 as the sulfate salt of AKG-28.

[0339] 84. AKG-28 liposome composition comprising lipids HSPC, cholesterol and PEG (2000) -DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1 and a pharmaceutically acceptable salt of AKG-28

[0340]

[0341] wherein the liposome composition is further characterized by any one or more of the following features:

[0342] a. The liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm; or the liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm; or the liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 100 to 130 nm;

[0343] b. The polydispersity index of the liposome composition is less than 0.15; or the polydispersity index of the liposome composition is less than 0.10;

[0344] c. The drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 230 to 280 g / mol; or the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 290 to 360 g / mol; or the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 300 to 340 g / mol; or the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is about 250 g / mol; or the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is about 330 g / mol;

[0345] d. The total concentration of AKG-28 in the composition is 8 to 15 mg / mL; or the total concentration of AKG-28 in the composition is 9 to 11 mg / mL;

[0346] e. The ratio of encapsulated AKG-28 to total AKG-28 in the liposome composition is at least 90%; or the ratio of encapsulated AKG-28 to total AKG-28 in the liposome composition is at least 95%; or the ratio of encapsulated AKG-28 to total AKG-28 in the liposome composition is at least 97%; or the ratio of encapsulated AKG-28 to total AKG-28 in the liposome composition is at least 98%;

[0347] f. The liposome composition comprises an aqueous medium containing sodium chloride and optionally containing ammonium ions;

[0348] g. The osmolarity of the aqueous medium is 270 to 330 mOsmol / kg; or the osmolarity of the aqueous medium is 270 to 310 mOsmol / kg;

[0349] h. the ammonium concentration in the aqueous medium is 20 to 60 mM; or the ammonium concentration in the aqueous medium is 50 to 80 mM; or the ammonium concentration in the aqueous medium is less than 0.5 mM; or the ammonium concentration in the aqueous medium is less than 0.130 to 150 mM;

[0350] i. The aqueous medium further comprises a buffer, wherein the buffer buffers the liposome composition at a pH of 7.3 to 7.7; a pH of about 7.5; or a pH of 7.5;

[0351] j. the aqueous medium further comprises HEPES or a phosphate buffer; or the aqueous medium comprises HEPES or a phosphate buffer at a concentration of 5 to 50 mM; or the aqueous medium comprises HEPES or a phosphate buffer at a concentration of about 20 mM; or the aqueous medium comprises HEPES or a phosphate buffer at a concentration of 20 mM;

[0352] k. The composition further comprises a chelating agent; or the composition further comprises a chelating agent at a concentration of 0.1 to 1 mM; or the composition further comprises a chelating agent at a concentration of about 0.5 mM; or the composition further comprises a chelating agent at a concentration of 0.5 mM; or the composition further comprises deferoxamine (DFO) or EDTA; or the composition further comprises deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM; or the composition further comprises deferoxamine (DFO) or EDTA at a concentration of about 0.5 mM; or the composition further comprises deferoxamine (DFO) or EDTA at a concentration of 0.5 mM; or

[0353] 1. AKG-28 is encapsulated within the liposomes as the sulfate salt of AKG-28.

[0354] 85. AKG-38 liposome composition comprising lipids HSPC, cholesterol and PEG (2000) -DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1 and a pharmaceutically acceptable salt of AKG-38

[0355]

[0356] wherein the liposome composition is further characterized by any one or more of the following features:

[0357] a. The liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm;

[0358] b. The liposome composition comprises unilamellar or oligolamellar vesicles having a z-average diameter of 100 to 130 nm;

[0359] c. the polydispersity index of the liposome composition is less than 0.15, or

[0360] The polydispersity index of the liposome composition is less than 0.10;

[0361] d. The drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 430 to 480 g / mol, or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 500 to 650 g / mol; or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 430 to 650 g / mol; or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is about 450 g / mol; or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is about 600 g / mol;

[0362] e. The total concentration of AKG-38 in the liposome composition is 12 to 25 mg / mL; or the total concentration of AKG-38 in the liposome composition is 13.5 to 16.5 mg / mL; or the total concentration of AKG-38 in the composition is about 15 mg / mL; or the total concentration of AKG-38 in the liposome composition is about 20 mg / mL.

[0363] f. The ratio of encapsulated AKG-38 to total AKG-38 in the liposome composition is at least 90%; or the ratio of encapsulated AKG-38 to total AKG-38 in the liposome composition is at least 95%; or the ratio of encapsulated AKG-38 to total AKG-38 in the liposome composition is at least 97%; or the ratio of encapsulated AKG-38 to total AKG-38 in the liposome composition is at least 98%;

[0364] g. The liposome composition comprises an aqueous medium containing sodium chloride and optionally containing ammonium ions;

[0365] h. the osmolarity of the aqueous medium is 270 to 330 mOsmol / kg; or the osmolarity of the aqueous medium is 270 to 310 mOsmol / kg;

[0366] i. The ammonium concentration in the aqueous medium is 20 to 60 mM; or the ammonium concentration in the aqueous medium is 50 to 80 mM; or the ammonium concentration in the aqueous medium is less than 0.5 mM; or the ammonium concentration in the aqueous medium is less than 0.5 mM;

[0367] j. The concentration of sodium chloride is 130 to 150 mM;

[0368] k. The aqueous medium further comprises a buffer, wherein the buffer buffers the liposome composition to a pH of 7.3 to 7.7; at a pH of about 7.5; or at a pH of 7.5;

[0369] 1. The aqueous medium further comprises HEPES or a phosphate buffer, or the aqueous medium comprises HEPES or a phosphate buffer at a concentration of 5 to 50 mM, or the aqueous medium comprises HEPES or a phosphate buffer at a concentration of about 20 mM, or the aqueous medium comprises HEPES or a phosphate buffer at a concentration of 20 mM;

[0370] m. The aqueous medium further comprises a chelating agent; or further comprises a chelating agent at a concentration of 0.1 to 1 mM, or further comprises a chelating agent at a concentration of about 0.5 mM, or further comprises a chelating agent at a concentration of 0.5 mM, or further comprises deferoxamine (DFO) or EDTA, or further comprises deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM, or further comprises deferoxamine (DFO) or EDTA at a concentration of about 0.5 mM, or further comprises deferoxamine (DFO) or EDTA at a concentration of 0.5 mM;

[0371] n. The liposome composition is storage stable; or

[0372] o. The AKG-38 is encapsulated in the liposomes as the sulfate salt of AKG-38.

[0373] 86. Using (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridyl]phenyl}-5-(methylamino)-1,3- AKG-28 liposomal dispersion prepared from oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

[0374] 87. Using (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridyl]phenyl}-5-(methylamino)-1,3- Liposomal dispersion prepared with oxazolidin-2-one dihydrochloride monohydrate.

[0375] 88. (5R)-3-{3-Fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- Isotonic liposomal dispersion of oxazolidine-2-one dihydrochloride monohydrate.

[0376] 89. The liposomal dispersion of any one of embodiments 86 to 88, comprising unilamellar lipid bilayer liposome vesicles enclosing an aqueous space containing (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- Oxazolidin-2-one.

[0377] 90. The liposomal dispersion of embodiment 89, wherein the liposomal vesicles are composed of hydrogenated soy phosphatidylcholine (HSPC), cholesterol and (PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine, PEG-DSPE) (PEG (2000)-DSPE).

[0378] 91. The liposomal dispersion of embodiment 90, comprising 45 to 65 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0379] 92. The liposomal dispersion of embodiment 90, comprising 50 to 60 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0380] 93. The liposomal dispersion of embodiment 90, comprising about 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0381] 94. The liposomal dispersion of embodiment 90, comprising about 55 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0382] 95. The liposomal dispersion of embodiment 90, wherein the lipid content of the liposomal dispersion consists of HSPC and PEG(2000)-DSPE.

[0383] 96. The liposomal dispersion of embodiment 95, comprising HSPCs and cholesterol in a weight ratio of about 5:3.

[0384] 97. The liposomal dispersion of embodiment 95, comprising HSPC and cholesterol in a molar ratio of about 45:55.

[0385] 98. The liposomal dispersion of embodiment 95, comprising HSPC, cholesterol, and PEG(2000)-DSPE in a weight ratio of about 5:3:1.

[0386] 99. The liposomal dispersion of embodiment 95, comprising HSPC, cholesterol, and PEG(2000)-DSPE in a molar ratio of about 45:55:2.25.

[0387] 100. The liposomal dispersion of any one of embodiments 87 to 99, further comprising a 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffer or a phosphate buffer.

[0388] 101. The liposomal dispersion of embodiment 100, further comprising sodium chloride at a concentration of 50 to 80 mM.

[0389] 102. The liposomal dispersion of any one of embodiments 99 to 101, further comprising ammonium at a concentration of 20 to 60 mM that is displaced during the drug loading process.

[0390] 103. The liposomal dispersion of any one of embodiments 99 to 102, wherein the z-average diameter of the liposomal vesicles is 90 to 130 nm.

[0391] 104. The use of (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridyl]phenyl}-5-(methylacetylamino)-1,3- AKG-38 liposomal dispersion prepared from oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

[0392] 105. The use of (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Liposomal dispersions of oxazolidin-2-one hydrochloride.

[0393] 106. (5R)-3-{3-Fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Isotonic liposomal dispersion of oxazolidin-2-one hydrochloride.

[0394] 107. The liposomal dispersion of any one of embodiments 104 to 106, comprising unilamellar lipid bilayer vesicles enclosing an aqueous space containing (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Oxazolidin-2-one.

[0395] 108. The liposomal dispersion of embodiment 107, wherein the liposomal vesicles are composed of hydrogenated soy phosphatidylcholine (HSPC), cholesterol and (PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine, PEG-DSPE) (PEG (2000)-DSPE).

[0396] 109. The liposomal dispersion of embodiment 108, comprising 50 to 65 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0397] 110. The liposomal dispersion of embodiment 108, comprising 50 to 60 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0398] 111. The liposomal dispersion of embodiment 108, comprising about 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0399] 112. The liposomal dispersion of embodiment 108, comprising about 55 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0400] 113. The liposomal dispersion of embodiment 108, wherein the lipid content of the liposomal dispersion consists of HSPC and PEG(2000)-DSPE.

[0401] 114. The liposomal dispersion of embodiment 113, comprising HSPC and cholesterol in a weight ratio of about 5:3.

[0402] 115. The liposomal dispersion of embodiment 113, comprising HSPC and cholesterol in a molar ratio of about 45:55.

[0403] 116. The liposomal dispersion of embodiment 113, comprising HSPC, cholesterol, and PEG(2000)-DSPE in a weight ratio of about 5:3:1.

[0404] 117. The liposomal dispersion of embodiment 113, comprising HSPC, cholesterol, and PEG(2000)-DSPE in a molar ratio of about 45:55:2.25.

[0405] 118. The liposomal dispersion of any one of embodiments 104 to 117, further comprising a 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffer or a phosphate buffer.

[0406] 119. The liposomal dispersion of embodiment 118, further comprising sodium chloride at a concentration of 50 to 80 mM.

[0407] 120. The liposomal dispersion of any one of embodiments 118 to 119, further comprising ammonium at a concentration of 20 to 60 mM that is displaced during the drug loading process.

[0408] 121. The liposomal dispersion of any one of embodiments 118 to 120, wherein the z-average diameter of the liposomes is 90 to 130 nm.

[0409] 122. The liposomal dispersion of any one of embodiments 86 to 120, wherein the dispersion comprises liposomal vesicles having a z-average diameter of 90 to 130 nm.

[0410] 123. The liposomal dispersion of any one of embodiments 86 to 121, wherein the dispersion comprises liposomal vesicles having a z-average diameter of 100 to 130 nm.

[0411] 124. The liposomal dispersion of any one of embodiments 86 to 121, wherein the dispersion comprises liposomal vesicles having a z-average diameter of about 100 nm.

[0412] 125. The liposomal dispersion of any one of embodiments 86 to 124, wherein the dispersion further comprises a chelating agent.

[0413] 126. The liposomal dispersion of any one of embodiments 86 to 124, wherein the dispersion further comprises a chelating agent selected from deferoxamine (DFO) and EDTA.

[0414] 127. The liposomal dispersion of any one of embodiments 86 to 124, wherein the dispersion further comprises a chelating agent selected from deferoxamine (DFO) and EDTA at a concentration of 0.1 to 1 mM.

[0415] 128. The liposomal dispersion of any one of embodiments 86 to 124, wherein the dispersion further comprises a chelating agent selected from deferoxamine (DFO) and EDTA at a concentration of 0.5 mM.

[0416] 129. The liposomal dispersion of any one of embodiments 86 to 128, wherein the dispersion further comprises ammonium at a concentration of 20 to 60 mM.

[0417] 130. The liposomal dispersion of any one of embodiments 86 to 129, wherein the dispersion further comprises sodium chloride at a concentration of 50 to 80 mM.

[0418] 131. An AKG-28 liposomal dispersion having a pH of 7.0 to 8.0, wherein the liposomal dispersion comprises:

[0419] a. a unilamellar lipid bilayer vesicle comprising phospholipids and more than 50 mol% cholesterol; and

[0420] b. (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- Oxazolidin-2-one.

[0421] 132. The liposomal dispersion of embodiment 131, wherein the liposomal dispersion is prepared using (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- Preparation of oxazolidin-2-one hydrochloride.

[0422] 133. The liposomal dispersion of embodiment 132, comprising 45 to 65 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0423] 134. The liposomal dispersion of embodiment 132, comprising 50 to 55 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0424] 135. The liposomal dispersion of embodiment 132, comprising about 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0425] 136. The liposomal dispersion of embodiment 132, comprising about 55 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0426] 137. The liposomal dispersion of embodiment 132, wherein the liposomal dispersion is obtained by a method comprising the steps of: reacting (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- Oxazolidin-2-one hydrochloride is dissolved in a drug loading solution, and the drug loading solution is contacted with the extracted purified liposome vesicles containing the ammonium sulfate capture agent to load AKG-28 into the liposome vesicles.

[0427] 138. The liposomal dispersion of any one of embodiments 131 to 137, wherein the unilamellar lipid bilayer vesicles comprise HSPC and cholesterol in a molar ratio of 45:55 or a mass ratio of 5:3.

[0428] 139. The liposomal dispersion of embodiment 138, wherein the unilamellar lipid bilayer vesicles are composed of HSPC, cholesterol and PEG(2000)-DSPE.

[0429] 140. The liposomal dispersion of embodiment 139, wherein the unilamellar lipid bilayer vesicles are composed of HSPC, cholesterol, and PEG(2000)-DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1.

[0430] 141. The liposomal dispersion of any one of embodiments 131 to 140, having a pH of 7 to 7.7.

[0431] 142. An AKG-28 liposomal dispersion having a pH of 7.0 to 8.0, wherein the liposomal dispersion comprises:

[0432] a. a unilamellar lipid bilayer vesicle containing phospholipids and at least 45 mol% cholesterol;

[0433] b. (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- Oxazolidin-2-one; and

[0434] c. A chelating agent selected from deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM.

[0435] 143. An AKG-38 liposomal dispersion having a pH of 7.0 to 8.0, wherein the liposomal dispersion comprises:

[0436] a. a unilamellar lipid bilayer liposome vesicle containing phospholipids and at least 50 mol% cholesterol; and

[0437] b. (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Oxazolidin-2-one.

[0438] 144. The liposomal dispersion of embodiment 143, wherein the liposomal dispersion is prepared using (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Preparation of oxazolidin-2-one hydrochloride.

[0439] 145. The liposomal dispersion of any one of embodiments 143 to 144, wherein the liposomal dispersion is obtained by a method comprising the steps of: reacting (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Oxazolidin-2-one hydrochloride is dissolved in a drug loading solution, and the drug loading solution is contacted with the extracted purified liposome vesicles containing the ammonium sulfate capture agent to load AKG-38 into the liposome vesicles.

[0440] 146. The liposomal dispersion of any one of embodiments 144 to 145, wherein the lipid vesicles comprise HSPC and cholesterol in a molar ratio of 45:55 or a mass ratio of 5:3.

[0441] 147. The liposomal dispersion of embodiment 146, wherein the lipid vesicles are composed of HSPC, cholesterol, and PEG(2000)-DSPE.

[0442] 148. The liposomal dispersion of embodiment 147, wherein the lipid vesicles are composed of HSPC, cholesterol, and PEG(2000)-DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1.

[0443] 149. The liposomal dispersion of any one of embodiments 146 to 148, having a pH of 7 to 7.7.

[0444] 150. An AKG-38 liposomal dispersion having a pH of 7 to 8, wherein the liposomal dispersion comprises:

[0445] a. unilamellar lipid bilayer vesicles containing phospholipids and at least 50 mol% cholesterol;

[0446] b. (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Oxazolidin-2-one; and

[0447] c. A chelating agent selected from deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM.

[0448] 151. The liposomal dispersion of embodiment 150, wherein the liposomal dispersion is prepared using (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Preparation of hydrochloride salt of oxazolidin-2-one.

[0449] 152. The liposomal dispersion of embodiment 151, wherein the liposomal dispersion is obtained by a method comprising the steps of: reacting (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- The hydrochloride salt of oxazolidin-2-one is dissolved in a drug loading solution, and the drug loading solution is contacted with the extracted purified liposome vesicles containing the ammonium sulfate capture agent to load AKG-38 into the liposome vesicles.

[0450] 153. The liposomal dispersion of any one of embodiments 150 to 152, wherein the lipid unilamellar and lipid bilayer vesicles comprise HSPC and cholesterol in a molar ratio of 45:55 or a mass ratio of 5:3.

[0451] 154. The liposomal dispersion of embodiment 153, wherein the unilamellar lipid bilayer vesicles are composed of HSPC, cholesterol and PEG(2000)-DSPE.

[0452] 155. The liposomal dispersion of embodiment 154, wherein the unilamellar lipid bilayer vesicles are composed of HSPC, cholesterol, and PEG(2000)-DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1.

[0453] 156. The liposomal dispersion of any one of embodiments 150 to 155, having a pH of 7 to 7.7.

[0454] 157. The liposomal dispersion of any one of embodiments 142 to 145 and 150 to 152, comprising 50 to 65 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0455] 158. The liposomal dispersion of any one of embodiments 142 to 145 and 150 to 152, comprising 50 to 55 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0456] 159. The liposomal dispersion of any one of embodiments 142 to 145 and 150 to 152, comprising about 50 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0457] 160. The liposomal dispersion of any one of embodiments 142 to 145 and 150 to 152, comprising about 55 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomal vesicles.

[0458] 161. pH 7 to 8 Oxazolidinone liposome dispersion, wherein the liposome dispersion comprises:

[0459] a. Unilamellar lipid bilayer vesicles containing phospholipids and more than 50 mol% cholesterol;

[0460] b. Formula (I) as a sulfate salt formed within the liposome vesicle Oxazolidinone;

[0461]

[0462] wherein R1 is a tetrazole ring substituted with an aminoalkyl group at the 2' position;

[0463] R2 is an amine (NH2) or an acetamide (NHCOCH3);

[0464] as well as

[0465] c. A chelating agent selected from deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM.

[0466] 162. The liposomal dispersion of embodiment 161, comprising phospholipids and cholesterol in a mass ratio of about 5:3.

[0467] 163. The liposomal dispersion of embodiment 161, further comprising PEG-DSPE.

[0468] 164. The liposomal dispersion of embodiment 163, wherein the liposomal composition comprises phospholipids, cholesterol, and PEG-DSPE in a mass ratio of approximately 5:3:2.25.

[0469] 165. The liposomal dispersion of embodiment 164, wherein the liposomal composition comprises phospholipids, cholesterol, and PEG-DSPE in a molar ratio of about 45:55:2.25 mol%.

[0470] 166. The liposomal dispersion of any one of embodiments 161 to 165, wherein the phospholipid is HSPC.

[0471] 167. The liposomal dispersion of any one of embodiments 161 to 166, wherein the Oxazolidinone is (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

[0472] 168. The liposomal dispersion of any one of embodiments 161 to 166, wherein the Oxazolidinone is (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- Oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

[0473] 169. The liposomal dispersion of any one of embodiments 167 to 168, wherein the Oxazolidinone is a sulfate salt formed within the liposomal vesicles containing an ammonium sulfate (AS) trapping agent within the liposomal dispersion.

[0474] 170. The liposomal dispersion of any one of embodiments 161 to 169, wherein the unilamellar lipid bilayer vesicles comprise a total of 55 mol% cholesterol relative to the total amount of phospholipids in the liposomal dispersion.

[0475] 171. The liposomal dispersion of any one of embodiments 161 to 170, wherein the phospholipids are present as a total of 45 mol% cholesterol relative to the total amount of phospholipids in the liposomal dispersion.

[0476] 172. The liposomal dispersion of any one of embodiments 161 to 171, wherein the phospholipids are present as a total of 45 mol% cholesterol relative to the total amount of phospholipids in the liposomal dispersion.

[0477] 173. The liposomal dispersion of any one of embodiments 161 to 172, wherein the The oxazolidinone is a compound selected from Table 1 or a pharmaceutically acceptable salt thereof:

[0478] Table 1

[0479]

[0480]

[0481]

[0482]

[0483]

[0484] 174. A liposomal dispersion comprising (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- Oxazolidin-2-one or a pharmaceutically acceptable salt thereof and a lipid vesicle formed of phospholipid, 55 mol% cholesterol and 5 mol% PEG-DSG.

[0485] 175. A liposomal dispersion having a pH of 7 to 8 comprising (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- Oxazolidin-2-one or a pharmaceutically acceptable salt thereof and a lipid vesicle formed of phospholipid and 55 mol % cholesterol.

[0486] 175. A liposomal dispersion comprising (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylamino)-1,3- Oxazolidin-2-one or a pharmaceutically acceptable salt thereof; a lipid vesicle formed of phospholipid and 55 mol % of cholesterol; and a chelating agent.

[0487] 176. The liposomal dispersion of embodiment 175, wherein the chelating agent is selected from the group consisting of deferoxamine (deferoxamine, Desferrioxamine), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), nitrilotriacetic acid (NTA), ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), N-(2-hydroxyethyl)ethylenediamine-N,N',N'-triacetic acid (HEDTA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).

[0488] 177. A liposomal dispersion comprising (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Oxazolidin-2-one or a pharmaceutically acceptable salt thereof, and a lipid vesicle formed of phospholipid, 55 mol% cholesterol and 5 mol% PEG-DSG.

[0489] 178. A liposomal dispersion having a pH of 7 to 8 comprising (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Oxazolidin-2-one or a pharmaceutically acceptable salt thereof, and a lipid vesicle formed of phospholipid and 55 mol % of cholesterol.

[0490] 179. A liposomal dispersion comprising (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Oxazolidin-2-one or a pharmaceutically acceptable salt thereof; a lipid vesicle formed of phospholipid and 55 mol % of cholesterol; and a chelating agent.

[0491] 180. The liposomal dispersion of embodiment 179, wherein the chelating agent is selected from the group consisting of deferoxamine (deferoxamine, Desferrioxamine), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), nitrilotriacetic acid (NTA), ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), N-(2-hydroxyethyl)ethylenediamine-N,N',N'-triacetic acid (HEDTA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).

[0492] 181. A liposomal dispersion comprising (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- Oxazolidin-2-one or a pharmaceutically acceptable salt thereof and a lipid vesicle formed of phospholipid, 55 mol% cholesterol and 5 mol% PEG-DSG.

[0493] Other implementation plans

[0494] Additional embodiments

[0495] The following additional embodiments are provided for illustrative purposes. Additional embodiments include those described below in the following additional embodiments. Oxazolidinone liposome composition, and other combinations of the features described above:

[0496] 1. A liposomal pharmaceutical composition having a pH of 7.3 to 7.7 and comprising:

[0497] a. a chelating agent selected from DFO, EDTA and DTPA;

[0498] b. a liposomal vesicle comprising a phospholipid and greater than 40 mol% cholesterol relative to the total phospholipids in the liposome composition, and

[0499] c. Sulfate salt of the compound of formula (I) encapsulated in liposome vesicles

[0500]

[0501] wherein R2 is an amine (NH2) or an acetamide (NHCOCH3), and

[0502] wherein R1 is a tetrazole ring substituted with an aminoalkyl group at the 2' position.

[0503] 2. The liposome composition of embodiment 1, wherein the aminoalkyl group is dimethylaminoethyl.

[0504] 3. The liposome composition of embodiment 1, wherein the liposome vesicles comprise a compound of formula 1b:

[0505]

[0506] 4. The liposome composition of embodiment 1, wherein the liposome vesicles contain the compound of formula 1c

[0507]

[0508] 5. The liposome composition of embodiment 1, wherein the liposome vesicles contain a compound of formula 1d or formula 1e

[0509]

[0510] 6. The liposome composition of any one of embodiments 1 to 5, wherein the liposome vesicles are in an aqueous medium.

[0511] 7. The liposome composition of any one of embodiments 1 to 5, wherein the compound is entrapped in the liposome vesicles with the aid of a capture agent, and wherein the capture agent comprises a polyanion.

[0512] 8. The liposome composition of embodiment 7, wherein the capture agent is sucrose octasulfate triethylammonium or ammonium sulfate.

[0513] 9. The liposome composition of embodiment 7, wherein the capture agent is sucrose octasulfate triethylammonium.

[0514] 10. The liposome composition of embodiment 7, wherein the capture agent is ammonium sulfate.

[0515] 11. The liposome composition of any one of embodiments 1 to 5, comprising a salt of the compound, wherein the salt is a sulfate salt, a citrate salt, a sulfosaccharide salt, a salt with a phosphorylated or sulfated polyol, or a salt with a phosphorylated or sulfated polyanionic polymer.

[0516] 12. The liposomal composition of any one of embodiments 1 to 5, comprising a salt of the compound, wherein the salt is a sulfate salt.

[0517] 13. The liposome composition of any one of embodiments 1 to 5, wherein the water solubility of the compound in the liposome vesicle is less than 1 mg / mL.

[0518] 14. The composition of any one of embodiments 1 to 5, wherein the aqueous solubility of the compound in the liposomal vesicle is less than 0.1 mg / mL.

[0519] 15. The liposome composition of any one of embodiments 1 to 5, wherein the liposome vesicle comprises a membrane comprising phosphatidylcholine and cholesterol.

[0520] 16. The liposome composition of embodiments 1 to 5, wherein the membrane separates the interior of the liposome vesicle from the aqueous medium.

[0521] 17. The liposome composition of embodiment 15, wherein the phosphatidylcholine is distearoylphosphatidylcholine (DSPC) or hydrogenated soybean phosphatidylcholine (HSPC).

[0522] 18. The liposome composition of embodiment 15, wherein the molar ratio of phosphatidylcholine to cholesterol is from about 60:40 to about 35:65.

[0523] 19. The liposome composition of embodiment 15, wherein the molar ratio of phosphatidylcholine to cholesterol is from about 55:45 to about 35:65.

[0524] 20. The liposome composition of embodiment 15, wherein the molar ratio of phosphatidylcholine to cholesterol is about 50:50 to about 45:55.

[0525] 21. The liposome composition of embodiment 15, wherein the molar ratio of phosphatidylcholine to cholesterol is about 50:50 to about 40:60.

[0526] 22. The liposome composition of any one of embodiments 15 to 21, wherein the membrane further comprises a polymer-conjugated lipid.

[0527] 23. The liposome composition of any one of embodiments 1 to 5, wherein the liposome vesicle comprises HSPC, cholesterol, and polymer-conjugated lipid in a molar ratio of about 45:55:2.75.

[0528] 24. The liposome composition of embodiment 22 or embodiment 23, wherein the polymer-conjugated lipid is PEG (molecular weight 2,000)-distearoylglycerol (PEG-DSG) or PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine (PEG-DSPE).

[0529] 25. The liposomal composition of any one of embodiments 1 to 5, wherein the composition is a liquid pharmaceutical formulation for parenteral administration.

[0530] 26. The liposome composition of any one of embodiments 1 to 5, wherein the Z-average particle size of the liposomes is about 80 to about 130 nm.

[0531] 27. A method of treating a bacterial infection, comprising administering to a subject in need thereof a therapeutically effective amount of the liposome composition of any one of embodiments 1 to 5.

[0532] 28. The method of embodiment 27, wherein the bacterial infection is a Mycobacterium tuberculosis infection.

[0533] 29. The method of embodiment 27 or embodiment 28, wherein the minimum inhibitory concentration (MIC) of the compound in the liposomal vesicle is about 0.01 μg / ml to about 0.25 μg / ml.

[0534] 30. The method of embodiment 27 or embodiment 28, wherein the MIC of the compound in the liposomal vesicle is about 0.01 μg / ml to about 0.1 μg / ml.

[0535] 31. The method of any one of embodiments 27 to 30, comprising administering the liposome composition parenterally.

[0536] 32. The method of embodiment 31, wherein the method comprises administering one or more active agents simultaneously or sequentially.

[0537] 33. The method of embodiment 32, wherein the one or more active agents include bedaquiline, premanid, pyrazinamide, moxifloxacin, a pharmaceutically acceptable salt thereof, or a combination thereof.

[0538] 34. The method of embodiment 31, wherein the liposome composition is administered once a week to once every six weeks.

[0539] 35. The method of embodiment 31, wherein following administration to a subject in need thereof, the percentage of the compound remaining in the blood at 6 hours is greater than 20% of the administered amount.

[0540] 36. The method of embodiment 31, wherein following administration to a subject in need thereof, the percentage of the compound remaining in the blood is greater than 10% of the administered amount.

[0541] 37. A method for preparing a liposome composition comprising the steps of:

[0542] (i) preparing a liposome comprising a phospholipid, cholesterol, and a PEG-lipid in a medium substantially free of a capture agent and having an interior space containing the capture agent;

[0543] (ii) contacting the liposomes with a compound according to any one of embodiments 1 to 8 in an aqueous medium to achieve encapsulation of the compound in the liposomes;

[0544] (iii) removing unencapsulated compounds; and

[0545] (iv) providing the liposomes in a physiologically acceptable medium suitable for parenteral use.

[0546] Example

[0547] The following examples, including the experiments performed and results achieved, are provided for illustrative purposes only and should not be construed as limiting the present disclosure.

[0548] Example 1- Synthesis of Oxazolidinone Derivatives

[0549] Compounds AKG-1, AKG-2, AKG-6, AKG-8, AKG-9, and AKG-19 were synthesized by reacting tedizolid mesylate (tedizolid-MS) with the corresponding amines in N-methyl-2-pyrrolidone (NMP) at 60°C (Scheme 1). Tedizolid-MS was obtained by mesylation of the 1° hydroxyl group of tedizolid with methanesulfonyl chloride in the presence of a base at room temperature (RT). Tedizolid-MS was treated with sodium azide and then reduced to the resulting azide (AKG-3-A) to afford intermediate-1 as the free base or AKG-3 as the hydrochloride salt, depending on the eluent selected for purification. Intermediate-1 was amidated with the corresponding acid and then the hydrochloride salt was formed using HCl / EtOAc to produce compounds AKG-17 and AKG-18. Tedizolid reacts with the corresponding dialkyl amino acids under standard esterification conditions to produce compounds AKG-5 and AKG-20. Using sodium hydride as a base, tedizolid is O-alkylated with 2-chloro-N,N-diethylaminoethylamine to give compound AKG-7.

[0550] Intermediate-2 was synthesized by borylation of commercially available aryl bromides using bis(pinacolato)diboron (Scheme-2). Suzuki coupling of intermediate-2 with readily available 5-bromo-2-fluoropyridine gave intermediate-3, which was heated in a sealed tube with the corresponding amine in NMP to afford compounds AKG-11 to AKG-15.

[0551] Compounds AKG-16, AKG-21 to AKG-27 (Schemes 3 and 4) were prepared in a convergent synthesis starting from intermediate-4. Click chemistry using sodium azide on 5-bromo-2-cyanopyridine gave intermediate-4. N-alkylation of tetrazole in intermediate-4 produced intermediates 5 and 6 in a 3:1 ratio. The structures of these intermediates were inferred by HMBC analysis. Intermediates 7 to 12 were synthesized, and regioisomers were obtained in a similar manner (only the desired isomer is shown in Scheme-4). Suzuki coupling of intermediates 5 to 12 with intermediate 2 and deprotection of the amine group (where applicable) produced compounds AKG-16, AKG-21 to AKG-27.

[0552] Intermediate-13 is synthesized by mesylation of readily available aryl bromides. Intermediate-15 is obtained by reducing intermediate-14 with hydrazine (Scheme-5). Boc protection or acetylation of the primary amine in intermediate-15 followed by borylation produces intermediates-18 and 19, respectively. Suzuki (U.S. Patent Application Publication No. 20100022772, PCT International Application Publication No. WO2013044845, which are incorporated herein by reference in their entirety) coupling of the borylated intermediate with the corresponding aryl bromide intermediate and deprotection of the amine group (where applicable) produces compounds AKG-28 to AKG-31 and AKG-38 to AKG-40.

[0553] Synthesis scheme

[0554] See U.S. Patent Application Publication No. 20100022772, PCT International Application No. 2013044845, which are incorporated herein by reference in their entireties, for the synthesis of Intermediate-19.

[0555] Figure 24 Synthesis Scheme-1 is shown.

[0556] Figure 25 Synthesis Scheme-2 is shown.

[0557] Figure 26 Synthesis Scheme-3 is shown.

[0558] Figure 27 Synthesis Scheme-4 is shown.

[0559] Figure 28 Synthesis Scheme-5 is shown.

[0560] synthesis

[0561] Materials and methods

[0562] Tedizolid, (R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxymethyl) Oxazolidin-2-one was purchased from Skychemical, and dimethyl-(2-piperidin-4-yl-ethyl)-amine was purchased from Enamine, and other reagents and solvents were purchased from Adams and used as received. The chemical structure of the final product was determined by nuclear magnetic resonance spectroscopy (NMR) on a Bruker NMR spectrometer (500 MHz or 400 MHz). 1 H NMR, 13 C NMR) characterization. 13 C NMR spectra are fully decoupled. Deuterated solvent peaks or tetramethylsilane (internal) are used as internal standards, and chemical shifts are reported in parts per million (ppm). 1 H NMR data were recorded as follows: chemical shift (d, ppm), multiplicity (s, singlet; br s, broad singlet; d, doublet; t, triplet; m, multiplet), integration, coupling constant (Hz). 13 The data of C NMR are recorded in the form of chemical shift (d, ppm). The purity of the final product (≥95%) was confirmed by analytical HPLC. Analytical HPLC was performed on an Agilent analytical HPLC system using a Sunfire column of 3.5 μm (150 cm × 4.6 mm) and a gradient system (water (0.01% TFA) / ACN (0.01% TFA)) with a flow rate of 1 mL / min and detection at 254 and 214 nm. Flash Chromatographic (FC) purification was performed using Silica Gel 60 (0.04 to 0.063 nm; 230 to 400 mesh) from Santai Technologies.

[0563] Procedure A. In a sealed tube, a reaction mixture of tedizolid-Ms (1.0 equiv.), R1R2NH (4.0 equiv.) in NMP (10 mL) was heated to 60° C. for 15 hours. After completion (LCMS), the reaction was diluted with H2O (40 mL) and extracted with EtOAc (2×50 mL). The combined extracts were washed with saturated brine, dried over Na2SO4 and filtered. The solvent was removed in vacuo, and the residue was purified using FC to give a product with a purity of >95%.

[0564] 1. Synthesis of Tedizolid-Ms

[0565]

[0566] To a solution of tedizolid (7.00 g, 18.90 mmol) and triethylamine (3.83 g, 37.80 mmol) in CHCl (50 mL) at 0°C under argon was added methanesulfonyl chloride (3.25 g, 28.36 mmol) dropwise. After stirring at room temperature for 2 hours, the reaction mixture was poured into water and extracted with CHCl. ​​The organic layer was washed with brine, dried over NaSO, and collected by filtration. The solvent was removed in vacuo to give the pure product tedizolid-Ms (7.0 g, 82.6% yield) as a yellow solid.

[0567] 1 H NMR (400MHz, DMSO-d6) δ8.95 (s, 1H), 8.31-8.14 (m, 2H), 7.88-7.65 (m, 2H), 7.53 (d, J=8.6Hz, 1H), 5.14-4. 96 (m, 1H), 4.59-4.39 (m, 5H), 4.28 (t, J=9.4Hz, 1H), 3.92 (dd, J=9.2, 6.3Hz, 1H), 3.28 (s, 3H).MS (ESI+) m / z 449.1([M+1] + ).

[0568] 2. Synthesis of AKG-1, 2, 6, 8, 9 and 19

[0569]

[0570] Using Procedure A, AKG-1 was obtained as a white solid from Tedizolid-Ms and dimethylamine (0.5 g, 56.4% yield).

[0571] 1 H NMR (400MHz, DMSO-d6) δ8.94 (s, 1H), 8.32-8.13 (m, 2H), 7.83-7.64 (m, 2H), 7.54 (d, J=7.6Hz, 1H), 4.87 (s, 1H), 4.49 (s, 3H), 4.21 (t, J=8.6Hz, 1H), 3.84 (t, J=7.4Hz, 1H), 2.62 (s, 2H), 2.25 (s, 6H). 13 C NMR (101MHz, DMSO-d6) δ164.3, 161.0, 158.6, 154.6, 149.9, 145.5, 140.9, 137.6, 13 2.1, 131.4, 122.6, 119.1, 114.6, 106.0, 72.0, 62.1, 48.7, 46.4, 40.2.MS(ESI+)m / z 398.2([M+1] + ).

[0572]

[0573] Using procedure A, AKG-2 was obtained as a white solid from tedizolid-Ms and diethylamine (0.52 g, 54.8% yield).

[0574] 1 H NMR (400MHz, DMSO-d6) δ8.94 (s, 1H), 8.29-8.11 (m, 2H), 7.81-7.65 (m, 2H), 7.52 (dd, J=8.6, 1.8Hz, 1H), 4.89-4.73 (m, 1H), 4.49 (s , 3H), 4.19 (t, J=8.8Hz, 1H), 3.82 (dd, J=8.7, 7.0Hz, 1H), 2.75 (dd, J=5.1, 3.7Hz, 2H), 2.57 (q, J=6.9Hz, 4H), 0.97 (t, J=7.1Hz, 6H). 13 C NMR (101MHz, DMSO-d6) δ164.3, 161.0, 158.6, 154.7, 149.9, 145.5, 141.0, 137.6, 132.1, 131. 3,122.5,119.1,114.6,106.1,72.6,56.1,48.6,47.7,40.3,12.3.MS(ESI+)m / z426.3([M+1] + )

[0575]

[0576] Using Procedure A, AKG-6 (0.66 g, 58.2% yield) was obtained as a white solid from Tedizolid-Ms and N,N-dimethyl-2-(piperidin-4-yl)ethan-1-amine.

[0577] 1H NMR (400MHz, CDCl3) δ8.93 (s, 1H), 830 (dd, J=8.1, 24Hz, 1H), 8.05 (d, J=7.8Hz, 1H), 7.62 ( d, J=12.9Hz, 1H), 7.56-7.47(m, 1H), 7.45-7.37(m, 1H), 4.89-4.74(m, 1H), 4.48(s, 3H), 4 .11 (t, J=8.6Hz, 1H), 3.86 (t, J=7.8Hz, 1H), 2.93 (dd, J=28.8, 10.9Hz, 2H), 2.80-2.64 (m, 2H), 2.50-2.04 (m, 11H), 1.69 (d, J=10.8Hz, 2H), 1.48 (d, J=7.1Hz, 2H), 1.37-1.19 (m, 4H). 13 C NMR (101MHz, CDCl3) δ164.7, 161.3, 158.8, 154.3, 149.9, 145.4, 140.2, 137.0, 132.3, 130.5, 122 .0, 120.0, 113.8, 106.4, 71.5, 61.4, 57.0, 55.3, 54.3, 48.9, 45.0, 39.7, 33.6, 32.4.MS(ESI+)m / z 509.2([M+1] + ).

[0578]

[0579] Using procedure A, from tedizolid-Ms and N 1 , N 1 -diethylpropane-1,3-diamine AKG-8 was obtained as a white solid (0.62 g, 57.6% yield).

[0580] 1 H NMR (400MHz, DMSO-d6) δ8.94 (s, 1H), 834-8.11 (m, 2H), 7.84-7.59 (m, 2H), 7.52 (dd, J=8.6, 2.0Hz, 1H), 4.80 (dd, J=8.3, 5.7Hz, 1H), 4.49 ( s, 3H), 4.18 (t, J=8.9Hz, 1H), 3.90 (dd, J=8.8, 6.5Hz, 1H), 2.94-2.77 (m, 2H), 2.66-2.53 (m, 7H), 1.65-1.51 (m, 2H), 0.99 (t, J=7.1Hz, 6H) 13C NMR (101MHz, DMSO-d6) δ164.3, 161.0, 158.6, 154.6, 149.9, 145.5, 141.0, 137.6, 132.1, 13 1.4, 122.6, 119.1, 114.6, 106.1, 73.2, 52.1, 50.7, 48.2, 48.0, 46.7, 40.3, 26.4, 11.4.m / z 483.2([M+1] + ).

[0581]

[0582] Using procedure A, from tedizolid-Ms and N 1 , N 1 -diethylethane-1,2-diamine AKG-9 was obtained as a white solid (0.36 g, 34.4% yield).

[0583] 1 H NMR (500MHz, DMSO-d6) δ8.94 (s, 1H), 8.26-816 (m, 2H), 7.78-7.66 (m, 2H), 7.53 (d, J=8.5Hz, 1H), 4.85-4.73 (m, 1H), 4.49 (s, 3H), 4.18 (t, J = 8.8Hz, 1H), 3.90 (t, J = 7.5Hz, 1H), 2.88 (t, J = 5.4Hz, 2H), 2.65 (t, J = 6.1Hz, 2H), 0.95 (t, J = 7.0Hz, 6H). 13 C NMR (101MHz, DMSO-d6) δ164.3, 161.0, 158.6, 154.7, 149.9, 145.5, 141.0, 137.6, 132.1 ,131.4,122.6,119.1,114.6,106.1,73.3,52.6,52.2,48.1,47.6,47.1,40.3,12.0.m / z 469.3([M+1] + ).

[0584] Using procedure A, AKG-19 was obtained as a white solid from tedizolid-Ms and ethane-1,2-diamine (0.60 g, 55% yield).

[0585] 1H NMR (500MHz, DMSO-d6) δ10.33 (s, 1H), 9.89 (s, 1H), 8.95 (s, 1H), 8.58 (s, 3H), 8.23 ​​(q, J = 8.3Hz, 2H), 7.79 (t, J = 8.8Hz, 1H), 7.69 (d, J = 13.5Hz, 1H), 7.49 (d, J=8.7Hz, 1H), 5.25-5.19 (m, 1H), 4.49 (s, 3H), 4.33 (t, J=9.2Hz, 1H), 4.05 (dd, J=9.1, 6.7Hz, 1H), 3.52 (s, 2H), 3.43-3.23 (m, 4H) 13 C NMR (101MHz, DMSO-d6) δ164.26, 160.94, 158.50, 153.79, 14984, 145.51, 140.58, 137.78, 1 32.04, 13142, 122.61, 119.50, 114.94, 106.46, 69.38, 49.59, 47.87, 45.16, 40.34, 35.58.

[0586] 3. Synthesis of AKG-3

[0587]

[0588] To a solution of tedizolid-Ms (1.00 g, 2.23 mmol) in DMF (20 mL) was added NaN (0.44 g, 6.69 mmol). After stirring at 90° C. for 3 hours, the reaction mixture was poured into water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO, filtered, and concentrated in vacuo. The residue was further purified by column chromatography to obtain the title compound AKG-3-1 (0.7 g, 79.4% yield) as a white solid.

[0589]

[0590] By AKG-3-1 (0.7g, 1.77mmol) and Ph P (1.39g, 5.31mmol) in H o (2mL) and the reaction mixture of THF (20mL) was heated to reflux for 1 hour. After completion (LCMS), the reactant was concentrated in vacuo and purified using reverse phase FC. Using MeOH 0 to 10% in DCM as eluent to purify and freeze-dry, the free base intermediate-1 (2.5g, 76.5% yield) as a yellow solid was obtained, while using MeCN / 0 to 30% in 0.006M HCl in H o as eluent to carry out FC purification, obtaining the hydrochloride AKG-3 (0.35g, 48.8% yield) as a yellow solid after freeze-drying.

[0591] 1 H NMR (400MHz, DMSO-d6) δ8.95 (s, 1H), 8.61 (s, 3H), 8.28-8.18 (m, 2H), 7.79 (t, J=8.8Hz, 1H), 7.69 (dd, J=13.5, 2.1Hz, 1H), 7.48 (dd, J=8.6, 2.1Hz, 1H), 5.13-5.00 (m, 1H), 4.49 (s, 3H), 4.29 (t, J=9.2Hz, 1H), 4.02 (dd, J=9.3, 6.6Hz, 1H), 3.34-3.23 (m, 2H). 13 C NMR (101MHz, DMSO-d6) δ163.8, 160.4, 158.0, 153.4, 149.4, 145.1, 140.2, 1 37.2, 131.5, 130.9, 122.1, 118.9, 114.3, 105.9, 69.8, 47.1, 41.4, 39.8.m / z 370.3([M-HCl+1] + ).

[0592] 4. Synthesis of AKG-17

[0593]

[0594] At room temperature under Ar, to a solution of 3-((tert-butoxycarbonyl)amino)propionic acid (0.62g, 3.25mmol, 1.2 equivalents) and TEA (0.63g, 6.25mmol, 2.5 equivalents) in DMF (10mL) was added HATU (1.44g, 3.78mmol, 1.4 equivalents). The mixture was stirred for 0.5 hour, and intermediate 1 (1.0g, 2.70mmol, 1.0 equivalents) was added subsequently. The whole mixture was stirred at room temperature overnight. LCMS showed that the reaction was complete, and it was poured into H o, and the solid was collected by filtration and washed with H o. The vacuum-dried solid, and the residue was directly used in the next step and subsequently added HCl / EtOAc (4M, 20mL) by being dissolved in EtOAc. The whole mixture was stirred for 16 hours, and passed through N to remove the solvent. The residue was purified by reverse phase FC (eluent with MeCN in 0.006 M HCl in H2O / 0 to 30%) to give the product AKG-17 as a yellow solid (0.5 g, 39.5% yield) after freeze drying.

[0595] 1H NMR (500MHz, DMSO-d6) δ8.95 (s, 1H), 8.67 (s, 1H), 8.23 ​​(q, J=8.3Hz, 2H), 8.14 (s, 3H), 7.77 (t, J=8.6Hz, 1H), 7.69 (d, J=13.5Hz, 1H), 7.50 (d, J=8.6Hz, 1H), 4 .87-4.78 (m, 1H), 4.49 (s, 3H), 4.22 (t, J=9.0Hz, 1H), 3.89 (dd, J=9.0, 6.5Hz, 1 H), 3.50 (t, J=5.3Hz, 2H), 2.98 (dd, J=12.5, 6.4Hz, 2H), 2.58 (t, J=7.1Hz, 2H).

[0596] 13 C NMR (101MHz, DMSO-d6) δ170.60, 164.22, 160.97, 158.53, 154.42, 149.78, 145.42, 140.89, 137.7 9, 132.11, 131.41, 122.61, 119.19, 114.72, 106.23, 105.95, 72.13, 47.77, 40.33, 35.58, 32.58.

[0597] 5. Synthesis of AKG-18

[0598]

[0599] Using the procedure of AKG-17, AKG-18 (0.5 g, 37.6% yield) was obtained as a yellow solid from Intermediate-1 and 4-((tert-butoxycarbonyl)amino)butanoic acid.

[0600] 1 H NMR (500MHz, DMSO-d6) δ8.95 (s, 1H), 8.52 (t, J=5.7Hz, 1H), 8.29-8.08 (m, 5H ), 7.77 (t, J=8.8Hz, 1H), 7.69 (d, J=13.6Hz, 1H), 7.50 (d, J=8.7Hz, 1H), 4.87 -4.76(m, 1H), 4.50(s, 3H), 4.22(t, J=9.0Hz, 1H), 3.93-3.83(m, 1H), 3.49(t , J=5.3Hz, 2H), 2.83-2.72(m, 2H), 2.28(t, J=7.2Hz, 2H), 1.88-1.75(m, 2H). 13C NMR (101MHz, DMSO-d6) δ172.59, 164.23, 160.96, 158.52, 154.44, 149.00, 145.39, 140.88, 137.78, 132.10, 131.40, 122.61, 119.17, 114.70, 106.21, 72.17, 47.78, 41.88, 40.37, 38.78, 32.44, 23.60.

[0601] 6. Synthesis of AKG-5

[0602]

[0603] Under N2, to a mixture of tedizolid (1.0 g, 2.70 mmol), 4-(dimethylamino)butyric acid hydrochloride (0.57 g, 3.37 mmol) and TEA (0.27 g, 2.70 mmol) and a catalytic amount of DMAP in DMF (20 mL) was added DCC (0.84 g, 4.05 mmol). The mixture was stirred at room temperature for 16 hours. After completion of the reaction (LCMS), it was diluted with H2O (100 mL) and filtered. The filtrate was acidified to pH = 5 to 6 with 0.02M HCl and subsequently purified using RP-FC (eluent with 0.5% formic acid / MeCN in H2O) to obtain the product AKG-5 as a formate salt after freeze drying. The product was redissolved in H2O and 1 equivalent of aq.HCl (0.02M) was added. The freeze-dried product obtained AKG-5 (600 mg, 42.7% yield) as an HCl salt.

[0604] 1 H NMR (400MHz, DMSO-d6) δ10.40 (br, 1H), 8.95 (s, 1H), 8.23 ​​(q, J=8.5Hz, 2H), 7.78 (t, J= 8.8Hz, 1H), 7.71 (dd, J=13.6, 2.1Hz, 1H), 7.53 (dd, J=8.6, 2.1Hz, 1H), 5.03 (dd, J=5.6, 3.1Hz, 1H), 4.48 (s, 3H), 4.36 (qd, J=12.4, 4.2Hz, 2H), 4.26 (t, J=9.3Hz, 1H), 3.95 (dd , J=9.2, 6.2Hz, 1H), 2.99-2.86 (m, 2H), 2.64 (s, 6H), 2.45 (t, J=7.3Hz, 2H), 1.87 (m, 2H) 13C NMR (126MHz, DMSO-d6) δ172.3, 164.3, 158.8, 154.3, 1499, 145.6, 140.8, 137.7, 132 .0, 131.5, 122.6, 119.4, 114.7, 106.2, 71.1, 64.8, 56.3, 46.7, 40.3, 30.9, 19.9.m / z 469.3([M+1] + )m / z 4841([M-HCl+1] + ).

[0605] 7. Synthesis of AKG-7

[0606]

[0607] At room temperature under N2, NaH (0.13 g, 60%, 5.40 mmol) was added to a mixture of tedizolid (1.0 g, 2.70 mmol) in DMF (20 mL). The mixture was stirred at 0 ° C for 0.5 hours, and then 2-diethylaminoethyl chloride hydrochloride (930 mg, 5.40 mmol) was added at a time. The whole mixture was stirred at room temperature for 3 hours. LCMS showed that the reaction was complete. The reactant was carefully poured into ice / H2O (20 mL) and extracted with DCM (2 × 50 mL). The combined organic extracts were washed with saturated brine and then dried over Na2SO4. The solvent was removed in vacuo, and the residue was purified using FC (eluent, which has 0 to 15% MeOH in DCM) to obtain AKG-7 (0.5 g, 39.4% yield) as a white solid.

[0608] 1 H NMR (500MHz, CDCl3) δ8.93 (s, 1H), 8.30 (d, J = 8.2Hz, 1H), 8.05 (d, J = 8.2Hz, 1H), 7.7 2(d, J=12.9Hz, 1H), 7.53 (t, J=8.5Hz, 1H), 7.42 (d, J=8.5Hz, 1H), 4.88 (d, J=3.5Hz, 1 H), 4.48 (s, 3H), 4.34-4.26 (m, 1H), 4.18-4.08 (m, 2H), 4.00-3.93 (m, 1H), 3.87 (qd, J=10.8, 2.9Hz, 2H), 3.19-3.11 (m, 2H), 3.06 (q, J=7.1Hz, 4H), 1.26 (t, J=7.2Hz, 6H). 13CNMR (126MHz, CDCl3)6164.7, 161.1, 159.1, 154.3, 149.8, 145.5, 140.0, 137.0, 132.2, 130.6 ,122.0,120.1,113.8,106.3,71.3,71.3,66.9,51.9,48.2,46.6,39.7,8.9.m / z470.3([M+1] + ).

[0609] 8. Synthesis of AKG-20

[0610]

[0611] At room temperature under N2, DCC (0.84 g, 4.05 mmol) was added to the reaction mixture of tedizolid (1.0 g, 2.70 mmol), 4-(diethylamino)butanoic acid hydrochloride (0.61 g, 3.37 mmol) and DMAP (0.05 g) in DMF (20 mL). The mixture was stirred at room temperature for 16 hours. After completion (LCMS), the reaction was diluted with H2O (100 mL) and filtered. The filtrate was acidified to pH = 5 to 6 with 0.02M HCl and subsequently purified with RP-FC (eluent having MeCN in 0.5% FA / H2O) to obtain the product as a formate salt after freeze drying. The salt was then redissolved in H2O and 1 equivalent of HCl (0.02 M) was added to obtain the product AKG-20 (0.61 g, 42% yield) as the HCl salt after freeze drying.

[0612] 1 H NMR (400MHz, DMSO-d6) δ8.94 (s, 1H), 8.28-8.14 (m, 2H), 7.82-7.66 (m, 2H), 7.53 (d, J=8.7Hz, 1H), 5.11-4.97 (m, 1H), 4.49 (s, 3H), 4.43-4.33 (m, 2H), 427 (t, J=9.3Hz, 1H), 401-391 (m, 1H), 3.08-2.99 (m, 2H), 2.90-269 (m, 6H), 108 (t, J=7.2Hz, 6H) 13C NMR (101MHz, DMSO-d6) δ17100, 164.33, 158.55, 154.32, 149.90, 145.58, 140.71, 137.63, 132.0 2, 131.45, 122.58, 119.33, 114.69, 106.21, 71.01, 65.04, 46.86, 46.63, 40.31, 29.99, 9.95 (s).

[0613] 9. Synthesis of Intermediate-3

[0614]

[0615] (R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxymethyl) A mixture of oxazolidin-2-one (9.0 g, 31.02 mmol), bis(pinacolato)diboron (11.88 g, 46.54 mmol) and KOAc (4.56 g, 46.54 mmol) in dioxane (200 mL) was purged with Ar for 10 minutes, and then (Ph P) PdCl (1.09 g, 1.55 mmol) was added. After the mixture was purged with Ar again, it was heated to 90 ° C for 15 hours. LCMS showed that the reaction was complete. It was cooled to room temperature and filtered through Celite to obtain Intermediate-2 as a filtrate. To the filtrate were added 5-bromo-2-fluoropyridine (6.55 g, 37.22 mmol), K PO (14.47 g, 6.80 mmol) and H O (20 mL). The mixture was purged with Ar for 10 minutes and (dppf) PdCl (2.27 g, 3.10 mmol) was added. The mixture was purged with Ar again. It was then heated to 90 ° C for 15 hours. The reaction was monitored by LCMS. After completion, vacuum concentration was performed, and the residue was diluted with H2O (200mL) and extracted with EtOAc (2 × 200mL). The combined extracts were washed with saturated brine and then dried over Na2SO4. Filtered and vacuum-removed the solvent to obtain a residue, which was purified using FC (eluent with 0 to 15% MeOH in DCM) to obtain the product intermediate-3 (6.8g, 71.6% yield for two steps) as a yellow solid.

[0616] 1H NMR (400MHz, DMSO-d6) δ8.43 (s, 1H), 8.23-8.14 (m, 1H), 7.72-7.61 (m, 2H), 7.49 (dd, J=8.6, 2.2Hz, 1H), 7.32 (dd, J=8.6, 2.7Hz, 1H), 5.27 (t, J=5.6Hz, 1H), 4.80-471 (m, 1H), 4.15 (t, J=9.1Hz, 1H), 3.90 (dd, J=8.9, 6.1Hz, 1H), 3.75-3.67 (m, 1H), 3.63-3.55 (m, 1H).MS (ESI+) m / z 307([M+1] + ).

[0617] 10. Synthesis of AKG-11, 12, 13, 14, and 15

[0618] Procedure B. A mixture of intermediate-3 (1.0 equivalents), R1R2NH (4.0 equivalents) and a catalytic amount of DMAP (10 mL) in NMP was heated to 100° C. in a sealed tube for 16 hours. Upon completion of the reaction (LCMS), the mixture was diluted with H2O (50 mL) and extracted with EtOAc (2×50 mL). The combined organic extracts were washed with saturated brine, then dried over Na2SO4 and filtered. The solvent was removed in vacuo, and the residue was purified using RPFC (eluent having 0 to 40% MeCN, C18 in 0.1% NH4HCO3 / H2O) to obtain the product.

[0619]

[0620] Using procedure B, AKG-11 (0.40 g, 30.1% yield) was obtained as a white solid from Intermediate-3 and N,N-dimethyl-2-(piperidin-4-yl)ethan-1-amine.

[0621] 1H NMR (400MHz, DMSO-d6) δ828 (s, 1H), 7.73-765 (m, 1H), 7.60 (dd, J=13.6, 2.1Hz, 1H), 7.54 (t, J=8.9Hz, 1H), 7.41 (dd, J=8.6, 2.1Hz, 1H), 6.89 (d, J=9.0Hz, 1H), 5.25 (t, J=5.6Hz, 1H), 4.78-4.68 (m, 1H), 4.33 (d, J=13.0Hz, 2H), 4.12 (t, J=9.0Hz, 1H), 3.87 (dd, J=8.9, 6.2Hz, 1H), 3.74-3.64 (m, 1H), 3.62-3.52 (m, 1H), 2.87-2.71 (m, 2H), 2.23 (t, J=7.3H z, 2H), 2.11 (s, 6H), 1.72 (d, J=11.5Hz, 2H), 1.64-1.49 (m, 1H), 1.34 (dd, J=14.3, 7.0Hz, 2H), 1.18-1.04 (m, 2H).13C NMR (101MHz, DMSO-d6) δ160.68, 158.33, 154.81, 147.54, 139.15, 137.82, 130.32, 120.72, 119.11, 114.3 5, 106.97, 106.03, 105.74, 73.82, 62.09, 56.98, 46.45, 45.73, 45.39, 34.29, 34.15, 31.94.MS(ESI+)m / z 443.1([M+1] + ).

[0622]

[0623] Using procedure B, from intermediate-3 and N 1 , N 1 -dimethylethane-1,2-diamine AKG-12 was obtained as a white solid (0.52 g, 42.6% yield).

[0624] 1H NMR (400MHz, DMSO-d6) δ8.16 (s, 1H), 7.64-7.46 (m, 3H), 7.39 (dd, J=8.6, 2.2 Hz, 1H), 6.58 (dd, J=9.9, 5.6Hz, 2H), 5.25 (t, J=5.6Hz, 1H), 4.80-4.66 (m, 1H) , 4.11 (t, J=9.0Hz, 1H), 3.86 (dd, J=8.9, 6.2Hz, 1H), 3.76-3.65 (m, 1H), 3.61- 3.49 (m, 1H), 3.37 (dd, J=12.3, 6.5Hz, 2H), 2.42 (t, J=6.6Hz, 2H), 2.18 (s, 6H) 13 C NMR (101MHz, DMSO-d6) δ160.60, 158.48, 158.19, 154.82, 147.57, 138.92, 137.10, 130.22, 121.18 ,118.53,114.30,108.37,106.02,105.74,73.81,62.10,58.76,46.45,45.76,39.21.MS(ESI+)m / z 375.1([M+1] + ).

[0625]

[0626] Using procedure B, from intermediate-3 and N 1 , N 1 -dichloroethane-1,2-diamine AKG-13 was obtained as a white solid (0.68 g, 51.9% yield).

[0627] 1 H NMR (400MHz, DMSO-d6) δ8.17 (s, 1H), 7.67-7.46 (m, 3H), 7.39 (dd, J=8.6 , 2.1Hz, 1H), 6.63-6.44 (m, 2H), 5.25 (s, 1H), 4.74 (dd, J=9.2, 5.8Hz, 1H), 4.12 (t, J=9.0Hz, 1H), 3.87 (dd, J=8.9, 6.2Hz, 1H), 3 .76-3.65(m, 1H), 3.63-3.52(m, 1H), 3.34(dd, J=13.2, 6.2Hz, 2H), 2.60-2.55(m, 2H), 2.54-2.50(m, 4H), 0.97(t, J=7.1Hz, 6H) 13C NMR (101MHz, DMSO-d6) δ160.60, 158.53, 158.18, 154.81, 147.62, 138.91, 137.13, 130.20, 121.16 ,118.54,114.29,108.24,105.87,73.80,62.10,52.19,47.13,46.45,39.48,12.31.MS(ESI+)m / z 417.1([M+1] + ).

[0628]

[0629] Using procedure B, from intermediate-3 and N 1 , N 1 -dimethylpropane-1,3-diamine AKG-14 was obtained as a white solid (0.6 g, 47.3% yield).

[0630] 1 H NMR (400MHz, DMSO-d6) δ8.16 (s, 1H), 7.63-7.54 (m, 2H), 7.50 (t, J=8.9Hz, 1H), 7.39 (dd , J=8.6, 2.2Hz, 1H), 6.73 (t, J=5.6Hz, 1H), 654 (d, J=8.7Hz, 1H), 5.25 (t, J=5.5Hz, 1H), 4 78-4.68 (m, 1H), 4.11 (t, J=9.0Hz, 1H), 3.87 (dd, J=8.9, 6.2Hz, 1H), 3.75-3.66 (m, 1H), 3 .64-3.53(m, 1H), 3.33-323(m, 2H), 228(t, J=7.1Hz, 2H), 213(s, 6H), 1.72-1.62(m, 2H). 13 C NMR (101MHz, DMSO-d6) δ160.60, 158.62, 158.18, 154.81, 147.62, 138.89, 137.08, 13 0.19, 121.21, 118.39, 114.29, 108.10, 106.02, 105.74, 73.81, 62.10.57.44, 46.45, 45.72.39.58.27.54.MS(ESI+)m / z 389.1([M+1] + ).

[0631]

[0632] Using procedure B, from intermediate-3 and N 1 , N 1-diethylpropane-1,3-diamine AKG-15 was obtained as a white solid (0.65 g, 48.0% yield).

[0633] 1 H NMR (400MHz, DMSO-d6) δ8.16 (s, 1H), 7.63-7.54 (m, 2H), 7.50 (t, J=8.9Hz, 1H), 7.39 (dd, J= 8.6, 2.2Hz, 1H), 6.75 (t, J=5.5Hz, 1H), 6.54 (d, J=8.7Hz, 1H), 5.25 (t, J=5.4Hz, 1H), 4.79- 4.68 (m, 1H), 4.12 (t, J=9.0Hz, 1H), 3.87 (dd, J=8.9, 6.2Hz, 1H), 3.75-3.66 (m, 1H), 3.63-3 .54(m, 1H), 3.32-3.23(m, 2H), 2.49-2.40(m, 6H), 1.70-1.61(m, 2H), 0.95(t, J=7.1Hz, 6H) 13 C NMR (101MHz, DMSO-d6) δ160.60, 158.65, 158.18, 154.81, 147.64, 138.89, 137.05, 130.18, 121.21, 118.3 7,114.29,108.01,106.02,105.74,73.80,62.09,50.81,46.80,46.45,40.11,27.10,12.23.MS(ESI+)m / z 417.1([M+1] + ).

[0634] 11. Synthesis of AKG-16

[0635]

[0636] At room temperature, by ZnCl (11.2g, 81.9mmol) is added to pyridine (40mL) portion by portion, then adds NaN (8.90g, 137mmol) and 5-bromo-2-cyanopyridine (10.0g, 54.6mmol), and reaction mixture is heated to reflux 2 hours at 120 ℃.After mixture is cooled to room temperature, dilute with water (200mL), at room temperature stir 1 hour, filter and wash with water (200mL).Collect the solid filtered, and at room temperature be suspended in HCl (200mL, 6M) and continue 2 hours.By filtering collection product, and use H o washing.Vacuum drying is to obtain intermediate-4 (10.0g, 81.3% productive rate) as white solid.

[0637] 1H NMR (400MHz, DMSO-d6) δ8.96 (s, 1H), 8.36 (dd, J=8.4, 2.2Hz, 1H), 8.18 (d, J=8.4Hz, 1H). MS (ESI+) m / z 225.9 227.9 ([M+1] + ).

[0638]

[0639] A mixture of intermediate-4 (10.0 g, 44.25 mmol) and Ca(OH)2 (7.20 g, 97.35 mmol) in H2O (150 mL) and DMF (20 mL) was stirred at room temperature for 0.5 h, and then (2-bromoethyl)dimethylamine hydrobromide (25.0 g, 107.3 mmol) was added. The mixture was heated at 80°C for 24 h. LCMS showed a 3:1 mixture of intermediates 5 and 6, respectively. The mixture was diluted with H2O (40 mL) and extracted with EtOAc (2×50 mL). The combined extracts were washed with saturated brine, dried over Na2SO4 and filtered. The solvent was removed in vacuo, and the residue was purified using FC (eluent with 0 to 15% MeOH in DCM) to give the crude product. The crude product was further purified by RPFC (0 to 30% MeCN in 0.1% NH4HCO3 / H2O, C18, eluting Intermediate-5 first and then Intermediate-6) to give Intermediate-5 (0.74 g, 5.6% yield) as a white solid and Intermediate-6 (0.25 g, as a light yellow solid).

[0640] Intermediate-5: 1 H NMR (400MHz, DMSO-d6) δ889 (dd, J=2.3, 0.6Hz, 1H), 8.27 (dd, J=8.4, 2.4Hz, 1H), 8.1 0 (dd, J=8.4, 0.6Hz, 1H), 4.87 (t, J=6.1Hz, 2H), 2.87 (t, J=6.1Hz, 2H), 2.17 (s, 6H). 13 C NMR (101MHz, DMSO-d6) δ 163.74, 151.48, 145.51, 140.81, 124.40, 122.21, 57.73, 51.54, 45.29.MS (ESI+) m / z 297.1, 299.1 ([M+1] + Intermediate-6: 1H NMR (400MHz, DMSO-d6) δ8.98 (s, 1H), 8.38 (dd, J=8.4, 2Hz, 1H), 8.20 (d, J=8.4Hz, 1H), 5.00 (t, J=6.4Hz, 2H), 2.75 (t, J=6Hz, 2H), 2.10 (s, 6H), MS (ESI+) m / z 297.1,2991([M+1] + ).

[0641]

[0642] Freshly prepared Intermediate-2 (1.68 g, 4.98 mmol) (from the procedure using Intermediate-3, 1.44 g of (R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxymethyl)- A mixture of (dppf)PdCl2 (182 mg, 0.25 mol) and (dppf)PdCl2 (182 mg, 0.25 mol) was added. The mixture was purged with Ar again. It was then heated to 90 ° C for 15 hours. LCMS showed that the reaction was complete. The residue was concentrated in vacuo and diluted with H2O (200 mL) and extracted with EtOAc (2×200 mL). The combined extracts were washed with saturated brine, dried over Na2SO4 and filtered. The solvent was removed in vacuo, and the residue was purified using RPFC (eluent having 0 to 40% MeCN in H2O) to obtain product AKG-16 (520 mg, 49.0% yield) as a white solid.

[0643] 1 H NMR (400MHz, DMSO-d6) δ8.95 (s, 1H), 8.23 ​​(dd, J=18.3, 8.2Hz, 2H), 7.82-7.66 (m, 2H), 7.54 (dd, J=8.6, 2.1Hz, 1H), 5.28 (s, 1H), 4.89 (t, J= 6.1Hz, 2H), 4.82-4.71 (m, 1H), 417 (t, J=9.0Hz, 1H), 3.98-3.87 (m, 1H), 3.77-3.65 (m, 1H), 364-353 (m, 1H), 290 (t, J=61Hz, 2H), 219 (s, 6H) 13C NMR (101MHz, DMSO-d6) δ164.17, 161.02, 158.58, 154.81, 149.91, 145.59, 141.03, 137.63, 132.10, 131 .39, 122.59, 119.05, 114.47, 105.97, 105.69, 73.95, 62.07, 57.72, 51.46, 46.46, 45.26.MS(ESI+)m / z 428.1([M+1] + )

[0644] 12. Synthesis of AKG-21

[0645]

[0646] A solution of intermediate-2 (1.5 g, 4.5 mmol), intermediate-6 (0.9 g, 3 mmol), Pd (dppf) Cl (247 mg, 0.3 mmol) and K PO (1.3 g, 6 mmol) in dioxane (30 mL) and H O (5 mL) was purged with Ar for 10 minutes and heated to 100 ° C for 15 hours. When the reaction was complete (LCMS), it was concentrated in vacuo, and the residue was diluted with H O (100 mL) and extracted with EtOAc (2 × 50 mL). The combined extracts were washed with saturated brine, dried over Na SO and filtered. The solvent was removed in vacuo, and the residue was purified using FC (eluent with 0 to 10% MeOH in DCM (10% NH OH)) to obtain AKG-21 (450 mg as a white solid) in 35% yield.

[0647] 1 H NMR (400MHz, DMSO-d6) δ9.01 (s, 1H), 8.36 (d, J = 8.4Hz, 1H), 8.30 (d, J = 8.4Hz, 1H), 7. 81 (t, J=8.8Hz, 1H), 7.74 (dd, J=13.6, 2.0Hz, 1H), 7.55 (dd, J=8.4, 2.0Hz, 1H), 5.26 (t , J=5.6Hz, 1H), 5.08 (t, J=6.4Hz, 2H), 4.79-4.75 (m, 1H), 4.18 (t, J=9.2Hz, 1H), 3.93- 3.89 (m, 1H), 3.74-3.68 (m, 1H), 3.62-3.56 (m, 1H), 2.80 (t, J=6.4Hz, 2H), 2.13 (s, 6H) 13C NMR (101MHz, DMSO-d6): δ161.09, 158.64, 154.80, 152.10, (149.45, 149.40), 143.46, (141.35, 141.23), (138.19, 138.15), (132.77, 1 32.76), (131.53, 131.48), 124.58, (118.69, 118.56), (114.51, 114.49), (105.97, 105.68), 73.96, 62.06, 58.38, 47.26, 46.47, 45.42.

[0648] 13. Synthesis of AKG-22

[0649]

[0650] To a mixture of Intermediate-7 (500 mg, 1.354 mmol) in H₂O (2 mL) and dioxane (8 mL) was added Intermediate-2 (685 mg, 2.03 mmol), K₃PO₄ (862 mg, 4.06 mmol), and (dppf)PdCl₂ (99 mg, 0.135 mmol). The flask was evacuated and backfilled with Ar. The mixture was then stirred at 90°C for 16 hours. Water (20 mL) was added and extracted with EtOAc (2 x 20 mL). The organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated. The residue was purified by silica gel column chromatography (Biotage, 40 g silica gel column @ 30 mL / min, eluting with 0 to 100% EtOAc in petroleum ether) to give the desired product AKG-22-1 (450 mg, yield: 66%) as a gray solid.

[0651]

[0652] To a mixture of AKG-22-1 (450 mg, 0.9 mmol) in DCM (8 mL) was added 4M HCl / dioxane (2 mL). The mixture was then stirred at room temperature for 5 hours. The solvent was removed under vacuum to give the desired product AKG-22 (390 mg, 99% yield) as a gray solid.

[0653] 1H NMR (400MHz, DMSO-d6) δ9.03 (s, 1H), 8.39 (d, J = 8.0Hz, 1H), 8.32 (d, J = 8.0Hz, 1 H), 8.19 (brs, 3H), 7.82-7.70 (m, 2H), 7.57 (dd, J=8.8, 2.0Hz, 1H), 5.18 (t, J=5 .8Hz, 2H), 4.81-4.74 (m, 1H), 4.17 (t, J=9.2Hz, 1H), 3.93 (dd, J=9.2, 6.4Hz, 1H ), 3.71 (dd, J=12.4, 3.2Hz, 1H), 3.59 (dd, J=12.4, 4.0Hz, 1H), 3.53-3.47 (m, 2H) 13 C NMR (400MHz, DMSO-d6) δ (161.07, 158.63), 154.82, 152.52, 149.54, 143.25, (141.39, 141.28), 1 38.24, 124.54, (118.66, 118.53), 114.60, (106.01, 105.73), 73.97, 62.02, 47.37, 46.48, 38.84.

[0654] 14. Synthesis of AKG-23

[0655]

[0656] To intermediate-8 (1.0 g, 2.71 mmol) in 20 mL of 1,4-dioxane and 5 mL of H O was added intermediate-2 (4.86 mmol, 1.63 g), K PO (1.14 g, 5.42 mmol) and (dppf) PdCl (0.23 g, 0.27 mmol), and the mixture was stirred at 100° C. for 16 hours. After the starting material was consumed, 100 mL of saturated NaHCO was added. The aqueous phase was extracted with EtOAc (3×30 mL), and the combined organic extracts were washed with H O, concentrated in vacuo, and purified by FC to give the desired compound AKG-23-1 (1.0 g, 70% yield).

[0657]

[0658] To AKG-23-1 (1.0 g, 2 mmol) in 30 mL of DCM was added 1 mL of HCl (4 M in 1,4-dioxane) and the mixture was stirred for 1 hour. After the starting material was consumed, the mixture was filtered to obtain a crude product. The crude product was stirred in 3 mL of MeOH for 1 hour and filtered to obtain the desired product AKG-23 (0.53 g, 63% yield) as a white solid.

[0659] 1 H NMR (400MHz, DMSO-d6) δ8.97 (s, 1H), 8.26 (m, 5H), 7.83-7.64 (m, 2H), 7.54 (dd, J=8.6, 1.9Hz, 1H), 5.09 (s, 2H), 4.77 (m, 1H), 4. 16 (t, J=9.1Hz, 1H), 3.92 (dd, J=8.8, 6.2Hz, 1H), 3.71 (dd, J=12.3, 3.2Hz, 1H), 3.61-3.57 (dd, J=12.3, 3.2Hz, 1H), 3.53 (m, 3H). 13 C NMR (125MHz, DMSO-d6) δ38.31, 46.49, 50.86, 62.01, 73.96, [105.69, 105.97], 114.46, [118.90, 119.03], 122.73, [ 131.37, 131.47], 132.21, [137.66, 137.70], [140.99, 141.10], 145.42, 149.86, 154.82, [158.57, 161.02], 164.50.

[0660] 15. Synthesis of AKG-24

[0661]

[0662] A mixture of intermediate-2 (1.66 g, 4.98 mmol), intermediate-9 (800 mg, 2.49 mmol) and K3PO4 (1.16 g, 5.48 mmol) in dioxane (50 mL) and H2O (5 mL) was purged with Ar for 10 minutes, and (dppf)PdCl2 (182 mg, 0.25 mmol) was added. The mixture was purged with Ar again. It was then heated to 90°C for 15 hours. LCMS showed that the reaction was complete; it was concentrated in vacuo, and the residue was diluted with H2O (200 mL) and extracted with EtOAc (2×200 mL). The combined extracts were washed with saturated brine, then dried over Na2SO4 and filtered. The solvent was removed in vacuo, and the residue was purified using RPFC (eluent with 0 to 40% MeCN in H2O) to give the product AKG-24 (440 mg, 39.0% yield) as a white solid.

[0663] 1H NMR (400MHz, DMSO-d6) δ8.95 (s, 1H), 8.28-8.16 (m, 2H), 7.81-7.67 (m, 2H), 7.54 (dd, J=8.6, 2.1Hz, 1H), 5.27 (t, J=5.6Hz, 1H), 4. 93-4.70 (m, 3H), 4.17 (t, J=9.1Hz, 1H), 3.92 (dd, J=8.9, 6.1Hz, 1H), 3.72 (m, 1H), 3.60 (m, 1H), 3.04 (s, 2H), 0.87 (t, J=6.9Hz, 6H). 13 C NMR (101MHz, DMSO-d6) δ164.13, 161.03, 158.59, 154.81, 149.94, 149.90, 145.66, 141.09, 140.98, 137.66, 137.62, 132.10, 132.08, 13 1.41, 131.37, 122.54, 119.15, 119.02, 114.50, 114.47, 105.99, 105.71, 73.95, 62.08, 52.09, 51.60, 46.85, 46.48, 12.26.MS(ESI+)m / z 456([M+H] + ).

[0664] 16. Synthesis of AKG-25

[0665]

[0666] To a mixture of intermediate-4 (2.25 g, 10 mmol) and K2CO3 (5.52 g, 40 mmol) in DMF (20 mL) was added 3-chloro-N, N-dimethylpropane-1-amine hydrochloride (3.95 g, 25 mmol), and the mixture was heated to 80°C for 4 hours. Diluted with H2O (40 mL) and extracted with EtOAc (2 x 100 mL). The combined extracts were washed with saturated brine, then dried over Na2SO4 and filtered. The solvent was removed in vacuo, and the residue indicated the presence of two regioisomers of N-alkylation. The isomers were separated using FC (eluent having 0 to 15% MeOH in DCM) to give intermediate-10 (0.98 g, 31.6% yield) as a white solid.

[0667] 1H NMR (400MHz, CDCl3) δ8.83 (dd, J=2.4, 0.8Hz, 1H), 8.16 (dd, J=8.0, 0.4Hz, 1H), 8.01 (dd, J=8.4, 2.4Hz, 1H), 4.78 (t, J=6.8Hz, 2H), 2.38 (t, J=3.2Hz, 2H), 2.27-2.22 (m, 8H).MS (ESI+) m / z311.1, 313.1 ([M+1] + ).

[0668]

[0669] A mixture of intermediate-10 (0.74 g, 2.4 mmol), intermediate-2 (1.62 g, 4.8 mmol) and K 3 PO 4 (1 g, 4.8 mmol) in dioxane (30 mL) and H 2 O (5 mL) was purged with Ar for 10 minutes, and Pd (dppf) Cl 2 (175 mg, 0.24 mmol) was added. The mixture was purged with Ar again and heated to 90 ° C for 15 hours. The mixture was concentrated in vacuo and the residue was diluted with H 2 O (80 mL) and extracted with EtOAc (2×100 mL). The combined extracts were washed with saturated brine, then dried over Na 2 SO 4 and filtered. The solvent was removed in vacuo, and the residue was purified using FC (eluent with 0 to 15% MeOH in DCM) to obtain the product AKG-25 (0.73 g, 69.5% yield) as a gray solid.

[0670] 1 H NMR (400MHz, DMSO-d6) δ8.94 (s, 1H), 8.24-8.26 (m, 1H), 8.19-8.21 (m, 1H), 7.78 -7.70 (m, 2H), 7.54 (dd, J=8.4, 2.0Hz, 1H), 5.27 (t, J=5.6Hz, 1H), 4.80 (t, J=6.8 Hz, 2H), 4.77-4.75 (m, 1H), 4.16 (t, J=9.2Hz, 1H), 3.92 (dd, J=8.8Hz, 6.0Hz, 1H) , 3.74-3.69 (m, 1H), 3.63-3.58 (m, 1H), 2.28 (t, J=7.2Hz, 2H), 2.10-2.17 (m, 8H). 13C NMR (101MHz, DMSO-d6) δ164.26, 161.03, 158.58, 154.81, 149.92, 145.58, 141.09, 137.65, 132.10, 131.37, 12 2.60, 119.12, 118.99, 114.46, 105.98, 105.70, 73.95, 62.07, 55.96, 51.65, 46.47, 45.53, 27.21.MS(ESI+)m / z 442.1([M+1] + ).

[0671] 17. Synthesis of AKG-26

[0672]

[0673] To a solution of Intermediate-4 (5.0 g, 22.12 mmol) in DMF (30 mL) was added (3-chloropropyl)diethylamine hydrochloride (8.23 g, 55.30 mmol) and KCO (9.17 g, 66.36 mmol) at 80° C. for 3 hours. The reaction was cooled and poured into an ice-water bath and extracted with EA (2×200 mL). The combined organic phases were washed with brine (2×50 mL) and dried over NaSO. After removal of the solvent, the crude product with the N-alkylated regioisomer was purified by FC (PE / EA=1:10) to give Intermediate-11 (1.70 g, 22.65%) as a white solid.

[0674] 1 H NMR (500MHz, CDCl3) δ8.34 (d, J=2.0Hz, 1H), 8.15 (d, J=8.0Hz, 1H), 8.00 (dd, J=8.0, 2.0Hz, 2H ), 4.77 (t, J=7.0Hz, 2H), 2.53-2.49 (m, 6H), 2.26-2.20 (m, 2H), 0.99 (t, J=7.5Hz, 6H).MS (ESI + )m / z 339.1,341.1([M+1] + ).

[0675]

[0676] A mixture of Intermediate-11 (0.68 g, 2.00 mmol), Intermediate-2 (1.07 g, 3.99 mmol), potassium phosphate tribasic (0.85 g, 3.985 mmol), and Pd(dppf)Cl (0.15 g, 0.20 mmol) was suspended in 1,4-dioxane:water (12 mL, 6:1). The reaction was stirred at reflux for 16 hours. The mixture was partitioned between EtOAc (2 x 100 mL) and water, washed with brine, dried over NaSO, and filtered. The residue, containing regioisomers, was purified using FC (DCM / MeOH = 20 / 1) to yield AKG-26 (0.54 g, 56.04%) as a gray solid.

[0677] 1 H NMR (500MHz, DMSO-d6) δ8.95 (s, 1H), 8.26-8.19 (m, 2H), 7.78-7.70 (m, 2H), 7.53 (dd, J=10.5, 2.5Hz, 1H), 5.27 (d, J=7.5Hz, 1H), 4.83-4.75 (m, 2H), 4.1 7(t, J=11.5Hz, 1H), 3.92 (dd, J=11.0, 7.5Hz, 1H), 3.74-3.69 (m, 1H), 3.62- 3.58(m, 1H), 3.51-3.28(m, 8H), 2.14(t, J=8.0Hz, 2H), 0.93(t, J=85Hz, 6H). 13 C NMR (101MHz, DMSO-d6) δ164.24, 161.03, 158.59, 154.52, 149.91, (d, J=3.2Hz), 145.59, 141.03 (d, J=11.8Hz), 137.64 (d, J=3.2Hz), 132.12, 131.40 (d, J=4.5Hz), 122.57, 119.06 (d, J=12.8Hz), 114.47 (d, J=2.8Hz,), 105.97, 105.70, 73.96, 62.07, 51.70, 49.19, 46.75, 46.48.MS (ESI + )m / z 470.1([M+1] + ).

[0678] 18. Synthesis of AKG-27

[0679]

[0680] To a solution of intermediate-4 (6.3 g, 27.87 mmol) in DMF (42 mL) was added BocNH(CH2)3Br (16.6 g, 69.71 mmol) and K2CO3 (11.1 g, 80.02 mmol) at 80°C for 3 hours. The reaction was cooled and poured into an ice-water bath and extracted with EtOAc (2×200 mL). The organic phase was washed with brine (2×50 mL), dried over Na2SO4 and filtered, and the solvent was evaporated under reduced pressure. The crude product with N-alkylated regioisomers was purified by FC (PE / EA=2:1) ​​to give intermediate-12 (14 g, 13.1%) as a yellow solid.

[0681] 1 H NMR (400MHz, DMSO-d6) δ8.89 (d, J=2.4Hz, 1H), 8.28 (dd, J=8.4Hz, 1H), 8.11 (d, J=8.4Hz, 1H), 6.97 (s , 1H), 4.77 (t, J=6.8Hz, 2H), 3.03 (q, J=12.4Hz, 2H), 2.15-2.08 (m, 2H), 1.37 (s, 9H)ppm.MS (ESI+) m / z 383.0([M+1] + ).

[0682]

[0683] A solution of Intermediate-12 (0.83 g, 2.15 mmol), NaHCO (0.36 g, 4.31 mmol) and Intermediate-2 (1.24 g, 3.68 mmol) was suspended in 1,4-dioxane (32 mL) and water (8 mL). The mixture was bubbled with N for 5 minutes and then charged with Pd(dppf)Cl (0.078 g, 0.095 mmol). The mixture was stirred at 90° C. for 15 hours and then cooled to room temperature. The mixture was partitioned between EtOAc (2×100 mL) and water. The organic layer was dried over NaSO, filtered and concentrated. The concentrated filtrate was purified by silica gel column chromatography on silica gel (DCM / MeOH=20 / 1) to give AKG-27-1 (0.75 g; 66.9%) as a white solid.

[0684] 1H NMR (400MHz, DMSO-d6) δ8.95 (s, 1H), 8.25 (d, J = 8.5Hz, 1H), 8.21 (d, J = 8.4Hz, 1H), 7.78-7.70 (m, 2H), 7.54 (d, J=8.5Hz, 1H), 6.93 (s, 1H), 5.26 (t, J=5.0Hz, 1H), 4.80 -4.75 (m, 3H), 4.17 (t, J=9.0Hz, 1H), 3.91 (t, J=8.5Hz, 1H), 3.71-3.69 (m, 1H), 3.6 0-3.59(m, 1H), 3.06-3.03(m, 2H), 2.15-2.12(m, 2H), 1.37(s, 9H)ppm.MS(ESI+)m / z 514.0([M+1] + ).

[0685]

[0686] To a solution of AKG-27-1 (0.9 g, 1.75 mmol) in anhydrous DCM (16 mL) was added HCl (4.0 mL) in dioxane at room temperature under N2 atmosphere. The reaction mixture was stirred at the same temperature for 6 hours and cooled to room temperature. The solvent was evaporated under reduced pressure to give AKG-27 (0.65 g, 82.5%) as a light yellow solid.

[0687] 1 H NMR (400MHz, DMSO-d6) δ8.95 (s, 1H), 8.26-8.20 (m, 5H), 7.77-7.70 (m, 2H), 7.53 (d, J = 7.6Hz, 1H), 4.94 (d, J = 6.4Hz, 2H), 4.77 (s, 1H), 4.51 (s, 2H) , 4.16 (t, J = 8.8Hz, 1H), 3.93 (t, J = 7.0Hz, 1H), 3.71 (d, J = 12.4Hz, 1H), 3.60 (d, J = 12.4Hz, 1H), 2.94 (s, 2H), 2.34 (t, J = 6.8Hz, 2H) ppm.MS (ESI+) m / z 414.0([M+1] + ).

[0688] 19. Synthesis of AKG-28 to 31

[0689] To (R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxymethyl) To a solution of oxazolidin-2-one (9 g, 31 mmol) in DCM (100 mL) was added oxazolidin-2-one (3.92 g, 34 mmol) and TEA (3.76 g, 37 mmol). The mixture was stirred at room temperature for 2 hours. The mixture was washed with water (2×30 mL) and brine (2×30 mL), dried over Na 2 SO 4 , filtered and concentrated to give Intermediate-13 (11.4 g, 99% yield). MS (ESI+) m / z 368 ([M+1] + ).

[0690] To a solution of Intermediate-13 (11.4 g, 31 mmol) in DMF (200 mL) was added potassium 1,3-dioxoisoindoline-2-ide (6.02 g, 32 mmol). The mixture was stirred at 90°C overnight. The mixture was cooled and poured into water (1000 mL) and stirred for 0.5 hours. The precipitate was collected and dried under vacuum to give Intermediate-14 (11 g, yield 85%). MS (ESI+) m / z 419 ([M+1] + ).

[0691] To a solution of Intermediate-14 (11 g, 26.3 mmol) in EtOH (150 mL) was added NH2NH2-H2O (85%, 7.7 g, 131 mmol). The mixture was stirred at 90°C overnight. The mixture was filtered and rinsed with EtOH (2×50 mL). The filtrate was concentrated to give Intermediate-15 (7.6 g, 100% yield). MS (ESI+) m / z 289 ([M+1] + ).

[0692] To a solution of Intermediate-15 (7.6 g, 26.4 mmol) in THF (50 mL) and water (50 mL) was added (Boc)20 (6.9 g, 32 mmol) and K2CO3 (7.29 g, 52.8 mmol), and the mixture was stirred for 2 hours. The mixture was diluted with water (100 mL) and extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (2×50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by FC (Biotage, 80 g silica gel column @ 65 mL / min, eluting with 0 to 60% EtOAc in petroleum ether over 30 minutes) to give Intermediate-16 (7.8 g, 75% yield). MS (ESI+) m / z 411 ([M+23] + ).

[0693] A mixture of Intermediate-16 (7.8 g, 20 mmol), bis(pinacolato)diboron (6.54 g, 30 mmol) and KOAc (2.94 g, 30 mmol) in dioxane (100 mL) was purged with Ar for 10 minutes, and then (Ph3P)2PdCl2 (1.06 g, 1.5 mmol) was added. The mixture was purged with Ar again and stirred at 90°C overnight. The mixture was cooled, diluted with water (300 mL), and extracted with EtOAc (3×100 mL). The combined extracts were washed with brine (2×50 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by FC (Biotage, 80 g silica gel column @ 65 mL / min, eluting with 0 to 60% EtOAc in petroleum ether over 30 minutes) to give Intermediate-18 (6.2 g, 70% yield). MS (ESI+) m / z 459 ([M+23] + ).

[0694] Procedure C: A mixture of one of Intermediates 5 / 8 / 9 / 10 / 11 (1.0 equiv), one of Intermediates 18 / 19 (1.5 equiv), Pd(dppf)Cl2DCM (0.1 equiv), and K3PO4 (2.0 equiv) in dioxane / H2O (10:1, 0.06 M) was purged with N2 and stirred at 90°C overnight. The mixture was diluted with EtOAc, washed with water and brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was purified by FC to give one of compounds AKG-28-1 / AKG-29-1 / AKG-30-1 / AKG-31-1 / AKG-38 / AKG-39 / AKG-40.

[0695] To a solution of one of the compounds AKG-28-1 / AKG-29-1 / AKG-30-1 / AKG-31-1 in DCM (1 mL / 100 mg) was added 3N HCl in EtOAc (20 equivalents). The mixture was stirred for 2 hours and then filtered. The solid was vacuum dried or lyophilized to give one of the final compounds AKG-28 / AKG-29 / AKG-30 / AKG-31 (yields of 35 to 44% for both steps).

[0696]

[0697] Procedure C was used. The product was obtained as a white solid from Intermediate-5 and Intermediate-18 (0.35 g, 35% yield).

[0698] 1H NMR (500MHz, DMSO-d6) δ10.53 (s, 1H), 8.97 (s, 1H), 8.37 (s, 3H), 8.29 (d, J=8.5Hz , 1H), 824 (d, J=8.5Hz, 1H), 7.80 (t, J=8.5Hz, 1H), 7.69 (dd, J=13.5, 2.0Hz, 1H), 7 .50 (dd, J=8.5, 2.0Hz, 1H), 5.31 (t, J=6.0Hz, 2H), 5.04-4.99 (m, 1H), 4.28 (t, J=9 .0Hz, 1H), 3.96 (dd, J=9.0, 6.5Hz, 1H), 3.84 (s, 2H), 3.28 (s, 2H), 2.87 (s, 6H)ppm. 13 C NMR (126MHz, D2O) 6163.90(s), 160.30(s), 158.33(s), 154.86(s), 148. 55(s), 142.64(s), 138.93(d, J=11.0Hz), 137.74(s), 132.43(s), 130.39 (s), 122.46(s), 119.03(s), 114.36(s), 106.41(s), 106.18(S), 70.31(s) ), 55.23(s), 48.07(s), 47.69(s), 43.29(s), 42.19(s)ppm.MS(ESI+)m / z 427.1([M+1] + ).

[0699]

[0700] Procedure C was used. The product was obtained as a white solid from Intermediate-8 and Intermediate-18 (0.4 g, 44% yield).

[0701] 1H NMR (400MHz, DMSO-d6) δ8.97 (s, 1H), 8.57-8.41m, 6H), 8.29-8.13 (m, 2H), 7.80 (t, J=9 .0Hz, 1H), 7.69 (dd, J=13.5, 2.5Hz, 1H), 7.49 (dd, J=8.5, 2.0Hz, 1H), 5.12-5.03 (m, 3H ), 4.28 (t, J=9.0Hz, 1H), 4.02-3.98 (m, 1H), 3.54-3.51 (m, 2H), 3.33-3.26 (m, 2H).8.2 8 (s, 1H), 7.73-7.65 (m, 1H), 7.60 (dd, J=13.6, 2.1Hz, 1H), 754 (t, J=8.9Hz, 1H), 7.41 (d d, J=8.6, 2.1Hz, 1H), 6.89 (d, J=9.0Hz, 1H), 5.25 (t, J=5.6Hz, 1H), 4.78-4.68 (m, 1H), 433 (d, J=13.0Hz, 2H), 4.12 (t, J=90Hz, 1H), 3.87 (dd, J=8.9, 6.2Hz, 1H), 3.74-3.64 (m, 1H), 3.62-3.52(m, 1H), 2.87-2.71(m, 2H), 2.23(t, J=7.3Hz, 2H), 2.11(s, 6H), 1.72(d , J=11.5Hz, 2H), 1.64-149 (m, 1H), 1.34 (dd, J=14.3, 7.0Hz, 2H), 1.18-1.04 (m, 2H)ppm. 13 C NMR (101MHz, D2O) 6161.52, 160.59, 158.12, 154.86, 145.70, 141.05, 140.16, 139.65, 133.57, 13 0.44, 123.64, 117.70, 114.54, 106.50, 10622, 70.34, 50.81, 47.68ppm.MS(ESI+)m / z3992([M+1] + ).

[0702]

[0703] Procedure C was used. The product was obtained as a white solid from Intermediate-10 and Intermediate-18 (0.36 g, 40% yield).

[0704] 1H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 8.96 (s, 1H), 8.52 (s, 3H), 8.28-8.22 (m, 2H), 7 79 (t, J=8.8Hz, 1H), 7.69 (dd, J=13.6, 2.0Hz, 1H), 7.49 (dd, J=8.8, 2.0Hz, 1H), 5.08- 5.01 (m, 1H), 4.93 (t, J=6.8Hz, 2H), 4.28 (t, J=9.2Hz, 1H), 4.00 (dd, J=9.2, 6.8Hz, 1H ), 3.29-3.26(m, 2H), 3.21-3.16(m, 2H), 2.75(d, J=4.8Hz, 6H), 2.49-2.43(m, 2H)ppm 13 CNMR (101MHz, D20) δ16239(s), 160.58(s), 15811(s), 154.88(s), 147.20( s), 141.66 (s), 139, 28 (d, J = 11.3Hz), 132.86 (s), 130.45 (s), 122.90 (s), 118.44(d, J=12.0Hz), 114.44(s), 106.46(s), 106.17(s), 70.30(s), 54.5 6(s), 5062(s), 47.68(s), 42.89(s), 42.16(s), 23.74(s)ppm.MS(ESI+)m / z 441([M+1] + ).

[0705]

[0706] Procedure C was used. The product was obtained as a white solid from Intermediate-11 and Intermediate-18 (0.36 g, 42% yield).

[0707] 1H NMR(400MHz,DMSO-d6)δ10.10(s,1H),8.96(s,1H),8.390-821(m,5H),7.80(t,J=8.8Hz,1H),7.69(dd,J=13.6,2.0Hz,1H),7.50(dd,J=8.8,2.0Hz,1H),5.04-4.97(m,1H),4.94(t,J=6.8Hz,2H),4.28(t,J=9.2Hz,1H),3.94(dd,J=9.6,6.4Hz,,1H),3.31-3.26(m,2H),3.21-3.17(m,2H),3.15-3.12(m,4H),2.46-2.42(m,2H),1.21(t,J=7.2Hz,6H)ppm. 13 C NMR(101MHz,D2O)δ163.04(s),160.53(s),158.07(s),154.84(s),147.95(d,J=5.4Hz),142.36(s),139.05(d,J=11.3Hz),138.32(s),132.44(s),130.38(d,J=4.0Hz),122.50(s),118.72(d,J=12.8Hz),114.35(s),106.37(s),106.09(s),70.29(s),50.65(s),48.55(s),47.64(d,J=7.4Hz),42.17(s),23.05(s),8.24(s)ppm.MS(ESI+)m / z469([M+1] + )。

[0708] To a solution of Intermediate-15 (7.6 g, 26.4 mmol) in DCM (150 mL) was added triethylamine (TEA, 4.57 g, 6.27 mL, 52.77 mmol, 2.0 equiv) at 0 to 5 ° C under N 2 , followed by acetyl chloride (AcCl, 2.6 g, 2.74 mL, 39.58 mmol, 1.5 equiv) and 4-N,N-dimethylaminopyridine (DMAP, 0.028 g, 2.64 mmol, 0.01 equiv). The resulting reaction mixture was then stirred at 0 to 5 ° C for 2 hours. When TLC and LCMS showed the reaction was complete, the reaction mixture was quenched with H 2 O (100 mL). The two layers were separated, and the aqueous layer was then extracted with C H 2 Cl 2 (2×50 mL), and the combined organic extracts were washed with H 2 O (2×100 mL) and saturated aqueous NaCl solution (100 mL), dried over MgSO 4 , and concentrated in vacuo. The residue was purified by FC (Biotage, 80 g silica gel column @ 65 mL / min, eluting with 0 to 60% EtOAc in petroleum ether over 30 min) to afford Intermediate-17 (6.5 g, 75% yield). MS (ESI+) m / z 332 ([M+1] + ).

[0709] To a solution of Intermediate-17 (6.5 g, 19.7 mmol) in 1,4-dioxane (100 mL) was added 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloromethane complex (1.61 g, 1.97 mmol), bis(pinacolato)diboron (10 g, 39.39 mmol) and KOAc (4.83 g, 49.24 mmol). The resulting reaction was stirred at 90°C for 4 hours. When TLC and LCMS showed the reaction was complete, the reaction mixture was cooled to room temperature and subsequently treated with water (100 mL) and EtOAc (100 mL). The two layers were separated and the aqueous layer was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (2 x 50 mL) and saturated aqueous NaCl solution (50 mL), dried over MgSO4, and concentrated in vacuo. The residual brown oil was purified by FC (Biotage, 80 g silica column @ 60 mL / min, eluting with 0 to 100% EtOAc in petroleum ether over 30 min) to afford Intermediate-19 (6.6 g, 88.7% yield). MS (ESI+) m / z 379 ([M+1] + ).

[0710] 20. Synthesis of AKG-38 to 40.

[0711]

[0712] Procedure C was used. The product was obtained as a white solid from Intermediate-5 and Intermediate-19 (0.48 g, 60% yield).

[0713] 1 H NMR (400MHz, DMSO) δ8.95 (s, 1H), 8.29-8.19 (m, 3H), 7.77 (t, J=8.8Hz, 1H), 7.69 (dd, J=13.6, 2.0Hz, 1H), 7.50 (dd, J=8.8, 2.0Hz, 1H), 4.89 (t, J=6.0Hz , 2H), 4.81-4.76 (m, 1H), 4.20 (t, J=9.2Hz, 1H), 3.82 (dd, J=9.2, 6.8Hz, 1H) , 3.45 (t, J=5.6Hz, 2H), 2.90 (t, J=6.0Hz, 2H), 2.19 (s, 6H), 1.85 (s, 3H)ppm 13 C NMR (101MHz, DMSO-d6) δ170.51, 164.17, 154.46, 149.94, 145.62, 140.90, 137.63, 132.07, 131.39, 122. 59, 119.25, 114.66, 106.18, 105.90, 72.34, 57.71, 51.45, 47.67, 45.25, 41.87, 22.92ppm.MS(ESI+)m / z 469.2([M+1] + ).

[0714]

[0715] Procedure C was used. The product was obtained as a white solid from Intermediate-9 and Intermediate-19 (0.35 g, 40% yield).

[0716] 1 H NMR (400MHz, DMSO) δ8.95 (s, 1H), 8.29-8.19 (m, 3H), 7.76 (t, J=8.8Hz, 1H), 7 .69 (dd, J=13.6, 2.0Hz, 1H), 7.50 (dd, J=8.8, 2.0Hz, 1H), 4.84-4.76 (m, 3H), 4 .21 (t, J=9.2Hz, 1H), 3.82 (dd, J=9.2, 6.4Hz, 1H), 3.46 (t, J=5.6Hz, 2H), 3.0 4 (t, J=5.6Hz, 2H), 2.50-2.47 (m, 4H), 1.85 (s, 3H), 0.87 (t, J=7.2Hz, 6H)ppm. 13C NMR (101MHz, DMSO-d6) δ170.50, 164.11, 154.46, 149.91, 145.68, 137.68, 132.04, 131.40, 122.53, 119.27 (d, J=13.3Hz), 114.65, 106. 18,105.90,7234,52.11,51.61,47.67,46.83,41.87,40.63,40.42,40.22,40.01,39.80,39.59,39.38,22.92,12.28ppm.MS(ESI+)m / z 497([M+1] + ).

[0717]

[0718] Procedure C was used. The product was obtained as a white solid from Intermediate-11 and Intermediate-19 (0.36 g, 50% yield).

[0719] 1 H NMR (400MHz, DMSO-d6) δ8.95 (s, 1H), 8.31-8.18 (m, 3H), 7.77 (t, J=8.8Hz, 1H), 7.69 (dd, J=13.6, 2.0Hz, 1H), 7.50 (dd, J=8.8, 2.0Hz, 1H), 4.88 -471 (m, 3H), 4.20 (t, J=9.2Hz, 1H), 3.81 (dd, J=9.2, 6.4Hz, 1H), 3.45 (t, J=5.6Hz, 2H), 2.45 (s, 6H), 2.14 (s, 2H), 1.85 (s, 3H), 0.93 (s, 6H)ppm. 13 C NMR (101MHz, DMSO-d6) δ 137.70, 131.45, 114.69, 46.79, 41.86, 40.64, 40.43, 40.22, 40.01, 39.80, 39.59, 39.38ppm.MS (ESI+) m / z 511 ([M+1] + ).

[0720] Example 2. In vitro activity assay of Mycobacterium tuberculosis

[0721] The broth microdilution MIC method used is described in Collins et al., 1997 and Gruppo et al., 2006. The MIC or minimum inhibitory concentration of a compound prevents visible growth of bacteria after overnight incubation.

[0722] Briefly, MICs were determined by broth microdilution assay with the aid of an Alamar blue endpoint (MABA) as described by Collins et al., 1997 (Collins L, Franzblau SG (1997). Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. AAC. 41(5): 1004–1009) and Gruppo et al., 2006 (Gruppo V, Johnson CM, Marietta KS, Scherman H, Zink EE, Crick DC, Adams LB, Orme IM, Lenaerts AJ. (2006) Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. AAC 50: 1245–1250). MABA is a 96-well colorimetric assay in which the redox indicator Alamarblue changes color from blue to pink in the presence of mycobacterial growth activity in broth.

[0723] In brief, 7H9 complete medium is prepared by following: in 1L flask, add the 7H9 broth powder (Millipore Sigma Cat#M0178) of Middlebrook 4.7g, 2mL glycerol and 898 purified water, and mix until dissolving, and then add the ADC solution (6g bovine serum albumin, 2g dextrose and 3mg catalase of 100mL, it is dissolved in 100mL water) of same 1L flask.Compound is made into 10mg / mL concentration in DMSO, and is further diluted to 80 μ g / mL with DMSO subsequently, or is diluted to desired 2 μ g / mL starting concentration forty times.By in drug preparation plate, 50 μ l drug solution in first well is added to 50 μ l DMSO in subsequent wells, and this process is carried out to next eight wells, thereby prepares a series of nine 1:2 dilutions. The stocks of Mycobacterium tuberculosis (M. tuberculosis, M. tb) H34Rv and M. tb Erdman strains were raised from 3 to 4 × 10 7 The initial CFU / mL concentration was diluted to 5 × 105 The final concentration of CFU / mL was determined and the mixture was mixed thoroughly by pipetting up and down with a multichannel pipette.

[0724] By adding 100 μl of 5 × 10 5 The CFU / mL inoculation culture medium is transferred in all holes to prepare assay plate. Subsequently, 2.5 μ L of each drug dilution from the drug preparation plate is transferred to the corresponding wells in the assay plate. Subsequently, the assay plate is placed in a ziplock bag, and placed in an incubator, where it is hatched at 37 ℃. Subsequently, at the 3rd day and the 10th day, on a plate reader, plate was read under OD 600nm. After the 10th day OD600 was read, 10 μ l Alamar Blue dye was added to each assay well. At the 12th day, all assay plates were scanned on a plate color scanner. Under Alamar Blue, do not produce visible color changes from blue to pink and / or demonstrate OD600 relative to the no-drug control wells to reduce the minimum continuous antimicrobial concentration (generally 2 times of serial dilutions) that is considered as the MIC of these compounds.

[0725] The assay was performed using two unique drug-sensitive strains (M. tb Erdman and M. tb H37Rv). MIC determinations can also be performed in the presence of 4% (w / v) human serum albumin (huSA) (Sigma #A1653) to assess potential protein binding (serum shift assay). Generally, a shift in the MIC across two wells (a 4-fold shift in the MIC) is considered significant. For PA-824 (positive control), a 4-fold shift in the MIC is expected.

[0726] MICs measured by Alamar Blue (MABA) readout or by optical density readout (OD600) were consistent or differed only at a 2-fold dilution, which was within the limits of the assay. All compounds tested, except one compound, AKG-40, showed consistent MIC values ​​against both Mtb Erdman and H37Rv, or within a 2-fold dilution range; this showed higher MIC values ​​(1 to 2 ug / mL) for Erdman and a lower MIC value (0.5) for H37Rv. This difference may be due to slower growth on Erdman plates (lower OD readings).

[0727] The results showed that the expected MIC value for linezolid was 2 μg / mL, the expected MIC value for tedizolid was 0.25 μg / mL, and the expected MIC value for bedaquiline was 0.125 μg / mL. These values ​​are consistent with past MIC data and published values ​​(Ruiz et al. Antimicrob. Agents Chemother. 2019, Mar 27; 63(4), pii:e01939-18; Reddy et al. Antimicrob Agents Chemother. 2010 Jul; 54(7): 2840-6; Torrea et al. J Antimicrob Chemother. 2015 Aug; 70(8): 2300-5). AKG-28 showed MICs of 0.03 to 0.015 μg / mL, which was significantly more active than tedizolid. In the presence of acetamide-containing Among the oxazolidinone analogs, AKG-39 showed an MIC of 0.5 μg / mL, and AKG-40 had an MIC of 1 to 0.5 μg / mL. AKG-38, with an MIC of 0.06 μg / mL, also showed several times greater activity than terazolidone.

[0728] exist Molecules with an amine or acetamide group at the C5 position of the oxazolidinone were more active (AKG-3 vs tedizolid, AKG-28 or AKG-38 vs AKG-16, AKG-39 vs AKG-24, AKG-40 vs AKG-26), and compounds with an aminoalkyl side chain on the tetrazole showed favorable activity. Substitution of the primary amine (AKG-28-1 vs. AKG-28) or acetamide (AKG-28-1 vs. AKG-38) at the C5 position of the oxazolidinone with a tert-butyloxycarbonylamino group (Boc-NH) resulted in decreased activity. Compounds containing dimethylaminoalkyl side chains were particularly superior when compared to aminoethyl or diethylaminoethyl analogs (AKG-16 vs. AKG-24, AKG-28 vs. AKG-29, AKG-30 vs. AKG-31). Similarly, shorter dialkylaminoalkyl side chains on the tetrazole ring (e.g., ethylene vs. propylene) showed greater activity (AKG-16 vs. AKG-25, AKG-24 vs. AKG-26, AKG-28 vs. AKG-30). Analogs substituted at the 2' position of the tetrazole were more active than those substituted at the 1' position (AKG-16 vs AKG-21, AKG-23 vs AKG-22).

[0729]

[0730] Table 2

[0731]

[0732]

[0733] Example 3. In vitro cytotoxicity assay against human kidney and human liver cells

[0734] Compounds were tested in vitro in a series of 10 dilutions to determine the IC50 in African green monkey kidney (Vero; ATCC #CCL81) or human hepatocytes / liver (HepG2; ATCC #HB8065) ​​cells. As these molecules are generally expected to be non-toxic, a positive control of doxorubicin was included in all studies. Data are reported as complete cell viability curves and the calculated actual IC50 value for each compound.

[0735] Adherent cells were grown to approximately 80% confluence. The cells were trypsinized and subsequently spun down by adding 0.25% trypsin-EDTA (Gibco#25200-072), and 5 ml of growth medium (MEM medium; Corning#10010CM) was added to disperse the cells. Cell density was determined using a hemocytometer. Growth medium (MEM medium containing 10% FBS; Corning#35015CV) was added to the cells to adjust to a suitable cell concentration. 200 μl of cells (5,000 cells / well) were then added to a 96-well transparent flat-bottom plate (Costar#9804) and incubated in a plate at 37°C in a humidified incubator with 5% CO2 for 24 hours.

[0736] Serial dilutions of the test compounds were prepared using growth medium as a solvent (Table 2). These compounds were provided in the form of sterile aqueous HCl salt solutions at a concentration of 5 mg / ml. To prepare the dilutions, each drug stock was warmed to room temperature, vortexed, and visually inspected for precipitation. If solid drug was present, the stock was heated in a 60°C water bath and subsequently cooled to near room temperature. Based on the treatment concentration, 20× working stocks were prepared by serial dilution. These were further diluted to 1× in growth medium to reach the highest test drug concentration of 250 μg / ml.

[0737] By sucking out the old culture medium and replacing it with 200 μ l of the culture medium comprising the drug, the compound is added to the hole with a series of 1:2 dilutions starting from the initial 250 μ g / ml concentration of each compound. The plate is incubated at 37 ° C for 72 hours in a humidified incubator with 5% CO. At the end of the compound incubation period, the culture medium in each hole is replaced with 100 μ l 1 × PrestoBlue cell viability reagent (ThermoFisher catalog # A13261). In a humidified incubator with 5% CO, the plate is incubated for 30 minutes to 2 hours at 37 ° C. Readings are taken at 30, 60 and 120 minutes. SpectraMax M5 plate reader (Molecular Devices) is used to read the fluorescence under 560nm excitation and 590nm emission. Background is corrected by subtracting the RFU of the control (background control well) comprising only culture medium from all sample readings. Cytotoxicity percentage is calculated using the following formula:

[0738] % cytotoxicity = [(RFU .培养基 -RFU 处理 ) / RFU .培养基 ]×100%

[0739] IC50 was determined using GraphPad Prism using the following formula:

[0740] Y=100 / (1+10^((LogIC50-X)*HillSlope)))

[0741] Table 3

[0742]

[0743]

[0744] Unexpectedly, in Most analogs containing a hydroxyl group on the C5 side chain of the oxazolidinone ring (which mimics the substituent on the active metabolite tedizolidide phosphate) were the most hepatotoxic, showing single-digit IC50s against the HepG2 hepatocyte cell line. Tedizolid is the most active currently approved MRSA drug. oxazolidinones and have structural similarities to the compounds described herein in the tetrazole D-ring, pyridyl C-ring, and aryl B-ring (see Figure 6 ). Here, however, when the isocyanate has an amino group or an acetamide group at the same position as the C5 side chain The increased toxicity to hepatocytes caused by the isocyanate with a hydroxyl group on the C5 side chain was observed when compared to the oxazolidinones (AKG28-31, AKG38-40 and AKG-3). The selectivity indices of the oxazolidinones (AKG-23, AKG-25, AKG-26, and AKG-27) were relatively low.

[0745] Example 4. Determination of Selectivity Index

[0746] The selectivity index (SI) was calculated to determine the relative inhibitory activity of the compound against two Mycobacterium tuberculosis strains, Erdman and H37Rv, compared to mammalian cells, namely African green monkey kidney (VERO) or human hepatocyte-derived (HepG2) cells, as described in Experimental Examples 2 and 3, respectively. A high SI is preferred because it indicates that the bacteria of the tuberculosis strain are preferentially killed at a drug concentration that is less harmful to normal cells in the body. The selectivity index was calculated using the following formula:

[0747] SI=IC 50,哺乳动物 / MIC 细菌

[0748] The bacteria are the Erdman or H37Rv strains of Mycobacterium tuberculosis and the mammalian cells are the VERO or HepG2 cell lines.

[0749] If IC50 is greater than the highest value tested for VERO or HepG2 cells, SI is shown as a ratio greater than (>) calculated using the highest concentration. Similarly, if the MIC for Erdman or H37Rv strains is greater than the highest concentration (8 mg / ml) of the test drug, SI is then shown as a ratio less than (<) calculated using the highest concentration. Wherein the calculation results of two numerical values ​​all higher than the highest tested concentration are shown as undetermined (not determined, nd). The results are shown in Table 4. SI is not directly associated with the molecular activity in mycobacterial strains or mammalian cell lines, and the improvement of effectiveness in mycobacterial strains is not directly associated with the improvement of toxicity for mammalian cell lines. For example, AKG-38 shows nanomolar MIC for two mycobacterium tuberculosis strains, and AKG-38 is relatively inactive for both VERO and HepG2 cell lines compared to other molecules in the group, which gives a high SI for AKG-38. The same is true for AKG-28. It is noteworthy that both molecules, AKG-28 and AKG-38, have a dimethylaminoethyl substituent at the 2' position of the tetrazole ring.

[0750] Table 4

[0751]

[0752]

[0753] In some embodiments, the SI index of the compound of interest against Erd / HepG2 and H37Rv / HepG2 is greater than 100, greater than 200, greater than 300, greater than 400, greater than 500, greater than 1000, greater than 1500, greater than 2000, greater than 2500, greater than 3000, greater than 3500, greater than 4000, greater than 4500, greater than 5000, greater than 5500, greater than 6000, greater than 6500, between 100 and 7000, between 100 and 6000, between 100 and 5000, between 100 and 4000, between 100 and 3000, between 100 and 2000, between 100 and 1000, between 100 and 900, between 100 and 800, between 100 and 700, between 100 and 600, between 100 and 5000. 00, 100 to 400, 100 to 300, 100 to 200, 200 to 7000, 200 to 6000, 200 to 5000, 200 to 4000, 200 to 3000, 200 to 2000, 200 to 1000, 200 to 900, 200 to 800, 200 to 700, 200 to 600, 200 to 50 0, 200 to 400, 200 to 300, 300 to 7000, 300 to 6000, 300 to 5000, 300 to 4000, 300 to 3000, 300 to 2000, 300 to 1000, 300 to 900, 300 to 800, 300 to 700, 300 to 600, 300 to 500, 300 to 400. In some embodiments, the SI index range of the compound of interest for Erd / HepG2 and H37Rv / HepG2 is 100 to 1700, 200 to 1700, 300 to 1700.

[0754] Compared with compounds with a hydroxyl group on the C5 side chain, Compounds with an amino or acetamido group on the C5 side chain of the oxazolidinone ring and an aminoalkyl group at the 2' position of the tetrazole ring exhibited relatively higher SI. Furthermore, specific tetrazole substitutions also improved SI, with dimethylaminoethyl substitution at the 2' position of the tetrazole ring (AKG-28 and AKG-38) outperforming methyl, diethylaminoethyl, aminoethyl, or dimethylaminopropyl substitutions at the same position. Moving the dimethylaminoethyl group to the 1' position of the tetrazole ring (compounds AKG-21 vs. AKG-28) unexpectedly resulted in a significant loss of anti-M. tuberculosis activity.

[0755] Example 5. In vitro activity assay against methicillin-resistant Staphylococcus aureus (MRSA).

[0756] Measured the lead The activity of the oxazolidinone inhibitor was shown to be effective against the Gram-positive bacterium methicillin-resistant Staphylococcus aureus (MRSA), thereby demonstrating its subsequent liposomal delivery for treating MRSA. In some embodiments, the MIC for two of the three evaluated strains was less than 6 μg / mL. In some embodiments, the MIC for two of the three evaluated strains was less than 2 μg / mL. Less than 2 μg / mL is more preferred.

[0757] The three Staphylococcus aureus strains were cultured overnight at 37°C in an ambient atmosphere on tryptic soy agar plates supplemented with 5% sheep blood cells. The cultures were aseptically swabbed and transferred to tubes of sterile water, and the optical density was adjusted to 0.5 at 600 nm. The cultures were then diluted 1:100 to deliver approximately 5 × 10 5 cells / well. After incubation, the MIC of the test article was determined by the presence or absence of growth in each well. MIC analysis was performed in triplicate.

[0758] Tedizolid showed an MIC of 0.206 to 0.617 μg / ml, similar to the 0.5 μg / ml described in U.S. Patent No. 7,816,379. All molecules (AKG-3, AKG-28, AKG-29 and AKG-30) with primary amine modification at the R2 position of the oxazolidinone ring showed negligible activity (>50 μg / ml) against all three MRSA strains. Molecules with acetamide at the same position (AKG-38, AKG-39 and AKG-40) were 1 / 3 to 1 / 9 as active as tedizolid itself against the three MRSA strains.

[0759] Table 5

[0760]

[0761] Example 6: Liposome composition.

[0762] General solution

[0763] 1. The lipid components (phospholipids (PhL), cholesterol, and optional PEG-lipid derivatives and / or lipid fluorescent labels) are combined in an amount of 100% ethanol equal to one-tenth the volume (V) calculated to obtain a lipid suspension with approximately 60 mM phospholipids and stirred at 65 to 68°C until the lipids are completely dissolved.

[0764] Neutral phospholipids may include diacylphosphatidylcholine, dialkylphosphatidylcholine, sphingomyelin and diacylphosphatidylethanolamine. Hydrogenated soybean phosphatidylcholine, distearoylphosphatidylcholine and egg sphingomyelin are some preferred phospholipids.

[0765] The PEG-lipid component may include PEG (molecular weight 2,000)-distearoylglycerol (PEG-DSG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), or N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]} (PEG-ceramide). The molecular weight of the PEG-lipid component may also vary from 1,500 to 6,000 g / mol, but is preferably about 2,000 MW.

[0766] Lipid fluorescent labels may include 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-5,5'-disulfonic acid (DiIC18(3)-DS), 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-5,5'-disulfonic acid (DiIC8(5)-DS), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(cyanine 7) (18:0Cy7 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]-N-(cyanine 7) (DSPE PEG(2000)-N-Cy7), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(cyanine 5) (18:0Cy5 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]-N-(cyanine 5) (DSPE PEG(2000)-N-Cy5), 1-oleoyl-2-[1,2-[(7-nitro-2-1,3-benzoyl)- oxadiazole-4-yl)amino]dodecanoyl]-sn-glycero-3-phosphocholine (18:1 to 12:0 NBD PC).

[0767] 2. Combine the ethanol lipid solution with volume V of capture agent solution (0.25 to 0.5 M ammonium sulfate or 1 N sucrose octasulfate triethylammonium) while stirring at 65 to 68°C until a homogeneous suspension is obtained.

[0768] Potential capture agents may include, but are not limited to, diethylammonium or triethylammonium salts of sucrose octasulfate, ammonium sulfate, ammonium citrate, citric acid, dextran sulfate, polyvinyl sulfonate, or ammonium salts of phytic acid, at concentrations of 0.1 to 2 g equivalents / L (0.1 to 2 N), preferably 0.2 to 1.5 N. Ammonium salts are typically used and may include ammonium itself, monoalkyl-, dialkyl-, or trialkyl-ammonium salts.

[0769] 3. The lipid suspension was extruded at least three times through a track-etched polycarbonate membrane stack using a thermobarrel extruder (Lipex, Canada) at 65 to 68° C. under a pressure of 400 to 450 psi. Typically, two or four membranes had a nominal pore size of 100 nm and one membrane had a nominal pore size of 200 nm (Whatman Nuclepore, USA). When two 100 nm membranes were used in a 100 ml Lipex extruder, the extrusion pressure was typically 260 to 300 psi. The resulting liposomes had a Z-average particle size (diameter) Xz of about 80 to about 130 nm and a PDI of less than 0.1.

[0770] 4. The extruded lipid suspension (known to contain unilamellar and / or oligolamellar liposomes) was cooled in a freezer (2 to 8°C) and filtered through a 0.2 micron polyethersulfone (PES) membrane filter under positive pressure.

[0771] 5. An aliquot of the thus prepared extruded, filtered liposome suspension was chromatographed on a gravity-fed Sepharose CL-4B size exclusion column (eluent - Type 1 water) to purify the liposomes from the extraliposomal capture agent. The purified liposomes were collected near the void volume fraction of the column. For scale-up studies, this step was performed using tangential flow filtration (TFF) on a hollow fiber cartridge (Repligen Spectrum MicroKros PS or mPES membrane with a MWCO of 500 kDa), achieving 8 to 10 volume changes with Type 1 or USP "Water for Injection" endotoxin-free water (or until the conductivity of the liposome suspension dropped below 200 μS / cm).

[0772] 6. Determine the lipid concentration in the purified extruded liposome preparation using HPLC with UV detection by measuring the cholesterol concentration and correcting for the known phospholipid / cholesterol molar ratio. Alternatively, use the spectrophotometric blue phosphomolybdate method to directly quantify the phospholipid content.

[0773] 7. Dissolve the drug in the form of a hydrochloride salt (e.g., AKG-3 and AKG-5 as monohydrochloride salts, AKG-28 and AKG-29 as dihydrochloride salts) at a drug concentration of 5 to 20 mg / ml in Type 1 or endotoxin-free purified water. Add an equal amount of HCl to the drug prepared in free base form (e.g., AKG-16, AKG-38). If necessary, adjust the pH of the solution to pH 2.5 to 5.5 using 1N NaOH, HCl, or tris(hydroxymethyl)aminomethane (Tris) base solution and filter the solution through a 0.2 micron PES filter under positive pressure. If necessary, verify the drug concentration in the stock solution thus prepared by HPLC with UV detection at 305 nm.

[0774] 8. Combine the purified liposomes from step 5 and the drug stock solution in the presence of an osmotic agent (typically dextrose) and water in an amount necessary to provide the desired drug to phospholipid (DL) ratio, with a drug concentration of 1.5 to 3.3 mg / ml and an osmolarity equal to the measured osmolarity of the capture agent solution in step 2. Optionally, add a buffer of the desired pH (typically pH 4 to pH 7). In some cases, the amount of osmotic agent added (e.g., about 45 g / L of dextrose) provides an osmolarity lower than the measured osmolarity of the capture agent solution, and achieves loading at 6 to 8 mg / ml of drug.

[0775] 9. Incubate the drug-liposome mixture at 65 to 68°C with constant stirring for approximately 15 to 20 minutes and quickly cool on ice. After 5 to 10 minutes, allow the mixture to reach ambient temperature and adjust to 0.1 M NaCl by adding the calculated amount of 3 M NaCl stock solution.

[0776] 10. The drug-loaded liposomes were purified from the unencapsulated drug by size exclusion chromatography (SEC) on a gravity-fed Sepharose CL-4B column, with the eluent being 10 mM HEPES buffer pH 7.0 (HBS-7) in 140 to 144 mM NaCl. The liposome fractions were collected near the column void volume. For scale-up studies, purification and buffer exchange were performed using TFF as described above under item 5, using 10-fold volume changes with HBS-7 buffer. During scale-up, approximately 8-fold volume changes were typically used. Optionally, the purified liposomes were concentrated by continuing the TFF process in the absence of buffer feed. The purified drug-loaded liposomes were sterile filtered under positive pressure using a 0.2 micron sterile PES filter and stored in a freezer (2 to 8°C).

[0777] 11. Determine drug and lipid concentrations in purified drug-loaded liposome preparations by HPLC. Alternatively, phospholipids are quantified spectrophotometrically (blue phosphomolybdate), and drug is quantified by UV absorbance (302 to 305 nm) in liposome samples dissolved in 70% isopropanol-0.1N HCl in the presence of 6.5 mg / ml sodium lauryl sulfate. Encapsulation efficiency is determined as follows:

[0778] EE,%=DL / DL0*100%

[0779] where DL0 is the drug to phospholipid ratio in the liposome loading mixture before SEC or TFF purification, and DL is the drug to phospholipid ratio in the drug-loaded liposomes after purification (step 10).

[0780] 12. Determine the mean liposome size (Z-mean diameter, Xz) and polydispersity index (PDI) using dynamic laser light scattering by the cumulant method on a Zetasizer mu-V, Zetasizer Nano or Zetasizer Pro (Malvern Panalytical, US).

[0781] Example 7. In vivo stability and blood clearance of liposomes.

[0782] The drug encapsulation stability and blood clearance of liposomes encapsulating compounds of the present disclosure were studied in mice according to the following general protocol. Mice (three per group) of a given laboratory strain (C3H female or CD-1 male) were injected with drug-loaded liposomes at a dose of 9 mg drug / kg body weight via the tail vein. Blood samples were taken from the retroorbital sinus at time points 1 and 2, and the animals were sacrificed. Generally, blood sampling time points included 5 minutes, 1 hour, 6 hours, and 24 hours after injection. Plasma was separated by centrifugation, extracted with acidified isopropanol optionally containing a solubilizing agent (sodium octane sulfonate), and analyzed for drug and lipids (when the liposomes incorporated the lipid marker DiIC18(3)-DS) by HPLC. The blood clearance of the liposomal drug was expressed as a percentage of the remaining injected dose at a given time point. The in vivo stability of the drug encapsulation was assessed by the percentage change (reduction) in the DL ratio in the plasma at a given time point compared to the DL value before injection.

[0783] Example 8. Loading of AKG-3, AKG-5 and AKG-16 into liposomes at different pH

[0784] Sucrose octasulfate trimethylammonium trap solution was prepared by passing a solution of commercially available sucrose octasulfate potassium heptahydrate (40.2 g in 145 ml of water) through a 500 ml Dowex 50Wx8 100 to 200 mesh ion exchange column (in hydrogen form) and titrating the resulting sucrose octasulfate free acid form to pH 6.2 with pure triethylamine. The concentration of sucrose octasulfate triethylammonium (TEA-SOS) (1 N, corresponding to 0.125 M sucrose octasulfate) was estimated by the amount of triethylamine consumed in the titration. Residual potassium was assessed by the method of addition using a Horiba LAQUATwin K-11 potassium analyzer and was less than 0.1% of the initial potassium content.

[0785] Liposomes composed of hydrogenated soyphosphatidylcholine (HSPC) (Lipoid, Germany), cholesterol (3:2 molar ratio) and methoxypoly(ethylene glycol) ether of 1,2-distearoylglycerol (PEG-DSG, PEG molecular weight 2000, NOF, Japan) (0.5 mol.% of HSPC) with 1N trimethylammonium sucrose octasulfate (TEA-SOS) as a capture agent were prepared essentially as described in the general protocol above. The drug loading step was performed at a DL ratio (DL0) of 500 g / mol PhL in the presence of 16 mM morpholinoethanesulfonic acid (MES)-4 mM sodium citrate buffer (pH range 4.3 to 7.1) and without any added buffer substances (pH 5.2 to 5.9). All drugs were encapsulated into the liposomes with high efficiency (over 98%, except for AKG-16 which was loaded with 93.3% efficiency at pH 4.38) throughout the pH range studied. Figure 1 ). Effective encapsulation does not require the addition of buffer substances.

[0786] Example 9. Encapsulation of AKG-3, AKG-5 and AKG-16 into liposomes with TEA-SOS trapping agent at different DL ratios.

[0787] Liposomes composed of HSPC, cholesterol (3:2 molar ratio) and PEG-DSG (0.5 mol% of HSPC) with 1N TEA-SOS as a capture agent were prepared essentially as described in the general protocol (Example 6). The drug loading step was performed with a DLO ratio in the range of 750 to 1500 g / mol PhL without the addition of a buffer (pH 4.98 to 6.22). Maximum drug loading of compounds 3, 5, and 16 was observed in the range of 900 to 930 g / mol PhL, 982 to 1197 g / mol PhL, and 938 to 951 g / mol PhL, respectively, and the loading efficiency at or near the maximum drug loading was at least 97.6%, 96.0%, or 85.2%, respectively. Figure 2A and Figure 2B ).

[0788] Example 10. Encapsulation of AKG-3, AKG-5 and AKG-16 into liposomes with a higher degree of PEGylation or with 0.25 M ammonium sulfate (AS) as a capture agent.

[0789] Liposomes composed of HSPC and cholesterol (3:2 molar ratio) with different PEG-DSG contents and capture agents were prepared according to the general protocol and loaded with compounds AKG-3, AKG-5, and AKG-16 at a DLO of 250 or 500 g / mol PhL as in Example 9. As shown in Table 6 below, all three compounds were loaded into the liposomes with high efficiency:

[0790] Table 6.

[0791]

[0792] *Data for this row are from Example 8, "no buffer added" loading.

[0793] Thus, compounds AKG-3, AKG-5, and AKG-16 were efficiently loaded into phospholipid-cholesterol liposomes with increased levels of PEGylation and with ammonium sulfate as an intraliposomal drug entrapment agent. However, when loaded at a higher drug to lipid ratio of 500 g drug / mol PhL using 0.25 M ammonium sulfate as the entrapment agent, the three The loading efficiency of two of the oxazolidinones (AKG-3 and AKG-16) was reduced.

[0794] Example 11. Loading of compounds AKG-3, AKG-5 and AKG-16 into liposomes using 0.5 M AS as a capture agent.

[0795] Liposomes composed of HSPC and cholesterol (3:2 molar ratio) with 0.5 mol% or 5 mol% PEG-DSG (relative to PhL) and 0.5 M ammonium sulfate (AS) as a capture agent were prepared according to the general protocol and loaded with compounds AKG-3, AKG-5 and AKG-16 at DLOs ranging from 500 to 1500 g / mol PhL as in Example 8. Figure 3A 、 Figure 3B 、 Figure 3C and Figure 3D All three compounds were loaded into both liposomes at DL ratios ranging from 420 to 450 g / mol PhL with encapsulation efficiencies ranging from 93 to 100%; the maximum drug payloads were as follows:

[0796] Table 7

[0797]

[0798] All three test compounds were loaded into 0.5M ammonium sulfate liposomes at greater than 500 g of drug per mol of PhL in formulations with 0.5 mol% PEG-DSG, and the same was true for compounds AKG-3 and AKG-16 in formulations containing 5 mol% PEG-DSG. These high levels of loading are important for achieving sufficient doses of administered drug for therapeutic purposes. Compared to Example 10, where loading efficiency was lower when 0.25 M ammonium sulfate was used, loading was significantly improved, indicating that the higher ammonium sulfate concentration of 0.5 M, despite the higher osmolarity and potential osmotic burst, increases the amount of drug that can be loaded per mol of phospholipid and is preferred for anti-infective applications where low toxicity and high dosing can lead to improved outcomes.

[0799] Example 12. Loading of compounds AKG-3, AKG-5, AKG-16, and AKG-28 into liposomes containing various compositions of fluorescent lipid labels.

[0800] Liposomes composed of HSPC and cholesterol (60:40 molar ratio) with 0.5 mol% PEG-DSG (relative to PhL), 0.15 mol.% lipid fluorescent marker DiIC18(3)-DS (ThermoFisher, USA) and 0.5 M ammonium sulfate (AS) or 1 N TEA-SOS as capture agents were prepared according to the general protocol and loaded with compounds AKG-3, AKG-5 and AKG-16 as described in Example 11 at pH 4.7 to 5.8 (without adding buffer substances). The liposomes had the following characteristics:

[0801] Table 8

[0802]

[0803] All three drugs were efficiently loaded into the liposomes.Degradation of AKG-5 during liposome loading was detected as the appearance of a second peak on HPLC.

[0804] Liposomes composed of various phospholipids (HSPC, distearoylphosphatidylcholine (DSPC, Avanti Polar Lipids, USA), or egg sphingomyelin (ESM, Lipoid, Germany) and cholesterol (60:40 molar ratio) containing different amounts of PEG-DSG or N-methoxypoly(ethylene glycol)oxycarbonyl-1,2-distearoylphosphatidylethanolamine (PEG-DSPE, PEG molecular weight 2000, Lipoid, Germany) and lipid fluorescent marker DiIC18(3)-DS (0.15 mol.% relative to PhL) were prepared according to the same general protocol with different capture materials and loaded with AKG-16 in a similar manner. When indicated, the liposome extrusion step of the general protocol was supplemented with extrusion through two stacked polycarbonate membranes with 50 nm pore size. The liposomes had the following characteristics:

[0805] Table 9

[0806]

[0807] Liposomes composed of HSPC and cholesterol (3:2 molar ratio) with 9.2 mol% PEG-DSPE (relative to PhL), 0.15 mol.% lipid marker DiIC18(3)-DS and 0.25 M ammonium sulfate (AS) as a capture agent were prepared according to the general protocol and Example 12 with an additional 50 nm extrusion, and loaded with AKG-28 at a drug-lipid ratio (DL0) of 150 g / mol PhL. The liposomes (batch ID 98) had a DL ratio of 73.8 g / mol PhL, a Z-average liposome size of 77.8 nm, and a size polydispersity index (PDI) of 0.090.

[0808] These studies show that AKG-3, AKG-5, and AKG-16 can be effectively loaded into liposomes with a wide range of lipid compositions (including HSPC, DSPC, or ESM as neutral phospholipid components) or low (0.5 mol%) or high (5 mol%) PEG-lipid content. However, when 0.25 M AS was used, the efficiency was significantly reduced from approximately 500 g AKG-16 / mol PhL to 128 g AKG-16 / mol PhL, as compared to 1 N TEA-SOS. When AKG-28 was loaded with 0.25 M AS, a similarly low loading efficiency (i.e., 73.8 g / mol PhL) was observed. This suggests that TEA-SOS or higher concentrations of AS may be preferred for loading high concentrations of compounds into liposomes.

[0809] Example 13. Blood persistence and in vivo encapsulation stability of the liposomes of Example 12 in mice.

[0810] Studies were performed in male CD-1 mice as described in the general protocol above.

[0811] Table 10

[0812]

[0813] These studies showed that liposomes composed of different neutral phospholipid components (HSPC, DSPC or SM) and loaded with AKG-16 using the TEA-SOS trap were slowly cleared, with more than 30% of the injected dose remaining in the plasma at 6 hours for most formulations. In addition, with the exception of liposome batch ID 97 containing AKG-16 loaded with 0.25M AS, most formulations showed good drug retention, indicating that loading the drug with 0.25M ammonium sulfate not only resulted in low loading efficiency (as shown in Table 9), but also resulted in a low DL ratio (3.7%) at 6 hours due to significant leakage of the liposomes in this formulation.

[0814] Example 14. Encapsulation of compounds AKG-28 and AKG-38 into liposomes with different capture agents at different DL ratios.

[0815] Liposomes composed of HSPC and cholesterol (3:2 molar ratio) with 0.5 mol% PEG-DSG (relative to PhL), 0.15 mol.% lipid marker DiIC18(3)-DS and 0.5 M ammonium sulfate (AS) or 1 N TEA-SOS as capture agents were prepared according to the general protocol and loaded with compounds AKG-28 and AKG-38 as described in Example 8 at pH 4.95 to 5.17 (no buffer added) and a DL0 ratio in the range of 300 to 1050 g / mol PhL (AKG-28) or 400 to 1400 g / mol PhL (AKG-38). Using 0.5 M AS, the maximum drug loadings for compounds AKG-28 and AKG-38 were 404 to 424 g / mol PhL and 818 to 842 g / mol PhL, respectively, and the loading efficiencies exceeding 95% were 302 g / mol PhL (quantitative loading) and 387 to 764 g / mol PhL (95.5 to 96.7% loading), respectively. Using 1 N TEA-SOS, the maximum drug loadings for compounds AKG-28 and AKG-38 were 315 to 328 g / mol PhL and 989 g / mol PhL, respectively, and the maximum loading efficiencies were 83.5%, at drug loadings of 250 g / mol PhL and 400 to 777 g / mol PhL (over 97.2% loading), respectively. Figure 4A and Figure 4B ).

[0816] AKG-38 showed almost quantitative loading between 400 and 800 g AKG-38 / mol PhL, while the resulting drug to lipid ratio of AKG-28 remained flat in the range of 250 to 1000 g AKG-28 / mol PhL, indicating that the maximum drug loading of AKG-28 was lower than that of AKG-38. It is understood that the higher potency previously demonstrated for AKG-28 will allow liposomal formulations of AKG-28 to be effectively used to treat infectious diseases such as tuberculosis.

[0817] Example 15. Encapsulation of compounds AKG-28 and AKG-38 into liposomes with different phospholipid compositions, degrees of PEGylation, and entrapment agents.

[0818] Liposomes composed of phospholipid (PhL) and cholesterol (3:2 molar ratio), PEG-DSG, and DiIC18(3)-DS (0.15 mol.% of PhL) with 0.5 M AS or 1 N TEA-SOS as the capture agent were prepared according to the general protocol and loaded with compounds AKG-28 and AKG-38 (in the absence of added buffer substances) at a DLO ratio selected to optimize drug loading and encapsulation efficiency (EE). The results are shown in Tables 10 and 11 below.

[0819] Table 11. Encapsulation of compound AKG-28.

[0820]

[0821] Table 12. Encapsulation of compound AKG-38.

[0822]

[0823] This example demonstrates that AKG-28 can be effectively loaded into liposomes composed of HSPC using either 0.5 M AS or 1 N TEA-SOS as a trapping agent, with maximum drug loadings ranging from 230 to 275 g AKG-28 / mol PhL. However, formulations containing sphingomyelin as the neutral phospholipid for this compound exhibited relatively low loadings, with a maximum of only approximately 110 g AKG-28 / mol PhL.

[0824] Compound AKG-38 was loaded at significantly higher D / L ratios of 525 to 600 g / mol using 0.5 MAS or 1 N TEA-SOS when the drug was added at 600 g AKG-38 / mol PhL, or greater than 735 g / mol when added at 800 g AKG-38 / mol PhL. The loading of compound AKG-38 was less sensitive to the presence of sphingomyelin than that of AKG-28.

[0825] Example 16. Encapsulation of compounds AKG-16, AKG-28, AKG-29, and AKG-38 into liposomes with enhanced PEGylation and 0.5 M ammonium sulfate as a capture agent.

[0826] Liposomes composed of HSPC and cholesterol (3:2 molar ratio), PEG-DSG (5 mol.%) and DiIC18(3)-DS (0.15 mol.%) with 0.5 M ammonium sulfate as a capture agent were prepared according to the general protocol and loaded with compounds AKG-16, AKG-28, AKG-29 or AKG-38 (in the absence of added buffer substances) at a DLO ratio selected to optimize drug loading and encapsulation efficiency (EE). The results are shown in Table 13 below.

[0827] Table 13

[0828]

[0829] The data show that all compounds containing a dimethylaminoethyl substituent at position 2 of the tetrazole ring were loaded into the liposomes with an efficiency greater than 80%, while AKG-29, which has an aminoethyl substituent at the same position, was only slightly loaded into the liposomes with an efficiency of 14.5% and a final drug load of 43.6 g AKG-29 / mol PhL. This suggests that, despite the presence of titratable amines in all compounds tested, compounds with substituted ammonium groups (e.g., N,N-dimethylaminoethyl groups) on the tetrazole ring unexpectedly allow for more efficient drug loading than those with a primary amine (aminoethyl group) at the same position.

[0830] Example 17. Blood persistence and in vivo encapsulation stability of the liposomes of Examples 15 and 16 in mice.

[0831] Studies were performed in male CD-1 mice as described in the general protocol above.

[0832] Table 14

[0833]

[0834]

[0835] The data showed that the drug in liposome batches ID 128, 132, 142, 144 and 145, all with 0.5M AS as a capture agent, lost 25 to 60% of the encapsulated drug almost immediately upon contact with blood, as shown by the low DL ratio at 5 minutes and the further decrease in DL ratio at 6 hours, which was particularly significant for liposomes loaded with AKG-38 and AKG-16. Thus, the formulations with 0.5 mol% or 5 mol% PEG-DSG and 40 mol% cholesterol, 0.5M AS (as a capture agent) were not as effective in retaining the drug as the formulations using 1N TEA-SOS (liposome batches ID 129, 130, 133 to 135), where the % of the initial DL ratio was greater than 80% at the 5 minute and 6 hour time points for both.

[0836] Example 18. Preparation and loading of AKG-28 and AKG-38 into PEGylated liposomes with different phospholipid to cholesterol ratios.

[0837] Liposomes containing 5 mol% PEG-DSG or PEG-DSPE (relative to PhL), 0.15 mol.% lipid marker DiIC18(3)-DS and 0.5 M ammonium sulfate (AS) or 1NTEA-SOS as capture agents were prepared according to the general protocol and loaded with compounds AKG-28 and AKG-38 as in Example 8 at pH 5.07 to 5.82 (without adding buffer substances).

[0838] In an attempt to stabilize liposomes with 0.5M AS as a trapping agent for rapid drug release upon contact with blood (as described in Example 17), liposomes were prepared using DSPC (generally known to produce more drug leakage-stable liposomes than HSPC) and a reduced ratio of cholesterol (Chol) and loaded with either AKG-28 at 250 g / mol PhL or AKG-38 at 600 g / mol PhL (Table 15). Contrary to expectations, reducing the cholesterol content from 40 mol% to 10 mol% cholesterol resulted in a significant decrease in the encapsulation efficiency for both AKG-28 and AKG-38. Lower cholesterol also destabilized the liposomes against aggregation. At 30 mol.% cholesterol (PhL-cholesterol molar ratio of 70:30), liposomes containing AKG-28 prepared using 1N TEA-SOS and 5 mol% PEG-DSG or PEG-DSPE irreversibly aggregated during drug loading, as did formulations of AKG-38 containing 30 mol% cholesterol, 5 mol% PEG-DSPE, while the formulation of AKG-38 with 5 mol% PEG-DSG showed a reduced loading efficiency of 77.1% at 30 mol% cholesterol, or 462.4 g / mol PhL.

[0839] Table 15

[0840]

[0841] In contrast, liposomes prepared using HPSC and containing 40 mol % or more cholesterol (up to 65 mol % cholesterol (the maximum studied)) for both AKG-28 (DL0 250 g / mol PhL) and AKG-38 (DL0 500 g / mol PhL), PEG-lipids (PEG-DSG and PEG-DSPE), and capture agents (AS or TEA-SOS) showed excellent encapsulation efficiencies exceeding 87% without liposome aggregation (Table 16).

[0842] Additionally, the potential for optimized formulation loading of linezolid, a current standard of care drug from this class, was evaluated in both 0.5M AS and 1N TEA-SOS formulations. Tedizolid was not sufficiently soluble in water for transmembrane gradient-assisted loading into liposomes following the general protocol of Example 6. In both cases with linezolid, the encapsulation efficiency was less than 5%, indicating that these liposomal formulations of AKG-28 and AKG-38 are significantly superior in their ability to stably encapsulate the drug compared to linezolid.

[0843] The z-average size (x) of the liposomes was determined by dynamic light scattering (DLS) cumulant method at a measurement angle of 173° using a Malvern Zetasizer Pro (Malvern Panalytical). z ) and polydispersity index (PDI).

[0844] Table 16

[0845]

[0846]

[0847] Example 19. In vitro burst release of PEGylated liposomes containing AKG-28 or AKG-38 and different phospholipid to cholesterol ratios in the presence of plasma.

[0848] In the presence of mouse CD-1 or people's merged plasma (lithium-heparin from Innovative Research is stable), the in vitro stability of the liposome formulations of AKG-28 and AKG-38 comprising 5mol%PEG-DSPE or PEG-DSG and different ratios of HSPC and cholesterol (40 to 65mol% cholesterol) was evaluated for stability. If necessary, plasma is thawed, adjusted to pH 7.4 with 1N HCl, and filtered sequentially through glass microfiber filter (GF / C), 1 μm polyethersulfone (PES) and 0.22 μm PES filter. Blood plasma (80 μl) is mixed with liposome drug formulation (20 μl) in 0.5mlEppendorf tube. Subsequently, mixture was hatched 20 minutes at 37°C, and subsequently placed in cold water. Mixture (0.1mL) is immediately carried out chromatography on 2mL Sepharose CL-4B post, eluted with Hepes buffered saline (pH 7.0), and 0.25mL liposome drug is collected in the void volume portion. The drug and DiI(3)-DS lipid marker were then analyzed by HPLC as described in Example 7, and the % drug retained encapsulated was determined using the following formula:

[0849] (A d / A I / (A d,0 / A I,0 )*100=retained encapsulated drug (%)

[0850] Among them A d ——area of ​​drug peak, A I ——Area of ​​lipid marker peak, A d,0 ——area of ​​the drug peak pre-incubated with plasma, and A I,0 - Area of ​​the pre-incubated lipid marker peak.

[0851] The results are Figure 5A 、 Figure 5B 、 Figure 5C and Figure 5D For liposomes with encapsulated AKG-28 ( Figure 5A ), a burst release phenomenon (a rapid drop in the DL ratio indicating drug release from the liposomes) was observed in human plasma for formulations containing 40 mol.% cholesterol, but not for formulations with 45 mol.% or more cholesterol. Figure 5B ), a burst release phenomenon was observed in both human and mouse plasma for formulations with cholesterol contents of 40 mol.% and 45 mol.%, but not when the cholesterol content was 50 mol.% or more.

[0852] Example 20. In vitro plasma release and in vivo pharmacokinetics of 5 mol% PEG-lipid liposomes containing AKG-38 and 40 mol% or 55 mol% cholesterol

[0853] The three liposome formulations of Example 18 (as described in Example 7) were evaluated in a two-time pharmacokinetic study in female CD-1 mice using a 0.5 M AS trap, and the percentage of the injected dose (% ID) of liposome lipids retained in the blood at both 5 minutes and 6 hours was measured, as well as drug release from the liposomes by determining the drug to lipid ratio (DL). Liposomes with 5 mol% PEG-DSG or 5 mol% PEG-DSPE and containing 55 mol% cholesterol showed a D / L ratio of more than 95% before injection at 5 minutes and >85% before injection at 6 hours, while the PEG-DSG formulation containing 40 mol% cholesterol showed a significantly reduced DL ratio at both 5 minutes and 6 hours, which is consistent with the drug leakage data in the presence of plasma in vitro (Table 17). This finding is in contrast to previous experience with drug-loaded liposomal formulations, as many highly stable liposomal drugs approved for clinical use (such as PEGylated liposomal doxorubicin and nanosomal irinotecan) contain cholesterol at a ratio of approximately 40 mol% (see, e.g., drug information package insert, updated 08 / 2019, and Drummond, DC, et al. (2006). "Development of a highly active nanoliposomal irinotecan using anovel intraliposomal stabilization strategy." Cancer Res. 66(6):3271-3277).

[0854] Table 17

[0855]

[0856] Example 21. Inhibition of mitochondrial protein synthesis (MPS) by AKG-3, AKG-16, AKG-22, AKG-28, AKG-29, AKG-30, AKG-38, AKG-39 and AKG-40, and selectivity of inhibition of Mycobacterium tuberculosis (H37Rv) over MPS inhibition.

[0857] Using the colorimetric MitoBiogenesis from AbCam TM Inhibition of mitochondrial protein synthesis was determined using an in-cell ELISA kit (Cat. No. ab11021) according to the manufacturer's instructions. The oxazolidinones are associated with important toxicities, most notably ocular and peripheral neuropathy and lactic acidosis (Renslo (2010) Expert Rev Anti Infect Ther 8(5)565-574; Flanagan et al. (2015) Antimicrob Agents Chemother 59(1)178-185; Santini et al. (2017) Expert Opin Drug Saf 16(7)833-843). The levels of two mitochondrial proteins, including the mitochondrial DNA-encoded subunit I of complex IV (COX-1) and the nuclear DNA-encoded 70 kDa subunit of complex II (SDH-A), were measured simultaneously. The H9C2 rat BDIX cardiac myoblast cell line was used in these studies in a 384-well plate assay format. The cells were cultured in DMEM medium with 10% FBS and 1× glutamine at 37°C and 5% CO2. Cells were plated in 384-well plates at a density of 1,500 cells / well in 47.5 μl / well. Ten concentrations of each compound (starting with a high concentration of 200 μM and including nine 3-fold dilutions and one replicate / condition) were added to 2.5 μl of cells and incubated with the cells at 37°C and 5% CO2 for 5 days. The compounds tested included tedizolid and linezolid controls, as well as AKG-3, AKG-16, AKG-22, AKG-28, AKG-29, AKG-30, AKG-38, AKG-39, and AKG-40.

[0858] Then carry out MitoBiogenesis intracellular ELISA according to manufacturer's instructions (Abcame catalog number ab11021), and alkaline phosphatase (AP) is developed in the plate reader to detect SDH-1A (20 seconds to 1 minute interval) at 405nm in a 15-minute kinetic model, and HRP is developed to detect COX-I (20 seconds to 1 minute interval) at 600nm in a 15-minute kinetic model.COX-1 and SDH-A signals are plotted for the concentration of each compound with the ratio of COX-1 / SDH-A, and IC50 is calculated for each of the 9 study compounds and two controls.

[0859] The MPS selectivity index (SI-MPS) was determined by dividing the MPS IC50 in μg / ml by the MIC in the drug-susceptible H37Rv M. tuberculosis strain as determined in Example 2. Two compounds tested, AKG-28 and AKG-29, had SI-MPS that were more than 10-fold higher than that determined for linezolid and more than 20-fold higher than that determined for tedizolid. Both of these compounds were The oxazolidinone ring contains a primary amino group at the R2 position. Due to its high potency (MIC < 0.1) and selectivity against M. tuberculosis compared to mitochondrial protein synthesis, AKG-28 is an excellent candidate for encapsulation in liposomes and treatment of tuberculosis or other mycobacterial diseases.

[0860] Table 18

[0861]

[0862]

[0863] Example 22. Scale-up preparation of liposome AKG-28 batch 275.

[0864] Batch 267.The general procedure of Example 6 was followed. HSPC (Lipoid AG) 4.95 g (6.30 mmol), cholesterol (Dishman, high purity) 2.98 g (7.71 mmol) and PEG-DSPE (Lipoid AG) 850 mg (0.315 mmol) (HSPC: cholesterol: PEG-DSPE 45:55:2.25 molar ratio) were combined with 9 ml of anhydrous ethanol (Sigma, E-7023) and heated with stirring in a 68°C bath until all lipids were dissolved. In a separate container, 93.3 g of 0.5 M aqueous ammonium sulfate (0.2 micron filtered) was preheated in a 68°C bath and poured into the hot lipid ethanol solution with stirring. The resulting suspension was stirred for 20 minutes in a 68°C bath and extruded eight times at 260 to 300 psi through a stack of two 47 mm 100 nm pore and one 200 nm pore polycarbonate track-etched membranes (Whatman Nucleopore) using a Lipex 100 ml thermobarrel liposome extruder (Northern Lipids, Inc.) heated with circulating 68°C water. The resulting extruded liposomes were kept overnight in a refrigerator (2 to 8°C) and filtered through a 0.2 μm polyethersulfone (PES) filter under positive pressure. The extraliposomal capture agent (ammonium sulfate) was removed by TFF buffer exchange with endotoxin-free water on a KrosFlo TFF system using a polysulfone hollow fiber cartridge with a MW cutoff of 500 kDa (Spectrum Laboratories) until the residual conductivity dropped to less than 200 μS / cm (143 μS / cm after 5.2 volume changes). The phospholipid concentration in the liposome suspension after TFF was determined to be 57.4 mM by the blue phosphomolybdate method.

[0865] In the presence of 45mg / ml dextrose and 6mg / ml concentration of AKG-28, 720mg AKG-28 (as dihydrochloride) in the form of 20mg / ml aqueous stock solution (being adjusted to pH 5.03 with NaOH) will be combined with the liposome suspension after TFF to form a loaded mixture of 250g / mol of drug and phospholipid (DL) ratio. Under continuous stirring, the mixture is rapidly heated to 60 to 63°C by external heating, and continues to hatch under stirring on 65°C baths. After hatching for 20 minutes, the mixture is rapidly cooled to less than 10°C in ice water, and kept at this temperature for about 10 minutes. After reaching ambient temperature and being adjusted to 0.1M NaCl, the polysulfone hollow fiber cartridge with a molecular weight cutoff of 500KD is used to purify the liposome of loaded drug by TFF. The liposomes were pre-concentrated to approximately 12 mg / ml AKG-28 by diafiltration and purified from any extraliposomal drug by TFF exchange into 10 mM HEPES-Na buffer (pH 7.0 containing 0.144 M NaCl (HBS-7 buffer) prepared with endotoxin-free water, for a total of approximately 8 volume changes. The proportion of unencapsulated drug prior to purification was estimated spectrophotometrically at 305 nm in the pre-concentrated diafiltrate and found to be approximately 0.9% (corresponding to a loading efficiency of 99.1%). The concentrated, purified liposomes were sterile-passed through a 0.2 μm sterile filter and analyzed for particle size by DLS and for drug and phospholipid concentration by spectrophotometry. This procedure was repeated three more times (batches 269, 271, 273). The liposomes obtained had the characteristics shown in Table 19.

[0866] Table 19

[0867]

[0868] These batches were combined to obtain batch 275, which had 12.0 mg / ml AKG-28 in liposomal form with a particle size Xz of 113.7 nm and a PDI of 0.0417.

[0869] Example 23. Scale-up preparation of liposome AKG-38 batch 276.

[0870] Batch 268.The protocol of Example 22 was used with the following differences: an aqueous stock solution of AKG-38 (as free base) was prepared by dissolving the drug in an equal amount of 1N HCl and adjusting the volume to obtain 20 mg / ml of AG-38 (as free base), pH 5.08. The loading mixture contained 1300 mg of AKG-38 and was prepared at a DL ratio of 8 mg / mL AKG-38 to 450 g / mol phospholipid, and additionally contained 10 mM NaCl. The loaded liposomes were pre-concentrated to approximately 22 mg / ml of drug; the proportion of unencapsulated drug prior to purification was estimated spectrophotometrically at 305 nm in the pre-concentration filtrate and found to be approximately 3.2% (corresponding to a loading efficiency of 96.8%). This process was repeated three more times (batches 270, 272, and 274). The liposomes obtained had the characteristics shown in Table 20.

[0871] Table 20

[0872]

[0873] These batches were combined to obtain batch 276, which had 22.3 mg / ml AKG-38 in liposomal form, a particle size Xz of 113.1 nm, and a PDI of 0.0454.

[0874] Example 24. Preparation of “Empty Liposomes” Batch 277.

[0875] Except adopting 0.13M sodium sulfate to replace 0.5M ammonium sulfate (sulfate of non-exchangeable cation), as described in Example 22, 2mmol HSPC, 2.444mmol cholesterol and 0.1mmol PEG-DSPE (HSPC: cholesterol: PEG-DSPE45:55:2.25 mol ratio) are dissolved in ethanol, form liposome suspension, and extrude through polycarbonate membrane.Extrude liposome is purified from sodium sulfate outside liposome, and uses polysulfone hollow fiber cartridge with MWCO 500KDa to make it enter HBS-7 buffer by TFF buffer exchange, a total of 10 times of volume exchange.Purified liposome has 42.9mM phospholipids, particle size Xz is 113.7nm, and PDI is 0.0612.It is sterile passed through 0.2 μm sterile filter, and is adjusted to 20mM phospholipids with sterile HBS-7.

[0876] Example 25. Liposomal AKG-38 Batch 279.

[0877] The general procedure of Example 6 was followed. HSPC (Lipoid AG) 13.102 g (16.67 mmol), cholesterol (Dishman, high purity) 7.877 g (20.37 mmol) and PEG-DSPE (Lipoid AG) 2.250 g (0.833 mmol) (HSPC: cholesterol: PEG-DSPE 45:55:2.25 molar ratio) were combined with 25 mL of anhydrous ethanol (Sigma, E-7023) and heated with stirring on a 68°C bath until all lipids were dissolved. In a separate container, 259.1 g (250 ml) of 0.5 M aqueous ammonium sulfate solution (filtered at 0.2 microns) was preheated on a 70°C bath and poured into the hot lipid ethanol solution under stirring. The resulting suspension was stirred in a 70°C bath for at least 20 minutes and divided into four portions. Each portion was extruded five times at 280 psi through a stack of two 47 mm 100 nm pore and one 200 nm pore polycarbonate track-etched membranes (Whatman Nucleopore) using a Lipex 100 ml thermobarrel liposome extruder (Northern Lipids, Inc.) heated with circulating 70°C water. The partially extruded liposomes were combined (Xz 129.7 nm) and extruded together through the same membrane stack five more times to obtain liposomes with a size Xz of 115.9 nm and a PDI of 0.0212. The liposomes were kept overnight in a refrigerator (2 to 8°C) and filtered through a 0.2 μm polyethersulfone (PES) filter under positive pressure. The phospholipid concentration was found to be 60.22 ± 0.34 mM. The extraliposomal capture agent (ammonium sulfate) was removed by exchanging the TFF buffer for endotoxin-free water on a KrosFlo TFF system using a polysulfone hollow fiber cartridge with a MW cutoff of 500 kDa (Spectrum Laboratories) until the residual conductivity dropped to 180 μS / cm after 5.1 volume changes. The phospholipid concentration in the liposome suspension after TFF was determined to be 54.97 ± 0.32 mM by the blue phosphomolybdate method.

[0878] AKG-38 (free alkali) is mixed with 0.95 equivalent of 1N HCl and is prepared with endotoxin-free water to obtain 20mg / ml aqueous stock solution (pH 5.16). Make solution pass through 0.2 μm filter, and in the case of the AKG-38 (pH 5.54) of the presence of 44.5mg / ml dextrose, 10mM NaCl and 8mg / ml concentration, the filtrate amount and TFF after the liposome suspension that will comprise 3958mg medicine are combined to form the load mixture that medicine and phospholipid (DL) ratio are 450g / mol.Mixture is heated to 61 ℃ by external heating in 5 minutes period under continuous stirring, and on 65 ℃ of baths, under agitation, continue to hatch other 22 minutes.Then mixture is transferred in ice-water bath, stirred 7 minutes so that the temperature is reduced to 10 ℃, and in ice-water bath, kept again 8 minutes. After removal from an ice bath, reaching ambient temperature, and adjusting to 0.1 M NaCl by adding a 3 M NaCl stock, the drug-loaded liposomes were purified by TFF (pH 6.53) using a polysulfone hollow fiber cartridge with a molecular weight cutoff of 500 kD. The liposomes were pre-concentrated to approximately 22 mg / ml of AKG-38 by diafiltration and purified from any extraliposomal drug by TFF with an exchange of HBS-7 buffer for a total of 8 volume changes. The concentrated, purified liposomes were sterile-passed through a 0.2 μm PES high-flow sterile filter and analyzed for particle size by DLS and for drug and phospholipid concentration by spectrophotometry. The liposomes had the following characteristics: 21.1 ± 0.19 mg / ml of AKG-38, a DL ratio of 454 ± 4.7 g / mol phospholipid, an Xz of 116.4 nm, and a PDI of 0.0231. The yield of the formulated drug was 3834 mg (96.9%).

[0879] Example 26. Liposomal AKG-28 Batch 281.

[0880] The general procedure of Example 6 was followed. Extruded liposomes containing 0.5 M ammonium sulfate were prepared as described in Example 25, consisting of HSPC, cholesterol, and PEG-DSPE in a molar ratio of 45:55:2.25. The extraliposomal trapping agent (ammonium sulfate) was removed by TFF on a KrosFlo TFF system using a polyethersulfone hollow fiber cartridge (Spectrum Laboratories) with a MW cutoff of 500 kDa, replacing endotoxin-free water until the residual conductivity dropped to 150 μS / cm (4.1 volume changes). The phospholipid concentration in the liposome suspension after TFF was determined to be 55.4 mM by the blue phosphomolybdate method.

[0881] In the presence of 44.5 mg / mL dextrose and 6 mg / mL concentration of AKG-28, 969.5 mg of AKG-28 (as dihydrochloride) in the form of a 20 mg / mL aqueous stock solution (adjusted to pH 5.24 with NaOH) was combined with the post-TFF liposome suspension to form a loaded mixture with a drug to phospholipid (DL) ratio of 250 g / mol. The mixture was heated to 65.4°C in 2.5 minutes by external heating under constant stirring and continued to incubate in a 65°C bath under stirring. After incubation for 20 minutes, the mixture was cooled to 9.3°C in ice water in 2.75 minutes and kept in the ice water bath for approximately 10 minutes. The mixture was then allowed to reach ambient temperature and adjusted to 0.1 M NaCl; pH 6.43. 133.4 g of the loaded mixture was purified by TFF using a polysulfone hollow fiber cartridge with a molecular weight cutoff of 500 kD. The liposomes were preconcentrated by diafiltration to approximately 12 mg / ml of AKG-28 and purified from any extraliposomal drug by TFF with HBS-7 buffer exchange for a total of 8.1 volume changes. The proportion of unencapsulated drug prior to purification was estimated spectrophotometrically at 302 nm in the preconcentrated diafiltrate and found to be approximately 0.7% (corresponding to a 99.3% loading efficiency). The concentrated, purified liposomes were sterile-passed through a 0.2 μm sterile filter and analyzed for particle size by DLS and for drug and phospholipid concentration by spectrophotometry. The liposomes had the following characteristics: 13.26 ± 0.21 mg / ml of AKG-28, a DL ratio of 258.2 ± 3.7 g / mol phospholipid, an Xz of 117.3 nm, and a PDI of 0.0421.

[0882] Example 27. Liposomal AKG-38 Batch 285.

[0883] The general procedure of Example 6 was followed. Extruded liposomes containing 0.5 M ammonium sulfate were prepared essentially as described in Example 25, consisting of HSPC, cholesterol, and PEG-DSPE in a molar ratio of 45:55:2.25. The extraliposomal trapping agent (ammonium sulfate) was removed by TFF on a KrosFlo TFF system using a polyethersulfone hollow fiber cartridge with a MW cutoff of 500 kDa (Spectrum Laboratories) with endotoxin-free water until the residual conductivity dropped to 138 μS / cm (5.6 volume changes). The phospholipid concentration in the liposome suspension after TFF was determined to be 53.1 mM by the blue phosphomolybdate method.

[0884] AKG-38 (free alkali) is mixed with 0.95 equivalent of 1N HCl and is prepared with endotoxin-free water to obtain 19.9mg / mL aqueous stock solution (pH 5.13).Solution is passed through 0.2 μm filter, and in the presence of 44.5mg / ml dextrose, 10mM NaCl and concentration is the AKG-38 (pH 5.58) of 8mg / ml, the filtrate amount that will comprise 1400mg medicine and TFF after liposome suspension combination are to form the load mixture that medicine and phospholipid (DL) ratio are 450g / mol.Mixture is heated to 63 ℃ by external heating under constant stirring in the period of 2.25 minutes, and under agitation, continues to hatch a total of 21 minutes on 65 ℃ of baths.Then mixture is transferred in ice-water bath, stirred 3 minutes so that the temperature is reduced to 10.3 ℃, and it is kept again 7 minutes in ice-water bath. After being taken out from ice bath, reaching ambient temperature and being adjusted to 0.1M NaCl by adding 3M NaCl stock, the liposomes (pH 6.70) loaded with drug were purified by TFF using a polysulfone hollow fiber cartridge with a molecular weight cutoff of 500KD. The liposomes were pre-concentrated to about 22mg / ml of AKG-38 by diafiltration and replaced with HBS-7 buffer by TFF to purify any extraliposomal drug, a total of 7.7 volume changes. The AKG-38 concentration of the concentrated, purified liposomes was 23.1mg / mL. The drug concentration was adjusted to 20mg / ml with HBS-7 buffer, the liposomes were sterile passed through a 0.2μm PES high flow sterile filter, and the particle size was analyzed by DLS and the drug and phospholipid concentrations were analyzed by spectrophotometry. The liposomes had the following characteristics: AKG-38 was 20.35±0.26 mg / ml, DL ratio was 437.8±6.5 g / mol phospholipid, Xz was 121.1 nm, PDI was 0.0200. The yield of the formulated drug was 1355 mg (96.8%).

[0885] Example 28. Liposomal AKG-28 Batch 286.

[0886] Extruded liposomes containing 0.5 M ammonium sulfate free of extraliposome entrapment agents were obtained as in Example 27 (HSPC:cholesterol:PEG-DSPE 45:55:2.25 molar ratio).

[0887] In the presence of 44.5 mg / mL dextrose and 6 mg / mL concentration of AKG-28, 600 mg of AKG-28 (as the dihydrochloride salt) in the form of a 20 mg / mL aqueous stock solution (adjusted to pH 5.18 with NaOH) was combined with the post-TFF liposome suspension to form a loaded mixture with a drug to phospholipid (DL) ratio of 250 g / mol. The mixture was placed in a 65°C water bath with stirring and reached 60°C within 4.5 minutes. The incubation was continued for a total of 20 minutes with stirring, and the mixture was cooled to 10.0°C in ice water within 2 minutes and kept in the ice water bath for approximately 10 minutes. The mixture was then allowed to reach ambient temperature and adjusted to 0.1 M NaCl; pH 6.23. 104.6 g of the loaded mixture was purified by TFF using a polysulfone hollow fiber cartridge with a molecular weight cutoff of 500 kD. The liposomes were preconcentrated by diafiltration to approximately 12 mg / ml of AKG-28 and purified from any extraliposomal drug by TFF with HBS-7 buffer exchange, for a total of 8.3 volume changes. The concentrated, purified liposomes were sterile-passed through a 0.2 μm sterile filter (chased with HBS-7 buffer) and analyzed for particle size by DLS and for drug and phospholipid concentrations by spectrophotometry. The liposomes had the following characteristics: AKG-28 at 12.05 ± 0.13 mg / ml, DL ratio of 239.4 g / mol phospholipid, Xz of 120.1 nm, and PDI of 0.0294. The yield of the formulated drug was 555.5 mg (92.6%).

[0888] Example 29. Liposomal AKG-38 Batch 292.

[0889] Batch 288.The general procedure of Example 6 was followed. HSPC (Lipoid AG) 9.17 g (11.67 mmol), cholesterol (Dishman, high purity) 5.51 g (14.26 mmol) and PEG-DSPE (Lipoid AG) 1.575 g (0.583 mmol) were combined with 17.5 mL of anhydrous ethanol (Sigma, E-7023) and heated with stirring in a 69 to 70°C bath until all lipids were dissolved. In a separate container, 181.4 g (175 ml) of a 0.5 M aqueous ammonium sulfate solution (filtered at 0.2 microns) was preheated in a 70°C bath and poured into the hot lipid ethanol solution under stirring. The resulting suspension was stirred in a 70°C bath for at least 20 minutes and divided into three portions. Each portion was extruded five times at 280 psi through a stack of two 47 mm 100 nm pore and one 200 nm pore polycarbonate track-etched membranes (Whatman Nucleopore) using a Lipex 100 ml thermobarrel liposome extruder (Northern Lipids, Inc.) heated with circulating 70°C water. The partially extruded liposomes were combined (Xz was 126.7 nm) and extruded together four more times through the same membrane stack to obtain liposomes with a size Xz of 119.2 nm and a PDI of 0.0385. The liposomes were kept overnight in a refrigerator (2 to 8°C) and filtered through a 0.2 μm polyethersulfone (PES) filter under positive pressure. The phospholipid concentration was found to be 59.08 ± 0.44 mM. The extraliposomal capture agent (ammonium sulfate) was removed by exchanging the TFF buffer for endotoxin-free water on a KrosFlo TFF system using a polysulfone hollow fiber cartridge with a MW cutoff of 500 kDa (Spectrum Laboratories) until the residual conductivity decreased to 152 μS / cm after 5.4 volume changes. The phospholipid concentration in the liposome suspension after TFF was determined to be 57.76 ± 0.53 mM by the blue phosphomolybdate method.

[0890] AKG-38 (free alkali) is mixed with the 1N HCl of 0.95 equivalent, and prepares the aqueous stock solution (pH 5.11) of 19.7mg / ml with endotoxin-free water.Solution is passed through 0.2 μm filter, and in the presence of 44.5mg / ml dextrose, 10mM NaCl and concentration, be the AKG-38 (pH 5.50) of 8mg / ml, by comprising the filtrate amount of 3509mg medicine and TFF after liposome suspension combination, to form the loaded mixture that medicine and phospholipid (DL) ratio are 450g / mol.Mixture is heated to 61.6 ℃ by external heating under constant stirring in the period of 5 minutes, and under agitation, continues to hatch other 20 minutes on 65 ℃ of baths.Then mixture is transferred in ice-water bath, stirred 7 minutes so that the temperature is reduced to 10 ℃, and it is kept 8 minutes again in ice-water bath. After removal from the ice bath, reaching ambient temperature, and adjusting to 0.1 M NaCl by adding a 3 M NaCl stock, the drug-loaded liposomes were purified by TFF using a polysulfone hollow fiber cartridge with a molecular weight cutoff of 500 kD. The liposomes were preconce...

Claims

1. A liposome composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in: R 1 is a tetrazole ring substituted with an aminoalkyl group at the 2' position; and R 2 is an amine or acetamide; The compound of formula (I) or a pharmaceutically acceptable salt thereof is encapsulated in liposomes in an aqueous medium at a pH greater than 6.7; and The liposomes comprise phosphatidylcholine, cholesterol and PEG polymer conjugated lipids, wherein there is 50 to 65 mol% cholesterol relative to the sum of cholesterol and non-PEGylated phospholipids in the liposomes.

2. The liposome composition of claim 1, wherein R 2 is acetamide (NHCOCH 3 ).

3. The liposome composition of claim 2, wherein R 1 Selected from:

4. The liposome composition of claim 3, wherein the amount of the PEG polymer-conjugated lipid is 5 mol% relative to phosphatidylcholine.

5. The liposome composition of claim 4, wherein the sulfate salt of the compound of formula (I) is encapsulated in liposomes comprising phosphatidylcholine, cholesterol and PEG polymer-conjugated lipids in a molar ratio of 45:55:2.

25.

6. The liposome composition of claim 5, wherein the phosphatidylcholine is distearoylphosphatidylcholine (DSPC) or hydrogenated soybean phosphatidylcholine (HSPC).

7. The liposome composition of claim 6, wherein the PEG polymer-conjugated lipid is PEG (molecular weight 2,000)-distearoylglycerol (PEG-DSG) or PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine (PEG-DSPE).

8. The liposome composition of claim 7, further comprising a chelating agent selected from deferoxamine (DFO) and EDTA, wherein the concentration of the chelating agent is 0.1 to 1 mM.

9. The liposome composition of any one of claims 1 to 8, wherein the compound of formula (I) is a compound selected from the group consisting of AKG-38, AKG-39 and AKG-40, or a pharmaceutically acceptable salt thereof.

10. The liposome composition of claim 9, wherein the compound of formula (I) is the sulfate salt of AKG-38.

11. The liposome composition of claim 10, wherein the pH of the liposome composition is greater than 7 and less than 8.

12. The liposome composition of claim 10, wherein the pH of the liposome composition is 7.3 to 7.

7.

13. The liposome composition of claim 10, wherein the pH of the liposome composition is 7.

5.

14. The liposome composition of claim 1, wherein the compound of formula (I) is a sulfate salt of AKG-38, The compound is encapsulated in liposomes formed by hydrogenated soybean phosphatidylcholine (HSPC), cholesterol and PEG (2000) -DSPE in a molar ratio of 45:55:2.25 in an aqueous medium with a pH of 7.3 to 7.

7.

15. The liposome composition of claim 14, further comprising a chelating agent, wherein the chelating agent is deferoxamine (DFO), and wherein the concentration of the chelating agent is 0.1 to 1 mM.

16. The liposome composition of claim 14 or claim 15, wherein the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the composition is 430 to 680 g / mol.

17. The liposome composition of claim 14 or claim 15, wherein the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the composition is 600 g / mol.

18. The liposome composition according to claim 14 or claim 15, in: a. The liposome composition comprises a single or oligolamellar vesicle having a z-average diameter of 90 to 130 nm; and b. The polydispersity index of the liposome composition is less than 0.

15.

19. The liposome composition of claim 14 or claim 15, wherein the ratio of encapsulated AKG-38 to total AKG-38 in the composition is at least 90%.

20. The liposome composition of claim 14 or claim 15, wherein the aqueous medium further comprises sodium chloride.

21. The liposome composition according to claim 20, in: a. The osmotic concentration of the aqueous medium is 270 to 330mOsmol / kg; b. the concentration of sodium chloride is 130 to 150 mM; and c. The concentration of the chelating agent is 0.5 mM.

22. The liposome composition of claim 20, wherein the aqueous medium comprises ammonium ions at a concentration of 20 to 60 mM, and the concentration of sodium chloride is 50 to 80 mM.

23. The liposome composition of claim 21 or claim 22, further comprising HEPES or phosphate buffer.

24. An AKG-38 liposome composition having a pH of at least 7.0 and not more than 8.0, the liposome composition comprising lipids HSPC, cholesterol and PEG(2000)-DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1 and a pharmaceutically acceptable salt of AKG-38, The liposome composition is further characterized by any one or more of the following features: a. The liposome composition comprises a monolayer or oligolayer vesicle having a z-average diameter of 90 to 130 nm, or the liposome composition comprises a monolayer or oligolayer vesicle having a z-average diameter of 100 to 130 nm; b. The polydispersity index of the liposome composition is less than 0.15 or the polydispersity index of the liposome composition is less than 0.10; c. The drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 430 to 480 g / mol, or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 500 to 650 g / mol; or the drug / lipid ratio of AKG-38 to total phospholipids (PhL) in the liposome composition is 430 to 650 g / mol; or the AKG -38 to total phospholipids (PhL) drug / lipid ratio is 450 g / mol; or the liposome composition in which the AKG-38 to total phospholipids (PhL) drug / lipid ratio is 450 g / mol; or the liposome composition in which the AKG-38 to total phospholipids (PhL) drug / lipid ratio is 600 g / mol; or the liposome composition in which the AKG-38 to total phospholipids (PhL) drug / lipid ratio is 600 g / mol; d. the total concentration of AKG-38 in the liposome composition is 12 to 25 mg / mL, or the total concentration of AKG-38 in the liposome composition is 13.5 to 16.5 mg / mL, or the total concentration of AKG-38 in the composition is 15 mg / mL, or the total concentration of AKG-38 in the liposome composition is 16 mg / mL (160 mg in a 10 mL vial); e. the ratio of encapsulated AKG-38 to total AKG-38 in the liposome composition is at least 90%, or the ratio of encapsulated AKG-38 to total AKG-38 in the liposome composition is at least 95%, or the ratio of encapsulated AKG-38 to total AKG-38 in the liposome composition is at least 97%, or the ratio of encapsulated AKG-38 to total AKG-38 in the liposome composition is at least 98%; f. The liposome composition comprises an aqueous medium containing sodium chloride and optionally containing ammonium ions; g. the osmotic concentration of the aqueous medium is 270 to 330 mOsmol / kg, or the osmotic concentration of the aqueous medium is 270 to 310 mOsmol / kg; h. the aqueous medium comprises ammonium ions at a concentration of 20 to 60 mM, or the aqueous medium comprises ammonium ions at a concentration of 50 to 80 mM, or the aqueous medium comprises ammonium ions at a concentration of less than 0.5 mM, or the aqueous medium comprises ammonium ions at a concentration of less than 1 mM, or the aqueous medium comprises ammonium ions at a concentration of 1 to 10 mM; i. the aqueous medium comprises sodium chloride at a concentration of 130 to 150 mM; j. the aqueous medium further comprises a buffer, wherein the buffer buffers the liposome composition at a pH of 7.3 to 7.7 or at a pH of 7.5; k. The aqueous medium further comprises HEPES or a phosphate buffer, or the aqueous medium further comprises HEPES or a phosphate buffer at a concentration of 5 to 50 mM, or the aqueous medium further comprises HEPES or a phosphate buffer at a concentration of 20 mM; 1. The aqueous medium further comprises a chelating agent, or the aqueous medium further comprises a chelating agent at a concentration of 0.1 to 1 mM, or the aqueous medium further comprises a chelating agent at a concentration of 0.5 mM, or the aqueous medium further comprises deferoxamine (DFO) or EDTA, or the aqueous medium further comprises deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM, or the aqueous medium further comprises deferoxamine (DFO) or EDTA at a concentration of 0.5 mM; m. The liposome composition is storage stable; or n. The AKG-38 is encapsulated in the liposomes as the sulfate salt of AKG-38.

25. The use of (5R)-3-{3-fluoro-4-[6-(2-(2-dimethylaminoethyl)-2H-tetrazol-5-yl)-3-pyridinyl]phenyl}-5-(methylacetylamino)-1,3- An isotonic AKG-38 liposome dispersion prepared with oxazolidin-2-one or a pharmaceutically acceptable salt thereof, wherein the liposome comprises hydrogenated soybean phosphatidylcholine (HSPC), cholesterol and (PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine, PEG-DSPE) (PEG (2000)-DSPE), and the aqueous medium comprises a chelating agent selected from the group consisting of deferoxamine (desferrioxamine, Desferroxamine), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), nitrilotriacetic acid (NTA), ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), N-(2-hydroxyethyl)ethylenediamine-N,N',N'-triacetic acid (HEDTA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).

26. The isotonic AKG-38 liposomal dispersion of claim 25, having a pH greater than 6.7 and not exceeding 8.

0.

27. The isotonic AKG-38 liposome dispersion of claim 26, in: a. The pH of the isotonic AKG-38 liposome dispersion is 7.5; b. The liposomes are formed by hydrogenated soy phosphatidylcholine (HSPC), cholesterol and PEG (2000) -DSPE in a molar ratio of 45:55:2.25; and The chelating agent is deferoxamine.

28. The isotonic AKG-38 liposomal dispersion of claim 25 or claim 26, wherein the liposomal dispersion comprises lipid vesicles formed from a composition comprising phosphatidylcholine, 55 mol% cholesterol, and 5 mol% PEG-DSG or 5 mol% PEG-DSPE.

29. A method for treating a methicillin resistant Staphylococcus aureus (MRSA) bacterial infection, the method comprising administering to a subject in need thereof a therapeutically effective amount of the liposome composition of any one of claims 1 to 28.

30. A method for preparing a liposome composition as claimed in any one of claims 1 to 28, comprising preparing an extruded lipid suspension, said method The following steps are involved: a. dissolving one or more phospholipids, cholesterol and PEG-lipid derivatives in ethanol to obtain a lipid solution; b. combining the lipid solution in step (a) with the capture agent solution to obtain a uniform lipid suspension having a desired phospholipid concentration; c. extruding the lipid suspension in step (b) through a membrane having a defined pore size, such as a polycarbonate track-etched (PCTE) membrane having a nominal pore size of 50 to 200 nm; d. purifying the liposomes from the extraliposomal capture agent in the extruded lipid suspension to obtain a purified extruded liposome preparation; e. contacting the liposome with the compound of formula (I) in an aqueous medium to achieve encapsulation of the compound in the liposome; f. optionally removing unencapsulated compounds; as well as g. providing the liposomes in a physiologically acceptable medium suitable for parenteral use; wherein the capture agent solution in step (b) comprises an aqueous solution of ammonium sulfate having a concentration greater than 0.25 M, and The physiologically acceptable medium in step (g) comprises a chelating agent.

31. The method of claim 30, wherein the capture agent solution in step (b) comprises ammonium sulfate at a concentration of 0.5 M.

32. The method of claim 30, wherein the chelating agent is deferoxamine.

33. The method of claim 30, wherein the liposomes extruded in step (c) are unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm.

34. The liposome composition of claim 1, wherein R 2 It is an amine (NH 2 ).

35. The liposome composition of claim 34, wherein R 1 Selected from:

36. The liposome composition of claim 34, wherein the amount of the PEG polymer-conjugated lipid is 5 mol% relative to phosphatidylcholine.

37. The liposome composition according to claim 36, in: a. The sulfate salt of the compound of formula (I) is encapsulated in liposomes comprising phosphatidylcholine, cholesterol and PEG polymer-conjugated lipids in a molar ratio of 45:55:2.25; b. The phosphatidylcholine is distearoylphosphatidylcholine (DSPC) or hydrogenated soy phosphatidylcholine (HSPC); and c. The PEG polymer conjugated lipid is PEG (molecular weight 2,000)-distearoylglycerol (PEG-DSG) or PEG (molecular weight 2,000)-distearoylphosphatidylethanolamine (PEG-DSPE).

38. The liposome composition of any one of claims 34 to 37, further comprising a chelating agent selected from deferoxamine (DFO) and EDTA, wherein the concentration of the chelating agent is 0.1 to 1 mM.

39. The liposome composition of claim 38, wherein the compound of formula (I) is selected from the group consisting of AKG-28, AKG-29, AKG-30, AKG-31, AKG-38 and AKG-39:

40. The liposome composition of claim 38, wherein the compound of formula (I) is a sulfate salt of AKG-28, The compound is encapsulated in liposomes formed by hydrogenated soybean phosphatidylcholine (HSPC), cholesterol and PEG (2000) -DSPE in a molar ratio of 45:55:2.25 in an aqueous medium with a pH of 7.3 to 7.

7.

41. An AKG-28 liposome composition comprising a liposome and a pharmaceutically acceptable salt of AKG-28 encapsulated in the liposome, wherein the liposome comprises lipids HSPC, cholesterol and PEG (2000) -DSPE in a molar ratio of 45:55:2.25 or a mass ratio of 5:3:1, The liposome composition is further characterized by any one or more of the following features: a. The liposome composition comprises a monolayer or oligolayer vesicle having a z-average diameter of 90 to 130 nm, or the liposome composition comprises a monolayer or oligolayer vesicle having a z-average diameter of 100 to 130 nm; b. The polydispersity index of the liposome composition is less than 0.15, or the polydispersity index of the liposome composition is less than 0.10; c. The drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 99 to 530 g / mol PhL, or 85 to 456 g / mol as AKG-28 free base (FB); 99 to 470 g / mol PhL, or 85 to 400 g / mol as AKG-28 free base (FB); 230 to 280 g / mol, or 190 to 240 g / mol as FB; or the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 290 to 360 g / mol, or 245 to 305 g / mol as FB; or The drug / lipid ratio of AKG-28 to total phospholipids (PhL) is 300 to 340 g / mol, or 256 to 290 g / mol as FB; or the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 250 g / mol, or 215 g / mol as FB; or the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 330 g / mol, or 280 g / mol as FB; or the drug / lipid ratio of AKG-28 to total phospholipids (PhL) in the composition is 330 g / mol, or 280 g / mol as FB; d. The total concentration of AKG-28 in the composition is 8 to 15 mg / mL, or 6.8 to 12.8 mg / mL as FB; or the total concentration of AKG-28 in the composition is 9 to 11 mg / mL, or 7.6 to 9.4 mg / mL as FB; or the total concentration of AKG-28 in the composition is 10 mg / mL, or 8.5 mg / mL as FB; or the total concentration of AKG-28 in the composition is 10 mg / mL (100 mg in a 10 mL vial), or 8.5 mg / mL (85 mg in a 10 mL vial) as FB; e. The ratio of encapsulated AKG-28 to total AKG-28 in the liposome composition is at least 90%; or the ratio of encapsulated AKG-28 to total AKG-28 in the liposome composition is at least 95%; or the ratio of encapsulated AKG-28 to total AKG-28 in the liposome composition is at least 97%; or the ratio of encapsulated AKG-28 to total AKG-28 in the liposome composition is at least 98%; f. The liposome composition comprises an aqueous medium containing sodium chloride and optionally containing ammonium ions; g. the osmotic concentration of the aqueous medium is 270 to 330 mOsmol / kg; or the osmotic concentration of the aqueous medium is 270 to 310 mOsmol / kg; or the aqueous medium is isotonic; h. the aqueous medium comprises ammonium ions at a concentration of 20 to 60 mM; or the aqueous medium comprises ammonium ions at a concentration of 50 to 80 mM; or the aqueous medium comprises ammonium ions at a concentration of less than 0.5 mM; or the aqueous medium comprises ammonium ions at a concentration of less than 1 mM; or the aqueous medium comprises ammonium ions at a concentration of 1 to 10 mM; or the aqueous medium comprises ammonium ions at a concentration of less than 130 mM; i. the aqueous medium further comprises a buffer, wherein the buffer buffers the liposome composition at a pH of 7.3 to 7.7 or at a pH of 7.5; j. The aqueous medium further comprises HEPES or a phosphate buffer; or the aqueous medium further comprises HEPES or a phosphate buffer at a concentration of 5 to 50 mM; or the aqueous medium further comprises HEPES or a phosphate buffer at a concentration of 20 mM; k. The composition further comprises a chelating agent; or the composition further comprises a chelating agent at a concentration of 0.1 to 1 mM; or the composition further comprises a chelating agent at a concentration of 0.5 mM; or the composition further comprises deferoxamine (DFO) or EDTA; or the composition further comprises deferoxamine (DFO) or EDTA at a concentration of 0.1 to 1 mM; or the composition further comprises deferoxamine (DFO) or EDTA at a concentration of 0.5 mM; or 1. AKG-28 is encapsulated in the liposomes as the sulfate salt of AKG-28.

42. A method for preparing a liposome composition according to any one of claims 34 to 41, comprising preparing an extruded lipid suspension, said method The following steps are involved: a. dissolving one or more phospholipids, cholesterol and PEG-lipid derivatives in ethanol to obtain a lipid solution; b. combining the lipid solution in step (a) with the capture agent solution to obtain a uniform lipid suspension having a desired phospholipid concentration; c. extruding the lipid suspension in step (b) through a membrane having a defined pore size, such as a polycarbonate track-etched (PCTE) membrane having a nominal pore size of 50 to 200 nm; d. purifying the liposomes from the extraliposomal capture agent in the extruded lipid suspension to obtain a purified extruded liposome preparation; e. contacting the liposome with the compound of formula (I) in an aqueous medium to achieve encapsulation of the compound in the liposome; f. optionally removing unencapsulated compounds; as well as g. providing the liposomes in a physiologically acceptable medium suitable for parenteral use; wherein the capture agent solution in step (b) comprises an aqueous solution of ammonium sulfate having a concentration greater than 0.25 M, and The physiologically acceptable medium in step (g) comprises a chelating agent.

43. The method of claim 42, wherein the capture agent solution in step (b) comprises ammonium sulfate at a concentration of 0.5 M.

44. The method of claim 42, wherein the chelating agent is deferoxamine.

45. The method of claim 42, wherein the extruded liposomes in step (c) are unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm.

46. ​​The method of claim 43, wherein the chelating agent is deferoxamine and the liposomes extruded in step (c) are unilamellar or oligolamellar vesicles having a z-average diameter of 90 to 130 nm.

47. A method of treating a mycobacterial infection, the method comprising administering to a subject in need thereof a therapeutically effective amount of the liposome composition of any one of claims 34 to 41.

48. The method of claim 47, wherein the mycobacterial infection is an infection with Mycobacterium tuberculosis, or an infection with a multidrug-resistant (MDR) strain of Mycobacterium tuberculosis, or an infection with an extremely drug-resistant (XDR) strain of Mycobacterium tuberculosis.

49. Use of the liposome composition of any one of claims 1 to 28 for treating methicillin-resistant Staphylococcus aureus (MRSA) bacterial infection.

50. Use of the liposome composition of any one of claims 34 to 41 for treating mycobacterial infection.

51. The liposome composition of any one of claims 1 to 28 for use in a method of treating a methicillin-resistant Staphylococcus aureus (MRSA) bacterial infection, the method comprising administering a therapeutically effective amount of the liposome composition to a subject in need thereof.

52. The liposome composition of any one of claims 34 to 41 for use in a method of treating a mycobacterial infection, the method comprising administering a therapeutically effective amount of the liposome composition to a subject in need thereof.

Citation Information

Patent Citations

  • Process for the synthesis of biaryl oxazolidnones

    US20100022772A1

  • Metal complexed therapeutic agents and lipid-based nanoparticulate formulations thereof

    US20180369143A1

  • Method of amphiphatic drug loading in liposomes by ammonium ion gradient

    US5316771A

  • Method for loading lipid vesicles

    US5800833A

  • Compound-loaded liposomes and methods for their preparation

    US6110491A